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In most patients with rheumatoid arthritis (RA), citrullinated autoantigens are 
targeted by autoantibodies (ACPA). However, the process leading to protein 
citrullination by peptidylarginine deiminases (PADs) in the joint remains unclear. 
In this thesis, I tested the hypothesis that generation of neutrophil extracellular 
traps (NETosis), can contribute to release of enzymatically active PADs and 
citrullinated autoantigens in inflamed joints. 
 
I have shown that in vitro induced NETosis leads to release of citrullinated 
proteins and enzymatically active PADs both attached to NETs and free in the 
supernatant. In the SF from RA patients DNA levels correlated with neutrophil 
concentrations, and DNA levels and PAD activity were found to be increased 
compared with OA patients. Finally, I demonstrated the antigenicity of in vitro 
generated NETs and identified citrullinated histone H3 as a NET-component 
recognised by ACPA and RA sera. 
 
Based on the findings in this thesis release of active PADs into SF by neutrophil 
cell death is a plausible explanation for the generation of citrullinated 
extracellular autoantigens. In ACPA positive RA patients the continuous 
production of these autoantigens combined with pre-existing ACPA may result 





“The point is that, whenever we propose a solution to a problem, we ought to try 
as hard as we can to overthrow our solution, rather than defend it. Few of us, 
unfortunately, practice this precept; but other people, fortunately, will supply the 












































I want to thank my supervisor Dr Dagmar Scheel-Toellner for all her support 
throughout my PhD, for the many opportunities to present and discuss my 
research in front of an international audience, for all the inspiring discussions 
about the exciting world of immunology, for giving me independence and 
teaching me a scientific approach to my reasoning, for her patience with me, for 
believing in me and encouraging me to believe in myself. 
 
I owe many thanks to my co-supervisors Prof Paul Cooper and Dr Mike Milward 
for all the discussions and advice, and for pain-stakingly proof-reading my 
thesis. I am also very grateful to Prof Karim Raza for his invaluable support and 
advice and, of course, for providing countless clinical samples. I would also like 
to thank Dr Andrew Filer for supplying clinical samples and sharing his medical 
and statistical knowledge, and whose involvement has been much appreciated. 
This work would not have been possible without the generosity of the patients 
and all the staff involved in collecting clinical samples, especially Jacqueline 
Cobb. I will also be eternally grateful to my faithful blood donors. 
 
Many thanks to Prof Chris Buckley, Dr Stephen Young and Dr Graham Wallace 
for their advice, support and encouraging words.  
 
I would also like to gratefully acknowledge the European Community's 
Collaborative project FP7-HEALTH-2010-261460 "Gums&Jonts" for funding this 
research project and for the collaboration with Prof Iain Chapple at the Dental 
School, University of Birmingham, UK. 
 
Many thanks also to my collaborators Prof Karin Lundberg and Dr Jimmy 
Ytterberg at the Karolinska Institutet in Stockholm for providing purified ACPA, 
for the mass spectrometry analyses and for their help with the peptide ELISA. 
 
I owe many thanks to members of the Scheel-Toellner Group, both past and 
present, whose help has been invaluable, especially Bozo Lugonja for 
introducing me into the work with the delicate neutrophils and for his sense of 
humour, and to Dr Farrah Ali, Nichola Adlard, Dr Lorraine Yeo and Dr Elizabeth 
Clay for their technical support. 
 
A owe huge thanks to the entire RRG for all the support and advice over the 
years and for making the lab a fun and very pleasant place to work. Especially, I 
would like to thank the world's best technician Holly Adams for feeding me with 
chocolate for my "late nights" and "bad days", for the forest trip and the roast 
dinner. Thank you also to Dr Guillaume Desanti for sharing his expertise, for his 
sense of humour and for all his advice (I will do my best to become a multi-
resistant bacterium!!) and thank you very much to Saba, Joana and Dominika 
for all their encouraging words, for their support, their friendship, for the dinners 
and all the fun that we have had. 
 
Thank you very much to all my friends and colleagues in Germany and to Prof 
Heiko Mühl for his time, support, advice and belief in me throughout my career. 
 
Finally, I would like to thank my family and my dear best friend Thomas for all 
your endless patience, love and support, and to my grandfather who taught me 
diligence and perseverance. I am very lucky to have learned from you and 





















Table of contents 
 
1 INTRODUCTION ............................................................................................................................ 1 
1.1 NEUTROPHILS..................................................................................................................................... 2 
1.1.1 Neutrophil maturation ......................................................................................................... 2 
1.1.2 Neutrophil recruitment ......................................................................................................... 4 
1.1.3 Neutrophil activation and antimicrobial strategies .............................................................. 5 
1.1.4 NETosis ................................................................................................................................. 7 
1.1.4.1 Signalling mechanisms leading to NETosis .................................................................................8 
1.1.4.2 The role of PAD4 in NET formation ..........................................................................................11 
1.1.4.3 NETs and autoimmunity ..........................................................................................................14 
1.2 RHEUMATOID ARTHRITIS .................................................................................................................... 16 
1.2.1 Clinical features and classification ..................................................................................... 17 
1.2.2 Phases of RA ....................................................................................................................... 18 
1.2.3 Synovial biology and pathology .......................................................................................... 20 
1.2.4 Role of neutrophils in RA .................................................................................................... 22 
1.3 AUTOIMMUNITY IN RHEUMATOID ARTHRITIS.......................................................................................... 27 
1.3.1 Autoantibodies in RA .......................................................................................................... 31 
1.3.2 Citrullination and ACPA generation .................................................................................... 35 
1.3.2.1 Physiological role of citrullination ............................................................................................35 
1.3.2.2 Regulation of PAD activity .......................................................................................................37 
1.3.3 Variability in clinical observations in RA ............................................................................. 39 
1.3.4 T and B cell responses to citrullinated proteins .................................................................. 41 
1.3.5 Role of ACPA in the pathogenesis of RA ............................................................................. 45 
1.3.5.1 The 'second hit' hypothesis .....................................................................................................45 
1.3.5.2 Fine specificity of ACPA and epitope spreading .......................................................................47 
1.3.5.3 Molecular mimicry –link between RA and periodontitis .........................................................50 
1.3.5.4 Possible effector mechanisms of ACPA....................................................................................52 
1.4 AIMS .............................................................................................................................................. 55 
2 MATERIALS AND METHODS ........................................................................................................56 
2.1 ANTIBODIES ..................................................................................................................................... 57 
2.2 QUANTIFICATION OF EXTRACELLULAR DNA IN SF SAMPLES (UNTREATED OR CELL-FREE) .................................. 58 
2.3 QUANTIFICATION OF CELLS IN SF SAMPLES ............................................................................................. 58 
2.4 ISOLATION OF NEUTROPHILS FROM PERIPHERAL BLOOD ............................................................................. 60 
2.5 INDUCTION OF NECROTIC CELL DEATH IN NEUTROPHILS ............................................................................. 61 
2.6 ISOLATION OF NETS .......................................................................................................................... 61 
2.6.1 Isolation of NETs from neutrophils stimulated with PMA (in vitro) .................................... 61 
2.6.1.1 Precipitation of proteins using trichloroacetic acid (TCA)........................................................63 
2.6.1.2 Measurement of DNA concentration in supernatants of neutrophils .....................................64 
2.6.2 Isolation of NETs from synovial fluid of RA patients (ex vivo) ............................................ 64 
2.7 SDS-PAGE (SODIUM DODECYL SULFATE- POLYACRYLAMIDE GEL-ELECTROPHORESIS) AND WESTERN BLOTTING 65 
2.7.1 Sample preparation ............................................................................................................ 66 
2.7.2 Depletion of albumin from the synovial fluid ..................................................................... 66 
2.7.3 Relative quantification of protein signal ............................................................................ 66 
2.7.4 Detection of citrulline modifications using the AMC-kit ..................................................... 67 
2.7.5 Staining of SDS-PAGE gels or PVDF membranes with Coomassie Blue .............................. 68 
2.7.6 Generation of gel slices for mass spectrometry ................................................................. 68 
2.7.7 Generation of PVDF strips and incubation with patient sera or antibodies ....................... 68 
2.8 IMMUNOPRECIPITATION OF PAD4 FROM THE SYNOVIAL FLUID ................................................................... 69 
2.9 PATIENT SELECTION AND SAMPLE COLLECTION ........................................................................................ 70 
2.10 MEASUREMENT OF PAD ACTIVITY (ABAP-ASSAY) .............................................................................. 70 
2.10.1 PAD activity measurement in the supernatants of neutrophils (in vitro) ...................... 72 
2.10.2 PAD activity assay in synovial fluid ................................................................................ 72 
2.11 IN VITRO CITRULLINATION .............................................................................................................. 73 
2.12 PEPTIDE ELISAS .......................................................................................................................... 73 
2.13 IMMUNOFLUORESCENCE MICROSCOPY ............................................................................................. 74 
2.13.1 Immunofluorescence staining of synovial fluid preparations and synovial tissue sections
 74 
2.13.2 Staining of in vitro isolated neutrophils on coverslips ................................................... 75 
2.13.3 Staining of cytospins of isolated neutrophils and synovial fluid cells ............................ 75 
2.13.4 Quantification of PAD4 signal in neutrophils ................................................................. 76 
2.14 MASS SPECTROMETRY ................................................................................................................... 79 
2.14.1 Quantification of proteins in the supernatants and NET fractions of activated 
neutrophils 79 
2.14.2 Qualitative analysis of the presence of citrullinated proteins in the supernatants and 
NET fractions of activated neutrophils ............................................................................................. 80 
2.15 STIMULATION OF NEUTROPHILS WITH ENRICHED IMMUNE COMPLEXES FROM THE SF OF RA PATIENTS .......... 81 
2.16 STATISTICAL ANALYSES .................................................................................................................. 81 
3 DETECTION OF NEUTROPHIL EXTRACELLULAR TRAPS IN THE JOINTS OF RA PATIENTS ................82 
3.1 INTRODUCTION ................................................................................................................................. 83 
3.2 EXTRACELLULAR DNA LEVELS IN THE SYNOVIAL FLUID OF PATIENTS WITH INFLAMMATORY ARTHRITIS CORRELATE 
WITH NEUTROPHIL CELL NUMBERS.................................................................................................................. 84 
3.3 VISUALISATION OF NETS IN THE SYNOVIAL FLUID AND TISSUE OF RA PATIENTS .............................................. 92 
3.4 ANTIBODIES AS POTENTIAL TRIGGERS OF NETOSIS IN THE SYNOVIAL FLUID OF RA PATIENTS ............................. 96 
3.5 DISCUSSION ................................................................................................................................... 102 
4 PEPTIDYLARGININE DEIMINASE ACTIVITY IN THE SYNOVIAL FLUID OF RA PATIENTS ................ 110 
4.1 INTRODUCTION ............................................................................................................................... 111 
4.2 METHOD DEVELOPMENT FOR THE IN VITRO ISOLATION OF NETS ............................................................... 112 
4.3 ANALYSIS OF PAD RELEASE DURING IN VITRO NETOSIS .......................................................................... 117 
4.4 PEPTIDYLARGININE DEIMINASES IN THE SF OF RA PATIENTS ..................................................................... 125 
4.5 LOCALISATION OF PAD4 IN NEUTROPHILS FROM RA PATIENTS ................................................................. 132 
4.6 DISCUSSION ................................................................................................................................... 136 
5 INVESTIGATION INTO THE ANTIGENICITY OF NETS IN RA PATIENTS .......................................... 145 
5.1 INTRODUCTION ............................................................................................................................... 146 
5.2 CITRULLINATED PROTEINS ARE RELEASED DURING NETOSIS IN VITRO ......................................................... 148 
5.3 QUALITATIVE ANALYSIS OF PROTEIN COMPOSITION OF NETS USING MASS SPECTROMETRY ............................. 153 
5.4 PURIFIED ACPA SPECIFICALLY RECOGNISE AN 11 KD BAND WITHIN IN VITRO AND EX VIVO NETS .................... 157 
5.5 CITRULLINATED HISTONE H3 IS AN AUTOANTIGEN IN RA PATIENTS ........................................................... 164 
5.6 ANTIBODIES DERIVED FROM SF B CELLS RECOGNISE HISTONES .................................................................. 168 
5.7 RA PATIENT SERA RECOGNISE CITRULLINATED EPITOPES IN HISTONE H3 ..................................................... 171 
5.8 DISCUSSION ................................................................................................................................... 173 
6 GENERAL DISCUSSION ............................................................................................................... 182 
7 REFERENCES .............................................................................................................................. 197 
8 APPENDIX ................................................................................................................................. 237 
8.1 PATIENT CLINICAL DATA .................................................................................................................... 238 
8.2 QUANTITATIVE PROTEOMICS DATA ON THE PROTEIN COMPOSITION IN THE SUPERNATANT OF CELLS GOING INTO 
NETOSIS................................................................................................................................................. 239 
8.2.1 Proteins enriched in the NET (D) fraction ......................................................................... 242 







List of figures 
FIGURE 1-1 ROLE OF PAD4 SIGNALLING IN NETOSIS ............................................................................................. 13 
FIGURE 1-2 AUTOANTIGENS PRESENT IN NETS ..................................................................................................... 14 
FIGURE 1-3 RHEUMATOID ARTHRITIS DEVELOPS IN SEVERAL PHASES ......................................................................... 19 
FIGURE 1-4 HISTOPATHOLOGIC APPEARANCE OF THE RA SYNOVIUM ......................................................................... 21 
FIGURE 1-5 NEUTROPHILS IN THE JOINTS OF RA PATIENTS ....................................................................................... 26 
FIGURE 1-6 ENZYMATIC CONVERSION OF PEPTIDYLARGININE INTO PEPTIDYLCITRULLINE ................................................. 35 
FIGURE 1-7 MECHANISMS OF EPITOPE SPREADING ................................................................................................ 49 
FIGURE 2-1 EXAMPLE IMAGE OF NEUTROPHILS AND MACROPHAGES IN THE SYNOVIAL FLUID INFILTRATE USED FOR CELL 
CHARACTERISATION AND QUANTIFICATION .................................................................................................. 60 
FIGURE 2-2 EXAMPLE IMAGES OF CELL MORPHOLOGY OF UNSTIMULATED AND PMA-STIMULATED NEUTROPHILS (25 NM 
PMA) AFTER 4H CELL CULTURE (20 X 10 ORIGINAL MAGNIFICATION) .............................................................. 62 
FIGURE 2-3 THE STEPS IN THE PROCESS USED FOR THE ISOLATION OF NETS USING DNASE-I .......................................... 63 
FIGURE 2-4 RELATIVE QUANTIFICATION OF PROTEIN BANDS USING IMAGE LAB 4.0 SOFTWARE ....................................... 67 
FIGURE 2-5 THE ANTIBODY BASED ASSAY FOR PAD ACTIVITY (ABAP) ...................................................................... 71 
FIGURE 2-6 IMAGE CALCULATOR FUNCTION OF THE ZEN 2010 SOFTWARE ................................................................ 78 
FIGURE 3-1 DETECTION OF EXTRACELLULAR DNA IN THE SYNOVIAL FLUID OF PATIENTS WITH INFLAMMATORY ARTHRITIS .... 87 
FIGURE 3-2 RELATIONSHIP BETWEEN DNA CONCENTRATION AND CLINICAL PARAMETERS IN RA PATIENTS ........................ 88 
FIGURE 3-3 DETERMINATION OF THE CELL COMPOSITION IN THE RA SYNOVIAL FLUID ................................................... 90 
FIGURE 3-4 NEUTROPHIL CELL COUNTS IN RA PATIENTS CORRELATE WITH DNA LEVELS AND DISEASE DURATION ............... 91 
FIGURE 3-5 NETS CAN BE DETECTED IN THE SYNOVIAL FLUID OF RA PATIENTS ............................................................. 93 
FIGURE 3-6 NEUTROPHIL AND MACROPHAGES STAINING IN SF INFILTRATE ................................................................. 94 
FIGURE 3-7 NETS WITHIN NEUTROPHIL INFILTRATE ATTACHED TO SYNOVIAL TISSUE OF RA PATIENTS ............................... 95 
FIGURE 3-8 INFLUENCE OF SERUM ANTIBODY LEVELS ON DNA LEVELS IN THE SF ......................................................... 97 
FIGURE 3-9 IMMUNE COMPLEXES ENRICHED FROM RA SF INDUCE NETOSIS ............................................................ 100 
FIGURE 3-10 INFLUENCE OF ENRICHED IMMUNE COMPLEXES FROM RA SYNOVIAL FLUID ON NEUTROPHILS ..................... 101 
FIGURE 4-1 IN VITRO TIME COURSE ANALYSIS OF DNA RELEASE POST-STIMULATION WITH PMA .................................. 114 
FIGURE 4-2 DNA LEVELS IN SUPERNATANTS GENERATED DURING IN VITRO NETOSIS .................................................. 116 
FIGURE 4-3 IDENTIFICATION OF PADS RELEASED DURING NETOSIS IN VITRO ............................................................ 120 
FIGURE 4-4 PAD ACTIVITY IN THE SUPERNATANTS OF IN VITRO STIMULATED NEUTROPHILS ENTERING INTO NETOSIS ........ 122 
FIGURE 4-5 TIME COURSE OF PAD2 AND PAD4 RELEASE DURING IN VITRO NETOSIS ................................................. 124 
FIGURE 4-6 PRESENCE OF PAD2 AND PAD4 IN THE SYNOVIAL FLUID OF RA PATIENTS................................................ 128 
FIGURE 4-7 PAD ACTIVITY AT PHYSIOLOGICAL AND SUPRAPHYSIOLOGICAL CALCIUM LEVELS ......................................... 129 
FIGURE 4-8 CORRELATION OF PAD ACTIVITY WITH DNA LEVELS, NEUTROPHIL NUMBERS AND DISEASE DURATION ........... 131 
FIGURE 4-9 CYTOPLASMIC LOCALISATION OF PAD4 IN A POPULATION OF SF NEUTROPHILS FROM RA PATIENTS .............. 134 
FIGURE 4-10 QUANTIFICATION OF PERCENTAGE OF CYTOPLASMIC PAD4 SIGNAL OF TOTAL PAD4 SIGNAL IN NEUTROPHILS 
USING THE ZEN 2010 SOFTWARE ........................................................................................................... 135 
FIGURE 5-1 RELEASE OF CITRULLINATED PROTEINS FROM NEUTROPHILS UNDERGOING NETOSIS ................................... 151 
FIGURE 5-2 DEMONSTRATION OF SPECIFIC DETECTION OF CITRULLINATED PROTEINS ................................................... 152 
FIGURE 5-3 ALIGNMENT OF PROTEIN SEQUENCES FROM HISTONE SUBTYPES ............................................................. 156 
FIGURE 5-4 SPECIFIC RECOGNITION OF THE CITRULLINATED FORM OF VIMENTIN AND CALF THYMUS HISTONES BY PURIFIED 
ACPA FROM RA PATIENT SERA .............................................................................................................. 159 
FIGURE 5-5 NO SPECIFIC RECOGNITION OF ANTIGENS IN THE SN FRACTION OF ACTIVATED NEUTROPHILS BY PURIFIED ACPA
 ........................................................................................................................................................ 160 
FIGURE 5-6 ACPA SPECIFICALLY AND CONSISTENTLY RECOGNISE A 11 KD ANTIGEN IN NETS ....................................... 161 
FIGURE 5-7 ACPA RECOGNISE AN 11KD BAND WITHIN EX VIVO NETS .................................................................... 163 
FIGURE 5-8 PURIFIED ACPA STRONGLY REACT WITH IN VITRO CITRULLINATED HISTONE H3.3 ...................................... 166 
FIGURE 5-9 ACPA POSITIVE RA PATIENT SERA RECOGNISE HISTONES ...................................................................... 167 
FIGURE 5-10 ANTIBODIES FROM SF B CELLS REACT WITH BOTH THE NATIVE AND CITRULLINATED FORM OF HISTONE H3 AND 
H4.................................................................................................................................................... 170 
FIGURE 5-11 REACTIVITY OF RA PATIENT SERA WITH THREE SYNTHETIC CITRULLINATED CYCLIC PEPTIDES FROM HISTONE H3
 ........................................................................................................................................................ 172 
FIGURE 6-1 MODEL OF NETS AS A SOURCE OF PADS AND CITRULLINATED PROTEINS IN RA PATHOGENESIS .................... 196 
FIGURE 8-1 ENRICHED PROTEINS IN D (DNASE-I TREATED NET FRACTION) FRACTION ................................................ 242 
 
 
List of tables 
TABLE 1-1 EXAMPLES SHOWING THE RANGE OF STIMULI KNOWN TO INDUCE NETOSIS .................................................. 10 
TABLE 4-1 PROTEINS ENRICHED IN THE NET FRACTION ......................................................................................... 121 
TABLE 5-1 CITRULLINATED PROTEINS RELEASED FROM NEUTROPHILS UNDERGOING NETOSIS – Q EXACTIVE MS ............. 155 
TABLE 5-2 CITRULLINATED PROTEINS RELEASED FROM NEUTROPHILS UNDERGOING NETOSIS – LTQ VELOS ORBITRAP ETD 
MS ................................................................................................................................................... 155 
TABLE 5-3 CITRULLINATED PROTEINS DETECTED IN THE 11 KD BAND OF THE NET FRACTION ........................................ 156 
TABLE 8-1 CLINICAL DATA FOR RA PATIENTS ...................................................................................................... 238 
TABLE 8-2 CLINICAL DATA FOR PSA PATIENTS ..................................................................................................... 238 
TABLE 8-3 CLINICAL DATA FOR OA PATIENTS ...................................................................................................... 239 
TABLE 8-4 CLINICAL DATA FOR OA PATIENTS ...................................................................................................... 239 






























ACR American College of Rheumatology 
ACPA Anti-citrullinated protein antibodies 
AFU Arbitrary fluorescence units 
AMC Anti-modified citrulline 
ANCA Anti-neutrophil cytoplasmic antibodies 
APCs Antigen presenting cells 
BCR B cell receptor 
BM Bone marrow 
CAIA Collagen antibody-induced arthritis 
CCP  Cyclic citrullinated peptide 
CDRs Complementarity determining regions 
CIA Collagen-induced arthritis 
CGD Chronic Granulomatous Disease 
CRP C-reactive protein 
DMARDs Disease modifying anti-rheumatic drugs  
ESR Erythrocyte sedimentation rate 
EULAR ACR//European League Against Rheumatism 
FDCs Follicular dendritic cells 
FcγR Fc-gamma receptor 
FLS  Fibroblast-like synoviocytes  
f-MLP N-formyl-methionine-leucine-phenylalanine 
FS Felty's syndrome 
G-CSF Granulocyte colony-stimulating factor  
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GWAS Genome- wide association studies 
H2O2 Hydrogen peroxide 
HLA Human leucocyte antigen 
HMGB1 High-Mobility-Group-Protein B1 
HRP Horseradish peroxidase 
ICs Immune complexes 
ICAM Intercellular adhesion molecule 
Ig Immunoglobulin 
IFN  Interferon 
IL Interleukin 
IQR Inter-quartile range 
LFA-1 Lymphocyte function-associated antigen 1 
LPS Lipopolysaccharide 
Mac-1 Macrophage-1 antigen 
MCP Metacarpophalangeal joints 
MHC Major histocompatibility complex 
MMPs Matrix metalloproteinases 
MPO Myeloperoxidase 
MRI Magnetic resolution imaging 
MS Mass spectrometry 
NADPH Nicotinamide adenine dinucleotide phosphate 
NE Neutrophil elastase 
NETs Neutrophil extracellular traps 
NSAIDs  Non-steroidal anti-inflammatory drugs 
OA Osteoarthritis 
PADs Peptidylarginine deiminases 
PAD1,2,3,4 Peptidylarginine deiminase 1,2,3,4  
PB Peripheral blood 
PD Periodontitis 
pDCs Plasmacytoid dendritic cells 
PEG Polyethylene glycol 
PKC Protein kinase C 
PMA Phorbol-12-myristat-13-acetate  
PMN Polymorphonuclear leukocytes 
PR3 Proteinase 3 
PRRs Pattern recognition receptors 
PSGL-1 P-selectin glycoprotein ligand-1  
PsA Psoriatic arthritis 
PTM Post-translational modification 
PVDF Polyvinylidene difluoride 
RA Rheumatoid arthritis 
Rac2 Ras-related C3 botulinum toxin substrate 2 
ReA Reactive arthritis 
RF  Rheumatoid factor 
ROS Reactive oxygen species 
RT Room temperature 
SCID Severe combined immunodeficiency 
SF Synovial fluid 
s.d. Standard deviation 
SLE Systemic lupus erythematosus 
SN Supernatant 
ST Synovial tissue 
SVV Small-vessel vasculitis 
TCA Trichloroacetic acid 
TCR T cell receptor 
TNF Tumor necrosis factor 
UK United Kingdom 
VAS Visual analogue score 
































Neutrophils are the most abundant leukocyte population in human blood and 
are the first cells which arrive at a site of inflammation. Historically they have 
been seen as simple phagocytes of the innate immune system playing only a 
limited role in the immune response. However over the past 10-20 years, 
research has revealed that neutrophils have complex and sophisticated 
mechanisms by which they locate and eliminate pathogens, and subsequently 
orchestrate the inflammatory responses. Importantly, many of these studies and 
concepts are still novel and need further scrutinisation before they are finally 
accepted by the scientific community. Nevertheless, the literature has 
highlighted a much more diverse role of these cells than previously appreciated 
which provides an important basis for further research. 
1.1.1 Neutrophil maturation  
Neutrophils are derived from hematopoietic stem cells within the bone marrow 
(BM) and develop in a process termed "granulopoiesis". On a daily basis, 
around 1011 neutrophils are generated in a normal adult human (1). 
Granulocyte-colony-stimulating factor (G-CSF) levels control the production of 
neutrophils in the BM and maintain neutrophil counts under homeostatic 
conditions or increase neutrophil numbers during infection (2). Aged neutrophils 
die by constitutive apoptosis in circulation and in the absence of activating 
stimuli (3). They can finally be ingested by macrophages to prevent the release 




The release and retention of neutrophils from the BM is tightly regulated by the 
expression of two chemokine receptors on neutrophils and their respective 
ligands on stromal cells of the BM. During neutrophil maturation the chemokine 
receptor CXCR4 is gradually down-regulated while CXCR2 increases in 
abundance leading to the egress of neutrophils from the BM (5). Depletion of 
both receptors subsequently results in constitutive release of neutrophils into 
the blood circulation, suggesting a dominant role for CXCR4 (6). Interestingly, 
G-CSF has been demonstrated to stimulate neutrophil release both directly and 
by down-regulating expression of CXCL12, the ligand of CXCR4, in BM stromal 
cells (7,8). 
The BM is also the site where neutrophil granules, the hallmark of granulocytes, 
are formed sequentially during granulopoiesis (8). Primary (or azurophilic) 
granules are the earliest-formed granules. Their main components include 
myeloperoxidase (MPO), antimicrobial peptides, such as defensins, and three 
predominant serine proteinases: cathepsin G, elastase, and proteinase 3, which 
enable their main functional role of killing and digestion of microbes (9). The 
secondary (or specific) granules, which are formed after the primary granules, 
help limit free radical reactions. Their characteristic constituent is the 
glycoprotein lactoferrin, which binds and sequesters iron and copper, lysozyme 
and lipocalin. The smallest tertiary (or gelatinase) granules are formed at a late 
stage of neutrophil maturation and contain only few antimicrobials. Instead, they 
hold a number of metalloproteases such as gelatinase, which are able to 
degrade many extracellular matrix proteins (10). In addition, neutrophils also 
have a fourth set of storage organelles, the so-called secretory vesicles. They 
are formed through endocytosis and their membrane serves as a reservoir for 
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membrane-bound molecules employed during neutrophil migration (8,11). 
Importantly, the distinction between these types of granules reflects differences 
in granule contents and their mobilisation. Nevertheless, this nomenclature is 
too rigid, since considerable overlap exists in the cargo of these granules, 
depending on the time-point at which they are produced (11–13). 
 
1.1.2 Neutrophil recruitment  
After being released from the BM neutrophils continuously and randomly survey 
blood vessel walls on their way through the circulation in search of endothelial 
inflammatory signals. In order to arrive at the site of the inflamed tissue they first 
need to traverse the blood vessel walls. This process largely takes place in 
post-capillary venules and typically involves the following steps of: tethering, 
rolling, adhesion, crawling and transmigration (8,14). Initial attachment of 
neutrophils is enabled by their constitutive expression of the glycoprotein PSGL-
1 and L-selectin. These molecules interact with their ligands on activated 
endothelial cells, P- and E-selectins, resulting in the tethering of neutrophils to 
the surface of the endothelium as they roll along it. During the process of 
“rolling”, interaction with selectins, chemoattractants and cytokines leads to 
activation and clustering of the β2 integrins LFA-1 and Mac-1 on the surface of 
neutrophils resulting in rolling arrest and firm adhesion (11,15). Neutrophils 
subsequently begin to crawl in a process dependent on integrins and ICAMs 
along the vessel wall until they find a site for transmigration. Once they have 
passed the endothelium, neutrophils follow chemotactic gradients, such as host-
produced cytokines or pathogen-derived chemoattractants, to the site of 
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inflammation and/or infection (11). Interestingly, neutrophil recruitment does not 
always involve the steps described above and varies substantially in different 
organs, such as in the lung and the liver (16).  
Importantly, whereas migration of neutrophils through activated endothelium is 
dependent on β2 integrins, long-distance migration of neutrophils in tissue 
distant from the site of injury was recently revealed not to be (5). Using two-
photon intravital microscopy Lämmermann and colleagues demonstrated that 
neutrophils recruited to a focus of inflammation drive a second wave of 
neutrophil recruitment and clustering in the form of "swarms" (17). "Neutrophil 
swarming" was found to be initiated through release of chemoattractants from 
dead cells in developing neutrophil clusters, with a key role of leukotriene B4 as 
communication signal between neutrophils identified (17). 
 
1.1.3 Neutrophil activation and antimicrobial strategies 
Neutrophil activation has been shown to be a multi-step process. Initially, they 
can be primed by cytokines, such as  TNF-α, GM-CSF, IL-8 and IFN-γ or 
bacterial products (18). This can result in the rapid transport of pre-formed 
receptors to the cell surface via mobilisation of intracellular granules and the 
partial assembly of the NADPH oxidase. Additionally, activation of transcription 
factors can trigger de novo expression of molecules such as cytokines or 
receptors enhancing neutrophil function or prolonging their lifespan (18). The 
second stage of activation occurs after their recruitment to the site of 
inflammation. Here, neutrophils apply several different mechanisms to kill 
pathogens including phagocytosis, degranulation and the generation of 
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neutrophil extracellular traps (NETs). Phagocytosis is an active, receptor-
mediated process by which particles are taken up by the neutrophil and are 
internalised into a vacuole known as a phagosome (2). The interaction between 
neutrophils and microorganisms can either be direct (through pattern-
recognition receptors (PRRs)), or opsonin-mediated (through FcγR-mediated 
phagocytosis of IgG-opsonised particles or through complement receptor-
mediated phagocytosis) (11,19). Following engulfment, phagosome maturation 
initiates fusion of granules to the phagosome so that antimicrobial molecules 
can enter the phagosomal lumen. After fusion, the NADPH oxidase complex 
assembles on the phagosomal membrane and begins ROS production by 
reducing molecular oxygen to superoxide (11). Spontaneous dismutation of 
superoxide or dismutation catalysed by the enzyme superoxide dismutase 
(SOD) yields hydrogen peroxide (H2O2) (20). In addition, myeloperoxidase 
(MPO) can react with H2O2 and lead to the generation of highly reactive 
products including hypohalous acids, the major molecule of which is 
hypochlorous acid (HOCl). These mechanisms create an environment which is 
highly toxic to most pathogens (11,19). 
The process of degranulation involves mobilisation of the previously described 
neutrophil granules, with those granules formed last during neutrophil 
maturation, released first. Granules can fuse either with the plasma membrane 
to release their contents into the extracellular space, or with the phagosome. 
Although many studies have shown that degranulation into tissue could 
contribute to the antimicrobial milieu during an immune response against 
microorganisms, most data were generated in vitro and have therefore to be 
interpreted with caution (9,11).  
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Finally, a further antimicrobial strategy and, simultaneously, a novel form of cell 
death of neutrophils was reported by Brinkmann and his team in 2004 (21). The 
formation of NETs was revealed to be part of an active form of cell death that 
leads to the release of highly decondensed chromatin structures into the 
extracellular space. Although NETs were primarily described not only to entrap 
and immobilise microorganisms but also to kill them, the killing capacity was 
recently been questioned (22) and requires further examination. Due to the 
significance of NET formation for this thesis, this antimicrobial mechanism will 
be discussed in more detail in the following section. 
 
1.1.4 NETosis 
Initially, the formation of NETs was described as a distinct form of active cell 
death and was therefore termed “NETosis” to distinguish it from apoptosis and 
necrosis (23). In contrast to apoptotic cells, no internucleosomal DNA 
fragmentation and exposure of phosphatidylserine or activation of caspases 
have been observed. Also, neutrophils undergoing NETosis do not appear to 
show morphological characteristics typical of necrotic cells (24). In vitro, 
activated neutrophils flatten, lose their characteristic lobular nuclear form and 
decondense their chromatin (23,25). Subsequently, the nuclei and granules 
begin to lose their integrity during the first hour of activation and the nuclear 
membrane fragments into vesicles. This process results in mixing of 
decondensed chromatin with the granule contents which is followed by cell 
membrane rupture and release of NETs into the extracellular compartment. 
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Although alternative models of NET formation (such as the release of 
mitochondrial DNA from intact neutrophils (26) or the presence of anuclear 
viable neutrophils after NET formation (27)) have recently been described, 
these mechanisms are not discussed in more detail in this thesis. In the 
following, the term "NET formation" will therefore only be used to describe the 
lytic cell death process of "NETosis" which has been characterised in the 
original publication by Brinkmann et al. (21) and also underpins the majority of 
publications in this area. 
 
1.1.4.1 Signalling mechanisms leading to NETosis 
To date, very little is known about the cellular processes leading to NET 
formation (23). Since the discovery of NETs, there have been a number of 
studies published which found that the formation of extracellular traps does not 
appear to be restricted to neutrophils. Indeed other cell types, such as 
eosinophils and mast cells, have been shown to release extracellular DNA 
complexed with antimicrobial proteins (26,28). In addition, the list of synthetic 
and physiological molecules, as well as microorganisms able to induce NETs is 
growing. Indeed NETs have been found to be induced by Gram-positive and 
Gram-negative bacteria, by fungi, viruses, parasites, LPS, IL-8 and antibodies 
(21,24,29–33) (Table 1-1).  
Additionally, NETs can also be induced by artificial chemical stimuli such as 
Phorbol-12-myristat-13-acetate (PMA), which actives protein kinase C (PKC), or 
the ionophore A23187 (34). The high diversity of stimuli found to induce NET 
formation so far, complicates investigation of shared signalling pathways. 
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Additionally, signalling molecules such as ROS are known to participate in 
several cell death programmes in the same cell (35) further adding to the 
complexity of the process. Currently, the vast majority of stimuli described to 
induce NETosis are dependent on ROS generation by NADPH oxidase. Thus, 
neutrophils from patients with Chronic Granulomatous Disease (CGD), who lack 
this enzyme are not able to form NETs (36). When neutrophils of CGD patients 
are treated with H2O2, however, the pathway downstream of the NADPH 
oxidase is rescued enabling NET formation (24). In addition, MPO which 
converts H2O2 and generates hypohalous acids, was also shown to be essential 
for NET formation (37). Accordingly, hypochlorous acid, one of the products 
generated by MPO, is also able to induce NET release (38). 
Moreover, MPO together with neutrophil elastase (NE), was recently shown to 
be involved in the chromatin decondensation observed during NETosis. Both 
proteins have been shown to enter the nucleus, via as yet an undescribed 
mechanism, whereby NE degrades histones and synergises with MPO driving 
chromatin decondensation independent of its known enzymatic activity 
(39). Furthermore, the autophagy pathway has been proposed to be required 
for NETosis since neutrophils upon stimulation with PMA, develop large 
vacuoles that are reminiscent of autophagosomes (40). This, however, has  
only been shown using a broad range inhibitor of autophagy and has yet to be 
confirmed in further studies (23).  
With regard to signalling pathways upstream of the NADPH oxidase, it has been 
proposed that the Raf-MEK-ERK pathway is implicated in NET formation (41) 
as is Rac2 (42). These observations may be explained by the finding that Rac2-
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Echerichia coli Grinberg et al. 2008
Shigella flexneri Brinkmann et al. 2004
Staphylococcus aureus Fuchs et al. 2007
Plisczek et al. 2010
Berends et al. 2010
Streptococcus pyogenes Mori et al. 2012
Buchanan et al. 2006
HIV-1 Saitoh et al 2012
Influenza viruses Narasaraju et al. 2011
Hemmers et al. 2011
Candida albicans Urban et al. 2009
Papayannopoulos et al. 2010
Aspergillus fumigatus Bruns et al. 2010
Leishmania spp. Guimaraes-Costa et al. 2009
Gabriel et al. 2010
Plasmodium falciparum Baker et al. 2010
PMA Brinkmann et al. 2004
H2O2, IL-8, LPS Fuchs et al. 2007
MSU christals Mitroulis et al.  2011
ANCA antibodies Kessenbrock et al. 2009
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1.1.4.2 The role of PAD4 in NET formation 
Several studies have demonstrated that NETosis also involves activation of the 
enzyme peptidylarginine deiminase 4 (PAD4) (34,43,44). PAD4 belongs to a 
family of five PAD isoforms, whose enzymatic activity leads to citrullination of 
the arginine side chains of proteins. This enzymatic reaction is discussed in 
more detail in chapter 1.3.2.  
PAD4 is the only PAD enzyme with a nuclear localisation signal sequence (45) 
and the importance of this enzyme in NETosis is underlined by the observation 
that neutrophils in PAD4-deficient mice cannot generate NETs (46). Initially it 
was assumed that citrullination was induced by elevated calcium concentrations 
during apoptosis, however this view has now been revised (34). Instead, PAD4 
is known to catalyse the citrullination of histones during NETosis and this 
mechanism is now proposed as an important step in the decondensation of the 
nuclear DNA. Whereas increased supraphysiological calcium concentrations 
are known to be required for full PAD4 activity (47–49), the exact mechanism 
inducing intracellular PAD4 activity still remains to be elucidated.  
Citrullination was initially implicated in an epigenetic form of gene regulation in 
the human HL-60 granulocyte cell line (23,50). Latterly, Neeli et al. were able to 
show citrullinated histone H3 within NET structures in LPS-stimulated 
neutrophils using confocal microscopy (34). In this report, it was demonstrated 
that citrullination of histones H2A, H3 and H4 in neutrophils forming NETs, but 
not during apoptosis, represents a response to inflammatory stimuli. This was 
also confirmed by Wang and coworkers who demonstrated that histone 
hypercitrullination mediates chromatin decondensation and NET formation (44). 
In this study it was proposed that the conversion of certain arginine residues to 
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citrullines by PAD4 leads to a loss of their positive charge and thereby weakens 
the interaction between histones and DNA (23). The elimination of these 
positive charges may enable the unwinding of chromatin and thus, the formation 
of NETs. PAD4 inhibitors, such as Cl-amidine, in contrast, significantly reduced 
histone decondensation and NET formation in response to either Ionomycin or 
Shigella flexneri (44). Moreover, neutrophils from PAD4-/- mice were shown to 
be incapable of forming NETs upon activation by different stimuli, and 
furthermore no hypercitrullination of histone H3 was detectable (46). In vivo, 
these mice exhibited more severe bacterial infections than wildtype mice and 
developed larger lesions when challenged with a S. pyogenes infection (23). 
Citrullination of histone H3 can be induced by a number of bacterial and pro-
inflammatory signalling molecules, including LPS, TNF, f-MLP, lipoteichoic acid 
(LTA), and H2O2 (34,46,51). Importantly, however, not all stimuli discovered to 
induce NETs so far have been clearly demonstrated to also induce histone 
citrullination. The significance of the stimulus PMA for histone citrullination, 
which is also utilised in this thesis, for example, is currently under debate. While 
a very recent publication by Neeli and colleagues has questioned as to whether 
PMA induces histone citrullination (52), several other studies (including those 
presented in this thesis) have observed the opposite (46,53) suggesting that 
factors such as the stimulation time or concentration of PMA, which differed 
between studies, may be important factors. Since the generation of ROS is also 
required for NETosis, it is likely that ROS may also be involved in the initiation 
of PAD4 activation. Indeed, H2O2, for example, is reportedly able to induce 
PAD4-dependent histone citrullination in neutrophils (34). Also, when 
neutrophils are pre-incubated with the NADPH oxidase inhibitor apocynin, LPS-
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induced citrullination of histone H4 is decreased (51). Furthermore, since NE 
was recently found to cleave histones to drive chromatin decondensation during 
NET formation, as described previously (see 1.1.4.1), and PAD4 is known to 
promote relaxation of the chromatin structure, the interaction of both these 
enzymes and their exact role in the chromatin decondensation during NETosis 
remains to be clarified. All proposed mechanisms upstream of PAD4 activation 





Figure 1-1 Role of PAD4 signalling in NETosis 
Decondensation of chromatin during NETosis has been shown to require PAD4 activity (44). 
However, the cellular pathways involved in PAD4 activation and whether they converge upon 
the chromatin decondensation process is currently unknown. Thus far, there are several lines of 
evidence implicating signalling involvement of elevated calcium levels (Ca
2+
), activation of PKC, 






1.1.4.3 NETs and autoimmunity 
Whereas initially NET formation was regarded mainly as an additional defence 
mechanism against extracellular microorganisms, recent work suggests that 
these structures could also serve as putative sources of immuno-stimulatory 
proteins with the potential of inducing autoimmunity and tissue damage (23).  
Indeed neutrophil components are well established as a source of autoantigens 
in a number of autoimmune conditions, primarily in small-vessel vasculitides 
(SVV) and SLE (Figure 1-2). For example, MPO and PR3 were discovered as 
the predominant autoantigens recognised by anti-neutrophil cytoplasmic 
antibodies (ANCA) in SVV  (54). Interestingly, ANCA were also shown to 
activate neutrophils in vitro (55), and are able to induce vasculitis in animal 
models (56,57). 
 
Figure 1-2 Autoantigens present in NETs 
The number of NET proteins reported to be autoantigens in various diseases is quantified and 
reveals that NET autoimmunity is most common in patients with vasculitis, SLE, and RA (Darrah 
et al., 2013). 
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In SLE, an autoimmune syndrome that is characterised by immune complex 
deposition, inflammation and organ damage (58), autoantibodies are primarily 
directed against nucleosomes, but also against neutrophil components such as 
NE, MPO and LL-37 (23,59). In addition, elevated plasma levels of defensins 
(60) and HMGB1 (61) can be detected in SLE patients. 
Thus, neutrophil-associated proteins appear to be targets for autoantibodies in 
patients with systemic autoimmunity, however, the reason why these cells are 
targeted still remains unclear. One possible explanation could be related to 
neutrophil death at sites of inflammation. However, neutrophil death by 
apoptosis generally does not lead to release of intracellular constituents unless 
the mechanisms involved in uptake and removal of these cells are 
compromised (23).  
In this context, the discovery of NETs has provided a new perspective for 
neutrophil research in the above-described autoimmune diseases. Not only, 
because a large proportion of NET components have been found to serve as 
autoantigens in systemic autoimmune diseases, but also because of their 
potential to induce tissue damage. For example, low density granulocytes 
(LDGs), have been isolated from SLE patients and characterised for their 
pathogenic role in endothelial damage and abnormal endothelial differentiation 
leading to accelerated atherosclerosis in SLE (59,62). Furthermore, impaired 
serological DNase-I activity has been reported in 36.1% of patients with SLE, 
leading to impaired degradation of NETs and more active disease (63,64) .  
In vivo, neutrophils releasing NETs have also been identified in kidney biopsies 
from patients with ANCA-positive vasculitis (33). Increased NET formation has 
also been reported in SLE (65). Lande et al. recently described a mechanism by 
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which antimicrobial peptides, such as LL-37, were able to protect self-DNA in 
SLE patients from degradation by nucleases, and, as such, stimulated self-
DNA-induced triggering of TLR9 signalling in plasmacytoid dendritic cells 
(pDCs) (66). In this study, these DNA-protein-complexes induced enhanced 
IFN-alpha synthesis by pDCs, which is in agreement with current models of 
lupus pathogenesis, in which an activation of the type I IFN pathway lowers the 
threshold for autoreactivity of both antigen-presenting and antibody-producing 
cells (23,67,68). 
 
1.2 Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is an inflammatory disease of unknown aetiology with 
a prevalence of 0.5-1.0 % within the adult population worldwide (69,70). Median 
age at disease onset is around 50 years and approximately 2.5 times more 
women are affected than men (71). Although the joints are the main affected 
location in the body, many organs can be involved so RA is generally 
considered a systemic disease. The aetiology and pathogenesis is complex and 
a combination of different genetic, environmental or other factors are known to 
play a role. Monozygotic twins exhibit a concordance rate of 12-30% (72,73) 
and while this provides evidence of the genetic component it also indicates that 
other environmental factors are involved in disease pathogenesis. In recent 
years several studies have shown that early and aggressive treatment with 
disease-modifying anti-rheumatic drugs (DMARDs) and biologic therapies can 
be effective in controlling inflammation and joint destruction (69). Nevertheless, 
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disease control is still insufficient in many RA patients and drug-free remission 
still remains a key future goal (74). 
 
1.2.1 Clinical features and classification 
The classic predominant clinical features of RA include bilaterally symmetric 
painful swelling of the metacarpophalangeal or proximal interphalangeal joints 
of the hands and the wrists (72,75). Many patients develop chronic inflammation 
eventually involving several joints which leads to cartilage damage and bone 
erosion, if not treated aggressively. Several classification criteria for RA were 
described by the American College of Rheumatology (ACR) in 1956 and were 
later revised in 1987 (76). Although these criteria are not used for the diagnosis 
of individual cases in clinical practice, they were developed to select patients for 
clinical trials and also serve as guidance for physicians. Since the criteria from 
1987 were developed based on data from patients with established RA, they 
were not suitable to diagnose patients with early disease who can present with 
very few or even no swollen or tender joints (69). New criteria were therefore 
published in 2010 by the ACR//European League Against Rheumatism 
(EULAR) (77), which were more adapted for early diagnosis and placed greater 
emphasis on serological markers such as the so-called anti-cyclic citrullinated 
peptide (anti-CCP) antibodies (also referred to as anti-citrullinated 







1.2.2 Phases of RA 
Rheumatoid Arthritis appears to develop in several phases (78–80) (Figure 1-3), 
beginning with a pre-clinical phase during which genetic susceptibility and 
environmental factors can lead to the breakdown of tolerance and appearance 
of autoantibodies such as ACPA (see section 1.3.1). These antibodies can be 
detected up to 14 years prior to the onset of disease symptoms (81). 
Additionally, other biomarkers, such as CRP or cytokines (82,83) associated 
with systemic inflammation, have been reported to be abnormal prior to disease 
onset. With regard to the local inflammation in  joints during this pre-clinical 
phase, some studies, using a range of imaging techniques, have reported 
subclinical inflammation in a small number of patients with serum ACPA and 
'arthralgia' but no clinically-evident synovitis (84–86). However the specificity of 
these techniques  is not clear, but most current studies agree on the fact that 
individuals who have RA-specific autoantibodies and joint pain but no clinically 
apparent joint swelling show no signs of synovial inflammation (histologically 
and by imaging) (87,88). Subsequently it has been proposed that autoimmunity 












Figure 1-3 Rheumatoid Arthritis develops in several phases 
The first phase of RA development is characterised by the influence of environmental and 
genetic risk factors and is followed by non-clinically apparent inflammation and appearance of 
autoantibodies. Following these two pre-clinical phases initial symptoms of inflammatory arthritis 
develop (undifferentiated arthritis) and may further progress to the phase of classifiable RA. 
Importantly, not all individuals at risk progress through all of these phases and there are also 
subjects who show resolution of inflammatory arthritis, autoimmunity or inflammation (indicated 




Disease progression from the preclinical phase to RA often involves a phase of 
undifferentiated arthritis. During this phase synovitis either resolves or becomes 
persistent. If joint inflammation becomes chronic the disease often fulfils the 
classification criteria for RA as is described in chapter 1.2.1. Importantly, while 
each of the above described phases are well recognised, the mechanisms of 
transition between these phases are far less well understood. Moreover, not all 
individuals who are at risk of developing RA will progress through all of these 
phases and ultimately develop RA so that the term 'preclinical RA', needs to be 











1.2.3 Synovial biology and pathology 
The primary site of inflammation in RA patients is the synovial membrane, 
which lines the cavity of synovial joints. It consists of an inner intimal lining layer 
and an outer synovial sublining layer, which mostly consists of connective tissue 
and merges with the joint capsule. The intimal lining layer in healthy individuals 
is composed of one or two cell layers of synoviocytes. This layer consists of 
macrophage-like (type A) and fibroblast-like synoviocytes (FLS) (type B) and 
lacks a definite basement membrane and tight junctions (72). Additionally, 
fenestrated capillaries are present through which blood plasma is ultra-filtrated 
to form an interstitial fluid. This fluid, together with additional constituents 
secreted by synoviocytes, forms the synovial fluid (SF). Nutrients and oxygen 
can diffuse through the SF and nourish the avascular cartilage.  
In patients with RA, an increase in synoviocyte numbers and SF volume can be 
observed, and the sublining layer is infiltrated by mononuclear cells including 
macrophages and lymphocytes (predominantly T cells) (4). Type A 
synoviocytes in RA secrete pro-inflammatory cytokines and growth factors, 
which can induce FLS to produce cytokines such as IL-6 and matrix 
metalloproteinases (MMPs) (90). RA FLS show aggressive tumour-like features 
such as loss of contact inhibition and anchorage independence, and can play a 
role in cartilage destruction (91). The lymphocyte infiltration shows different 
patterns of distribution, which varies from a diffuse infiltrate to discrete focal 
aggregates, particularly around blood vessels (Figure 1-4). Sometimes these 
focal aggregates contain clusters of follicular dendritic cells (FDCs) within 
structures resembling germinal centres (92), and synovial-vessel endothelial 
cells, which are transformed into high endothelial venules. Although focal 
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lymphoid aggregates seem to be associated with a more severe synovial and 
systemic inflammation in some studies, the function of these structures and the 
relation to a specific clinical phenotype is currently the subject of debate (93–
96). 
 
Importantly, the histological changes of the synovium described above are not 
specific for RA but can also be observed in other forms of persistent 
inflammatory arthritides irrespective of the diagnosis (97). In early RA, however, 
it has been proposed that the degree and pattern of vascularity may be used to 
distinguish RA from other inflammatory arthritides (97,98). Additionally, the 
formation of a destructive synovial tissue at the cartilage-bone interface, the so-
called pannus, is regarded as a characteristic feature of erosive RA (71,97). 
 
Figure 1-4 Histopathologic appearance of the RA synovium 
Different patterns of leukocyte infiltration in the RA synovium can be observed, ranging 
from scarce infiltration (left), diffuse infiltration (centre) to the formation of focal 
lymphocytic aggregates (right). Arrows indicate thickened synovial lining layer and 
stars indicate blood vessels in the sublining layer. Images courtesy of Dr. Dagmar 
Scheel-Toellner (University of Birmingham). 
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The pannus consists of mostly fibroblasts, macrophages and osteoclasts, which 
express high levels of proteases and invade cartilage and bone (99). At the 
pannus-cartilage junction, the site of active tissue damage, an accumulation of 
polymorphonuclear granulocytes (PMNs) can be seen, suggesting a role in 
tissue destruction (see chapter 1.2.4). 
 
1.2.4 Role of neutrophils in RA 
The early stages of most inflammatory responses are characterised by the 
influx of neutrophils into the tissue in which the response is triggered (23). 
Although in a very small sample of RA patients has it been suggested, that in 
the earliest stages of synovial inflammation, neutrophils may predominate the 
infiltrate (100). Furthermore only relatively low numbers of these cells can be 
found in the chronically inflamed synovium of RA patients (23,101). Primarily, 
neutrophils are present in the SF but can also be observed at the 
pannus/cartilage interface (102,103). To understand the role of neutrophils in 
the complex microenvironment of the inflamed joint, it is important to consider 
the different dynamics which regulate the cell pool of neutrophils and allow the 
accumulation of these cells in the inflamed joints at different phases of 
inflammation. Mature neutrophils are considered to be terminally differentiated 
cells, hence they do not divide and show only a low level of de novo protein 
synthesis. After their recruitment into the joints of RA patients, neutrophils can 
be removed from the joints through different cell death mechanisms such as 
apoptosis (35). On the other hand, neutrophils can contribute to the 
enlargement of the cell pool in the joints by their prolonged survival (Figure 
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1-5A). In patients with early RA, synovial neutrophils show significantly lower 
levels of apoptosis compared with patients with other persistent forms of 
arthritis or a self-limited disease course (104). This may relate to high levels of 
anti-apoptotic cytokines such as GM-CSF and G-CSF (105). Additionally, 
neutrophils are also able to secrete IL-8, which creates a "feed-forward" 
response that drives further recruitment of neutrophils from the circulation. 
Interestingly, recent in vitro (106) and in vivo studies using mouse (107) and 
zebrafish models (108) have shown that neutrophils may be able to migrate 
from peripheral organs back into the bloodstream through "reverse migration". 
Although the relevance of this mechanism in humans, and particularly in 
inflamed joints, would need to be determined, it represents one possible 
mechanism for neutrophils to escape cell death within the joints and thus an 
additional factor how the neutrophil cell pool in the inflamed joint may be 
regulated and inflammation modulated (Figure 1-5A). 
 
Once neutrophils have been recruited to the joints, they can interact with other 
immune cells and regulate inflammation in the joints in several ways (Figure 
1-5B). Neutrophils from the peripheral blood of RA patients are primed for the 
generation of ROS (109) and neutrophils isolated from RA SF show evidence of 
enhanced intracellular ROS production in vivo (110). Due to the presence of 
aggregates of immunoglobulins such as RF in the SF or on the surface of the 
joint, neutrophils can be activated through the engagement of Fcγ receptors on 
the surface of the neutrophil (Figure 1-5B). Whereas soluble immune 
complexes from RA SF were shown to induce extracellular secretion of ROS 
and proteases through FcγRIIIb, generation of intracellular ROS is mediated 
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through FcγRIIa (111,112). In addition to ROS, neutrophils are able to release 
other substances with cytotoxic potential. Neutrophil granular enzymes such as 
gelatinase (113,114) and NE (115) are likely to promote cartilage damage, 
however, no in situ demonstration of direct neutrophil attack on cartilage has yet 
been demonstrated (72). Granule proteases cannot only activate or deactivate 
cytokines (116) but also cleave complement proteins and generate chemotactic 
activity (72). High levels of these neutrophil proteases could overwhelm the 
antiprotease protective mechanisms and also lead to tissue damage.  
RA SF neutrophils have also been demonstrated to release a range of 
cytokines. Aside from IL-8, neutrophils can shed the B cell stimulating cytokine 
BLyS or BAFF from their surface following stimulation with TNF-α (117). 
Additionally, neutrophils express many of the cytokines produced by 
macrophages such as IFN-α and BAFF (118). Since neutrophils vastly 
outnumber macrophages in the RA synovial fluid, it is likely that they 
considerably contribute to the cytokines present in the SF. Interestingly, 
neutrophils isolated from RA SF have also been demonstrated to be able to 
transdifferentiate into MHC class II-expressing antigen presenting cells (APCs) 
(119). These cells can present antigens to T cells in an MHC class II restricted 
manner (18,119). Since neutrophils express different proteases compared with 
other APCs it is possible that MHC-II+ neutrophils could play a particular role in 
antigen presentation in the RA SF. Recently, it has also been demonstrated that 
neutrophils from the peripheral blood and SF of RA patients show enhanced 
rate of NETosis compared with neutrophils from healthy individuals and that 
NETs produced by activated neutrophils can augment inflammatory responses 
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in fibroblasts. These data suggest they may play an important role in the 
perpetuation of pathogenic mechanisms (120). 
Although data from animal models of RA are difficult to extrapolate they may 
provide an important insight into the mechanisms of human disease 
pathogenesis. Both in the Collagen-induced arthritis (CIA) model and in the 
K/BxN murine autoantibody-mediated model of arthritis (described in more 
detail in Chapter 1.3.5.4) neutrophils are required for full expression of the 
disease (72). Depletion of neutrophils in these models results either in a 
significantly decreased severity or a complete abrogation of arthritis (121,122). 
Additionally, antibody blockade or knockout of key neutrophil signalling 
receptors such as the C5aR (123), FcγR (124) or leukotriene B4 receptors (125) 






Figure 1-5 Neutrophils in the joints of RA patients 
(A) Regulation of the neutrophil cell pool in RA joints by mechanisms including 
neutrophil recruitment, cell death, prolonged survival and possible exit through reverse 
migration. Cell numbers may alter over time depending on the phase of the 
inflammatory response. (B) Neutrophils can modulate inflammation in several ways. 
Secretion of cytokines is important for the recruitment of other inflammatory cells into 
the joints as well as activation of other immune cells. Release of granule enzymes can 
activate or deactivate cytokines but can also lead to tissue destruction. Generation of 
reactive oxygen species (ROS) can, for example, occur following stimulation by 
immune complexes, which are taken up through Fc receptors. Finally, increased 
expression of MHC class II molecules on SF neutrophils may enable presentation of 


























1.3 Autoimmunity in Rheumatoid Arthritis 
At the turn of the 20th century Paul Ehrlich proposed the threat of an 
organism´s uncontrolled immune system, potentially causing a condition called 
“horror autotoxicus” in which an immune response is evoked against self (126). 
Approximately 50 years later, studies by Rose and Roitt for the first time 
demonstrated the presence of an autoimmune component in Hashimoto’s 
thyroiditis (127,128) and Frank McFarlane Burnet published his hypothesis 
regarding “the forbidden clone” in 1949 (129), in which he proposed that 
autoimmune diseases develop from the escape of self-reactive lymphocyte 
clones which should have been deleted through normal immune tolerance 
mechanisms. Further research followed and finally laid the foundation for the 
current, more complex, understanding that autoreactivity is indeed present even 
in a healthy organism and is essential for the establishment of normal immune 
system homeostasis during lymphocyte selection. According to this view 
autoreactive T and B cells are negatively selected and deleted in primary 
lymphoid organs during maturation while lymphocytes that are non-reactive to 
self survive (central tolerance) (130). Autoreactive lymphocytes, which escape 
deletion in primary lymphoid organs, can still be suppressed in the periphery by 
mechanisms of peripheral tolerance. Importantly, tolerance mechanisms are 
mediated through the engagement of antigenic receptors (BCR and TCR) and 
co-stimulatory signals (largely provided by cells of the innate immune system) 
and are controlled by the developmental stage of lymphocytes as well as 
additional modulating factors including cytokines (131). It is therefore rather the 
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transformation from subclinical self-reactivity to pathogenic autoimmunity that is 
believed to play an important role in clinical practice (132). 
 
There are over 80 autoimmune diseases known to date which affect about 6% 
of the world population (133) and a wide range of these conditions are 
encompassed by the medical subspecialty of rheumatology. Although the 
prevalence of autoimmune diseases in general is low, their effects on mortality 
and morbidity are high and the incidence for some of these conditions is 
reported to be increasing (134–137). Altogether, autoimmune diseases are 
currently the third-largest clinical burden after cardiovascular diseases and 
cancer (138). 
There are currently no universally accepted criteria for the classification of 
autoimmune diseases. One possibility is to categorise them based on the site-
specificity of their clinicopathology (131). According to this categorisation 
diseases such as Hashimoto´s thyroiditis, idiopathic thrombocytopenic purpura 
or Multiple Sclerosis are termed organ-specific and are characterised by an 
immune response against specific cells or tissues. End-organ damage in organ-
specific autoimmune diseases can be mediated by antibodies and/or T cells. In 
comparison, diseases such as RA, SLE or primary Sjögren´s syndrome belong 
to the systemic category where the immune system targets ubiquitously 
expressed autoantigens. This type of condition typically leads to tissue 
destruction mediated by autoantibodies and, less commonly, by T cells (132).  
Additionally, autoimmune diseases can share symptoms with so-called auto-
inflammatory syndromes. Although autoinflammatory syndromes are typically 
only mediated through the innate arm of the immune system and are in most 
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cases rare monogenic disorders, they could also be considered as one end of a 
broader definition of autoimmunity. In this context, McGonagle and McDermott 
proposed in 2006 that the disease categories “autoimmune” and 
“autoinflammatory” should not be seen as completely separate (139). Instead, 
they should be regarded as a part of a broad spectrum of diseases, ranging 
from autoimmune to autoinflammatory. Based on this idea the place on the 
spectrum of a particular disorder would therefore depend on the relative 
importance of the innate versus the adaptive immune system in disease 
pathogenesis (140).  
In general, autoimmune diseases are defined by the presence of autoreactive B 
and T cells, which leads to tissue injury. However, not only has autoreactivity 
been found to play a role in autoimmune diseases but also target-organ 
vulnerability (141,142). It is thought that genetic factors governing specific organ 
vulnerability differ from those governing autoreactivity (141–143). This means 
that individuals may present with different autoimmune diseases despite sharing 
the same pathways promoting autoreactivity. For example, while nephritis in the 
two diseases SLE and Goodpasture syndrome differs in the nature of the 
inciting antibodies and the localisation of the immune deposits, animal models 
of the diseases have shown that a significant fraction of the differentially 
expressed genes that distinguish the nephritis-sensitive strains from the control 
strains belong to the kallikrein gene family (142). Kallikreins are involved in the 
regulation of inflammation, apoptosis, redox balance, fibrosis and local blood 
pressure within the kidneys and possibly impact both diseases concordantly in 




The clustering of autoimmune disorders in families suggests that the genetic 
background has an influence on the development of autoimmunity. Genome-
wide association studies (GWAS) have recently identified a large number of 
genetic associations with human autoimmune diseases. In particular, variations 
in the MHC locus are linked to most autoimmune diseases studied so far (130). 
In addition, monogenic primary immunodeficiencies, some of which are 
associated with autoimmunity (145), and animal models, have been useful in 
exploring a wide range of defects in tolerance mechanisms (131). One example 
of a defect in central tolerance leading to autoimmunity, is the mutation of the 
transcription factor AIRE (autoimmune regulator), which causes a rare disease 
in humans, the autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED) and leads to the destruction of multiple endocrine organs 
(146). Another very common primary immunodeficiency is selective IgA 
deficiency, which not only results in an increased number of infections in 
affected individuals but is also associated with several autoimmune diseases 
(147). Nevertheless, the aetiology of most autoimmune diseases is believed to 
be more complex. Current evidence suggests that the breakdown of central 
and/or peripheral tolerance is influenced not only by genetic but also 
environmental and gender-specific factors.   
 
In the following sections, the mechanisms of autoimmunity in RA patients will be 
described with a particular emphasis on autoimmunity against antigens which 
have been post-translationally modified by citrullination. Additionally, unresolved 





1.3.1 Autoantibodies in RA 
Throughout history, Rheumatoid Arthritis has been considered to be a chronic 
inflammatory disease. The discovery of autoantibodies in 1940 demonstrated 
an autoimmune component in RA pathogenesis. Eric Waaler initially observed 
that sera from patients with RA are able to agglutinate sheep red blood cells 
sensitised by subagglutinating doses of rabbit antibodies (148) and this 
phenomenon led to the discovery of autoantibodies now known as rheumatoid 
factor (RF), and their specificity for the Fc fragment of the IgG heavy chain. 
Rheumatoid factor can be detected in up to 50% of patients with early RA, 
however, sensitivity increases with long-standing disease to between 60–80% 
(149). These antibodies can be of any isotype, but IgM-RF is not only the most 
frequently identified isotype but also the one exhibiting the highest sensitivity 
subsequent to disease onset (150). Prior to disease onset, IgA-RF has been 
shown to have the highest sensitivity of the rheumatoid factors (151). RFs are 
not specific for RA and can also be detected in up to 15% of healthy individuals 
and in patients with other autoimmune conditions (152). IgM-RFs in healthy 
individuals have been shown to be produced by natural CD5-expressing B cells 
and these antibodies are polyreactive, at low titre and of low affinity (153,154). 
Interestingly, whereas IgM-RF levels increase with age, IgG-RF levels decline in 
the elderly (155). IgM-RFs in healthy individuals also exhibit a low ratio of 
replacement to silent mutations in their complementarity determining regions 
(CDRs) (156) suggesting mechanisms preventing affinity maturation. Potentially 
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beneficial effects of RFs in healthy individuals include binding to immune 
complexes (ICs), leading to complement fixation and an enhanced clearance of 
ICs (157,158). Nevertheless, the presence of RF in healthy individuals is 
associated with up to 26-fold higher risk of developing RA (159). In RA patients 
RFs can undergo somatic hypermutation and isotype switching (160), however, 
at the same time also highly conserved IgM-RFs are present (161). It therefore 
remains unclear as to how exactly RF antibodies from RA patients differ from 
RFs produced in healthy individuals and whether or not they depend on T cell 
help (162). Interestingly, IgM-RFs can be detected before the onset of RA and, 
at relatively high levels, are associated with more severe joint damage (81,163). 
Conversely, RF levels were shown to decrease with effective therapy (164). RF 
has therefore remained a component of the classification criteria for RA (77) 
and RF titres are part of routine clinical assessment  (165). 
 
In addition to RFs a variety of other autoantibodies exist in RA patients, 
however,  most of them are not specific for RA (166) and some are directed 
against nuclear antigens. For example, anti-heterogeneous nuclear 
ribonucleoprotein (hnRNP) A2 (anti-RA33) is detected in 30-40% of RA patients 
and may have a diagnostic potential in early inflammatory joint disease (167). 
Other types of autoantibodies in RA are the anticollagen antibodies, which 
appear to play a more important role in experimental arthritis models rather than 
in human RA (165,166). 
In the past two decades, the anti-citrullinated protein antibodies (ACPA), a new 
group of autoantibodies has received a considerable amount of attention. These 
autoantibodies were demonstrated to be more specific for RA than RF (168–
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170).  In contrast to RF, ACPA only exist in about 2% of healthy individuals and 
are also very rare in other inflammatory conditions (171). Originally, these 
antibodies were described as “anti-perinuclear factor antibodies” or “anti-keratin 
antibodies” by Guy Serre’s group in France and the target of these antibodies 
was initially shown to be filaggrin (170,172). At that time, however, it was not 
known that these antibodies recognise specifically citrulline residues. Notably in 
1998, did Walther van Venrooij’s group in the Netherlands demonstrate that 
antibodies in the sera of RA patients recognise filaggrin-derived peptides, which 
have been citrullinated at their arginine residues (169). In the following years, it 
was soon understood that ACPA display strong cross-reactivity and react not 
only with one specific target antigen but with a wide range of citrullinated 
autoantigens, of which vimentin (173), α-enolase (174), fibrinogen (175,176) 
and type II collagen (177) are the best characterised. Assays to determine the 
ACPA status of patients in clinical practice were therefore developed by 
screening libraries of citrulline-containing peptides for reactivity with RA sera to 
identify those yielding the highest sensitivity and specificity (178). Soon after the 
development of the first assay using artificial cyclic citrullinated peptides (CCP), 
the first commercial version of this test, the CCP2 assay, became available in 
2002 and was followed by the third-generation CCP3 assay in 2010 (179). The 
CCP assay was included in the 2010 revised classification criteria for RA (77). 
All of these assays slightly differ in terms of specificity and sensitivity, and 
although the identity of the peptides used in these assays remains a 
commercial secret, it is likely that they are of non-physiologic origin (178). For 
this reason, despite their usefulness in clinical practice, CCP assays do not 
provide insight into real physiologic antigenic targets of ACPA. Future studies 
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are needed to study the immune response against citrullinated proteins in more 
detail to be able to understand the fine specificity of the anti-citrulline 
autoimmune response in RA patients. Current knowledge regarding ACPA fine 
specificity, the citrullinated targets and the role that ACPA may play in the 
pathogenesis of RA patients will be discussed in the subsequent sections. 
 
Recently an additional autoantibody system, the so-called anti-carbamylated 
(anti-CarP) antibodies, has been discovered (180). Carbamylated proteins are 
generated through post-translational modification (PTM) of lysine residues into 
homocitrulline. Interestingly, the structure of homocitrulline highly resembles 
that of the citrulline residue. Surprisingly, however, it was reported that most 
ACPA do not react with homocitrulline residues (181,182) and reactivity can be 
detected in both ACPA positive and ACPA negative RA patients with 13-20% of 
ACPA negative RA patient sera reacting with carbamylated proteins (180,182). 
Interestingly, anti-CarP antibodies are associated with a higher rate of joint 
damage, which was most prominent in ACPA negative patients (181). This new 
antibody system may therefore represent an additional disease entity and could 
potentially be used to better characterise ACPA-negative patients. 
Nevertheless, many questions with regard to the anti-CarP response in RA 
patients still remain to be answered in order to understand the relevance of this 




1.3.2 Citrullination and ACPA generation 
1.3.2.1 Physiological role of citrullination 
ACPA in RA patients are directed against protein post-translational 
modifications termed citrullination (or deimination). This process is a hydrolytic 
enzymatic reaction catalysed by Ca2+- dependent peptidylarginine deiminases 
(PADs) and leads to the conversion of the positively charged peptidylarginine 
into the neutral peptidylcitrulline with ammonia released as a reaction by-
product (Figure 1-6). The enzymatic reaction results in an increase in molecular 
mass of less than 1 Da (183). Importantly, the loss of a positive charge per 
citrulline also reduces the net charge of the protein and thus has consequences 




Figure 1-6 Enzymatic conversion of peptidylarginine into peptidylcitrulline 
Citrullination is catalysed by the family of peptidylarginine deiminase enzymes (PADs). The 
guanidino group of the positively charged arginine residue is hydrolysed yielding a neutral 




Citrullination is implicated in several physiologic processes such as gene 
regulation or the terminal differentiation of keratinocytes in the skin. There are 
five mammalian isoenzymes of PADs that are highly homologous and 
functionally similar, but differ in their expression pattern throughout organ 
systems and cell types (23,185,186). Whereas PADs 1, 3, and 6 are primarily 
expressed in the skin and female reproductive organs (185,187), PAD2 
expression can be detected in a wide range of tissues including the central 
nervous system and skeletal muscle (185). PAD4 expression is found in 
granulocytes, as well as in some cancerous cell lines and tumours (187,188). 
The human PAD4 gene was originally named PAD5, but when the close 
similarity to murine PAD4 was observed, it was renamed PAD4. Subsequently 
there is no human PAD5 isoform, and when another PAD isoform was identified 
it was named PAD6 to avoid confusion with this previous work (185,186,189). 
Since PADs 1, 2, and 4 are the only PADs expressed in cells of the 
hematopoietic lineage, they are of special immunological interest.  
Importantly, several in vitro studies suggest that theoretically all arginine 
residues can be citrullinated. Nevertheless, different kinetic parameters were 
determined depending on the primary and secondary structure of the substrates 
(184). Interestingly, in vitro studies have shown that a high degree of 
citrullination (over 10% of arginine residues in a given protein) can denature 
proteins (190). Whether this also takes place in vivo, is not yet known. It can be 
assumed that citrullination causes changes in the protein structure which results 
in a looser, more open configuration (190). In the skin, for example, it was 
shown that citrullination of (pro)filaggrin is essential for its degradation by the 
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protease calpain, which enables aggregation of keratin filaments into an 
organised matrix (184,185). Further citrullination is also believed to facilitate 
degradation of filaggrin to free amino acids (191), which are a component of the 
so-called ‘Natural Moisturising Factor’ responsible for the hydration of the 
stratum corneum (192). Thus citrullination is believed to change the protein 
structure in a way that makes it more susceptible to proteolysis, a process that 
was also recently shown to play a role in the degradation of the myelin basic 
protein (MBP) by cathepsin D in the brain (185,193). Here citrullination was 
shown to open up the structure of MBP so that Phe-Phe peptide bonds within 
the protein could be exposed and targeted by cathepsin D five-times faster than 
the native form of the protein (184).  
Another process in healthy individuals where citrullination plays an important 
role is gene regulation. Cuthbert and colleagues proposed a model in which 
citrullination of arginines in histones antagonises arginine methylation and 
thereby represses transcription (194). Since PADs cannot only convert arginine 
residues but also monomethylated arginine residues into citrulline (50), only 
dimethylation of arginine residues was shown to prevent citrullination and 
maintain transcriptional activation.  
 
1.3.2.2 Regulation of PAD activity 
PADs require high calcium concentrations for their activity (184) and treatment 
of cells with calcium ionophores can therefore induce the generation of 
citrullinated residues in proteins (195,196). Nevertheless, little is known about 
the physiologic stimuli capable of inducing calcium-dependent PAD activity 
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(186). Interestingly, in vitro enzymatic assays measuring PAD activity have 
demonstrated that calcium concentrations that are required for half maximal 
activity, are between 0.15-0.5 mM (48,197,198), which is much higher than 
physiological calcium concentrations. This therefore suggests there must be an 
additional regulatory mechanism present in vivo to either raise calcium levels to 
above normal levels or lower the calcium dependence of PADs. 
Research into the mechanism of regulation of PAD4 activity revealed that PADs 
also auto-citrullinate upon activation by calcium. Although Andrade et al. 
reported that citrullination of a cluster of arginines around the active site cleft 
can lead to inactivation of the enzyme (199), subsequent studies from 
Thompson and colleagues argued that auto-citrullination does not affect its 
enzymatic activity (200).  
On activation, binding of Ca2+ moves the key catalytic thiolate anion C645 
residue to the enzyme active site (47), which is essential for PAD4 activity 
(201). Since PADs may represent potential therapeutic targets for a variety of 
inflammatory diseases including RA, inhibitors are being developed to prevent 
PAD activity. For example, F- and Cl-amidine covalently bind to C645 and act 
as irreversible PAD inhibitors (201). The efficacy of Cl-amidine in vivo has been 
demonstrated in the CIA model in rodents as it was able to significantly reduce 
disease severity, by up to 55% (202). Interestingly, however, it did not show any 
effect in the collagen antibody-induced arthritis (CAIA), which is a model 
generally used to study the effector phase of RA pathogenesis (202).  
Furthermore, a recent study suggests that different PAD isoenzymes have 
different substrate specificities (203), which may be essential for the 
pathogenesis of the inflammatory conditions mentioned above including RA, 
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since only one of the PAD enzymes could be essential for the citrullination of 
target proteins. The development of PAD-selective inhibitors may therefore 
prove to be more useful than pan-PAD inhibitors in the future for disease 
treatment. 
 
1.3.3 Variability in clinical observations in RA 
RA is a complex and heterogeneous disease. Patients often vary in disease 
course, have diverse extra-articular manifestations, experience different 
patterns of disease flares, remissions, and response to treatment. Nevertheless, 
in recent years research of the anti-citrulline immune response in RA patients 
has provided a more comprehensive picture regarding the role of possible 
environmental triggers and susceptibility genes in this disease compared to 
many other autoimmune diseases. Based on the presence of ACPA it has been 
proposed to divide RA into separate subsets of disease: ACPA positive and 
ACPA negative RA (168). Clinically, ACPA positive patients generally develop a 
considerably more severe disease course with more radiological joint damage 
than ACPA negative patients, irrespective of treatment provided (204,205). 
Also, ACPA positive RA patients were demonstrated to show differences in 
disease risk factors. Most of the HLA-DR alleles that confer susceptibility to RA 
(particularly HLA-DRB1*) have a common amino acid motif – named the shared 
epitope (SE) – at positions 70–74 in the third hypervariable region of the DRβ1 
chain of the HLA-DR molecule (206). According to the SE hypothesis the SE 
motif (QKRAA, QRRAA, or RRRAA) allows the presentation of an arthritogenic 
peptide to T cells and is thus directly involved in the RA pathogenesis (206). 
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The second most important susceptibility gene, PTPN22, identified in 2005 
(207), codes for a tyrosine phosphatase.  A single nucleotide polymorphism in 
this gene was shown to be involved in deregulation of T cell and B cell 
signalling in RA and  also in other autoimmune diseases (207–209). 
Interestingly, both the above mentioned risk alleles are associated with the 
ACPA positive but not the ACPA negative RA subset (210,211). APCA negative 
RA, in contrast, is associated with other genes such as HLA-DRB1*03 
(212,213). 
Among autoimmune diseases, RA is well-known for the thorough 
characterisation of the role of smoking as an environmental risk factor and 
constitutes as a risk factor for the ACPA positive RA subset (214). Furthermore, 
several studies have shown that this risk factor interacts with the HLA-DR SE 
genes (209,214,215) supporting the possible nature of an MHC class II-
dependent immune response. In this context, using the large case-controlled 
Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) cohort, 
Lundberg and colleagues have recently demonstrated that HLA-DRB1 SE, 
PTPN22 and smoking are associated with the presence of specific ACPA 
reactivities rather than overall anti-CCP levels (216). The strongest association 
of HLA-DRB1 SE, PTPN22 and smoking was identified for the RA subset which 
was defined by the combined presence of antibodies to citrullinated 
autoantigens α-enolase and vimentin.  
On the basis of these studies on environmental and genetic associations, it is 
therefore considered that the two forms of ACPA positive and ACPA negative 
RA are likely to exhibit overlapping but individually distinctive pathogenic 




1.3.4 T and B cell responses to citrullinated proteins 
The current view of the critical role of both T and B cells in the pathogenesis of 
RA is supported by the observations that i) the ST of RA patients is strongly 
infiltrated by T and B cells, ii) defined HLA-DR alleles are associated with 
disease, and iii) in many patients disease specific circulating autoantibodies can 
be detected.  
In RA synovium predominantly CD45RO+ expressing CD4+ as well as CD8+ T 
cells  cells with characteristics of memory T cells can be detected (218,219). 
Although T cells have long been thought to be major drivers of disease, their 
relevance and contribution to RA pathogenesis has recently been challenged 
(220). In RA, T cells generally display an activated phenotype with relatively 
high expression of HLA-DR, CD27, CD69 and CD28, their proliferation and 
cytokine secretion in synovial T cells are usually less pronounced compared 
with autologous peripheral blood T cells from the same patient (72). In this 
context it has also been suggested that synovial T cells functionally resemble 
resting T cells that have been activated by cytokines rather than by antigen 
(221). Furthermore, the memory cell phenotype of synovial T cells suggests the 
presence of already mature T cells that have been previously stimulated 
elsewhere and recruited to the joints as opposed to the stimulation and 
maturation of these cells inside the joints (72).  
Synovial T cells have been shown to have a restricted T cell repertoire in ACPA 
positive RA patients compared with OA and SpA patients (222). In a recent 
study using peptide:TCR tetramers and looking at proliferative responses, Snir 
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and colleagues  demonstrated enhanced reactivity to a citrullinated vimentin 
peptide in HLA-DRB1*0401 SE positive patients compared with healthy controls 
(223). The binding of this HLA-DR*0401 tetramer loaded with an autoantigenic 
citrullinated vimentin demonstrated the presence of autoreactive CD4+ T cells 
both in RA patients and healthy controls but with the difference that RA patients 
had significantly increased pro-inflammatory responses following stimulation. In 
a more recent study, crystal structures and peptide elution experiments 
demonstrated that whereas citrullinated peptides can be bound by RA-
predisposing HLA-DRB1 proteins and RA non-associated HLA-DRB1*04:02 
protein, only RA-predisposing HLA-DRB1 molecules could not accommodate 
arginine peptide side chains in the P4 pocket of the molecules (224). These 
data therefore suggest that the absence of presentation of non-citrullinated 
peptides may be critical in RA pathogenesis and suggest a possible altered 
negative selection of T cells in the thymus dependent on the DR4 allotype. 
Nevertheless, many questions regarding the importance of autoreactive T cells 
in RA still remain to be answered. For example, despite extensive research it is 
still not clear whether the high numbers of T cells in the synovium are a result of 
clonal expansion to a specific antigen (225,226). Furthermore, limited efficacy of 
T cell-depleting therapies (227) may reflect the need to look at different T cell 
subsets in RA in more detail to avoid simultaneous deletion of both effector T 
cells as well as immune-suppressing regulatory T cells. 
 
To better understand the development of autoimmunity in RA, it is important to 
also investigate the role of B cells. B cells and plasma cells constitute only 
about 5% of cells in most RA synovia compared with 30-50% T cells (72) and 
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different studies investigating the significance of B cell infiltration with regard to 
disease prognosis have reported conflicting results (95,228,229). Nevertheless, 
the success of the B cell depleting therapy using anti-CD20 antibody 
(rituximab), has focussed much attention on the contribution of B cells to RA 
pathogenesis. In particular, autoantibody production and differentiation into 
plasma cells have been intensely studied. As described in section 1.3.1, a 
growing number of autoantibodies generated towards a variety of antigens have 
been identified in recent years. Importantly, however, mechanisms that initiate 
and maintain autoantibodies may not only be different from antibody responses 
against recall antigens (for instance following vaccination) but may also differ 
between different autoantibody systems in RA (179). Rheumatoid factor, for 
example, which consists predominantly of non-switched IgM antibodies, is 
suggested to be generated outside of germinal centres upon TLR signalling 
and, at least initially, independent of T cell help (230). At the same time, 
however, some RF clones from RA patients have been identified to be 
somatically mutated compared with those from healthy subjects (161). Since 
there is only minimal evidence for extrafollicular responses in human 
autoimmune disease (231), T cell dependent germinal centre responses are 
more likely to be involved in the generation of pathogenic autoantibodies (232). 
Nevertheless, the role of T cells for the induction of RFs still remains unclear 
and differences between RA patients and healthy individuals cannot be 
excluded.  
In contrast with RF, ACPA are strongly associated with HLA-DR alleles (216) 
and there is a growing body of data showing immune reactions against 
citrullinated autoantigens and other antigens locally inside joints of RA patients 
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(73,233). In comparison with ACPA negative RA patients (234), the ST 
architecture of ACPA positive RA patients is primarily characterised by a 
generally higher lymphocyte infiltrate and lower degree of fibrosis (234). 
Furthermore, it has been demonstrated that variable region genes coding for 
ACPA in joint-derived B cells are hyper-mutated. If these mutations were 
reverted back to the corresponding germline sequences autoantibody binding 
was nullified (235) suggesting that B cells producing these antibodies were 
most likely driven toward differentiation by local T cells in germinal centres. 
Given these data, however, it still remains elusive why ACPA IgG show a much 
lower avidity when compared with normal protective antibody responses against 
pathogens in the same patients (236). If B cells undergo affinity maturation and 
isotype switching in germinal centres, the avidity of immunoglobulins expressed 
by these B cell clones would normally be expected to increase due to the 
competition for antigens bound on the surface of FDCs. ACPA avidity in 
individual RA patients, therefore suggests different regulation mechanisms of 
autoantibody responses, which still remain to be elucidated (179). 
In addition to antibody production, it should not be overlooked that B cells are 
efficient APCs and also able to release cytokines during immune responses. 
For example, Flores-Borja and colleagues have shown that 
CD19+CD24hiCD38hi regulatory B cells in healthy individuals can inhibit naïve T 
cell differentiation into Th1 and Th17 effector T cells in vitro while converting 
CD4+CD25- into regulatory T cells, in part through the production of IL-10 (237). 
In RA patients, numbers of regulatory B cells were found to be reduced in the 
peripheral blood and no suppressive Treg cells could be induced by these 
regulatory B cells. This study therefore indicates that CD19+CD24hiCD38hi 
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regulatory B cells in RA patients may fail to prevent autoreactive responses, 
which could finally result in autoimmunity (237). 
Furthermore, work from our group has shown that B cells in the RA synovium 
are capable of producing pro-inflammatory and bone-destructive cytokines 
including RANKL (118). RANKL-producing B cells in RA synovial tissue and 
fluid were identified as belonging to a distinct subset of B cells defined by 
expression of the transmembrane protein FcRL4 (238) suggesting that FcRL4+ 
B cells are likely to represent a pathogenic B cell subset in RA. 
 
1.3.5 Role of ACPA in the pathogenesis of RA 
Recent data have contributed considerably to our understanding of APCA in the 
pathogenesis of RA. Nevertheless, the sequence of events involved in the 
different stages of disease pathogenesis still remains unclear. Several currently 
discussed concepts are detailed below:  
1.3.5.1  The 'second hit' hypothesis 
As previously described, citrullination is a physiological process of post-
translational modification of proteins, but hyper- or hypo-citrullination can also 
play a role in   pathobiological settings distinct from RA. An increased amount of 
MBP or histone H3 protein citrullination has been observed in the brain of 
patients with Multiple Sclerosis (193,239,240) or Alzheimer’s disease (241), 
while a reduced amount of citrullination of cytokeratin K1 in the epidermis was 
reported to be pathological in Psoriasis (242). Furthermore, citrullination of 
proteins such as α-enolase (243) and PAD4 overexpression (244) were 
observed in a number of different tumours. In RA, the presence of citrullinated 
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proteins was initially considered to be specific to the synovium (245) and 
generated a great deal of interest in this PTM. In this context, Suzuki and 
colleagues also found that one haplotype of PAD4 was associated with 
increased susceptibility for RA due to increased PAD4 mRNA stability (246), 
which could explain a possible increased citrullination of proteins. However, 
thus far these findings have not been repeated in Caucasian populations.  
The presence of PAD isoenzymes and citrullinated proteins in the inflamed ST 
and SF of RA patients has been well characterised (175,247–249). PAD2 and 
PAD4 expression in the synovium was found in close proximity to citrullinated 
fibrin deposits and correlated with the inflammatory cell infiltration (250). 
However, soon after it was recognised that citrullination is an inflammation-
dependent process and also present in non-rheumatoid arthritis (251,252), 
attention focussed on the role of the highly specific ACPA antibodies which can 
be detected in approximately 60-70% of RA patients (168,171,253). ACPA 
levels are elevated in SF compared with the peripheral blood, and ACPA 
production was described in the inflamed RA joint (254) suggesting a local, 
antigen-driven B cell response at the site of inflammation. Similar to 
autoantibodies in many other autoimmune diseases, ACPA emerge several 
years before the onset of disease (81,151) and very few RA patients develop 
ACPA after the start of their symptoms (204,255). As several studies also 
suggest the absence of synovial inflammation in ACPA positive individuals with 
no clinically apparent joint swelling, the concept has been proposed that the 
initiating event leading to ACPA production is more likely to be located outside 
the joint and that another, “second hit” (for example, infection or trauma) needs 
to take place in ACPA positive individuals that causes joint inflammation and 
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generation of citrullinated proteins which are then targeted by the already 
present ACPA (168). Currently, there are several lines of evidence suggesting 
that RA-related autoimmunity may be generated at mucosal surfaces such as 
the gingiva, lungs or gut. As described in section 1.3.3, smoking represents the 
most established environmental risk factor for RA. The lung was therefore 
suggested to be one of the possible sites where anticitrulline immunity could be 
triggered (168). Despite this association, however, recent studies have 
demonstrated that increased expression of citrullinated proteins can be found 
not only in smokers, but also in ACPA positive non-smokers (256). Furthermore, 
only one-third of ACPA-positive RA cases can be attributed to smoking (257). It 
can therefore be assumed that other environmental triggers are involved. For 
example, it has been reported that airway exposures like coal dust (258), silica 
dust (259) or air pollution from traffic (260) could play a role. Additionally, in 
support of the notion that autoimmunity might originate at mucosal sites, ACPA 
are enriched in both bronchoalveolar fluid of early untreated RA patients and 
even in induced sputum of arthritis-free individuals at risk of developing RA 
(256,261). Finally, several species of microorganisms at mucosal sites have 
been implicated in RA pathogenesis, notably overexpansion of Prevotella copri 
in the gut (262) or Porphyromonas gingivalis of the oral microbiome (discussed 
in section 1.3.5.3). 
 
1.3.5.2 Fine specificity of ACPA and epitope spreading 
Another possible mechanism by which ACPA may be involved in RA 
pathogenesis may be related to the process of 'epitope spreading', which 
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enables the diversification of the immune response from a single epitope to 
many epitopes on the same molecule (intramolecular epitope spreading) or 
from one molecule to other molecules (intermolecular epitope spreading). 
Essential for this mechanism to occur is a need for the ability of  B cells to take 
up antigens, process them intracellularly, load a limited number of peptides from 
the antigens on MHC class II molecules, and present them on the cell surface to 
T cells. Intriguingly, although a large number of peptides can theoretically be 
presented, only a few 'immunodominant' peptides will be selected (263). As 
shown in Figure 1-7, following T cell dependent or -independent activation of a 
B cell that is specific for one epitope of an antigen, the same B cell can activate 
and receive help from T cells that are specific for other epitopes of the antigen 
(Figure 1-7A). In turn, T cells that are specific for a certain epitope of an 
antigen, can trigger different B cell specificities (Figure 1-7B) (264). By 
expanding the number of antigenic epitopes that are recognised, the immune 
system can thus optimise the immune response to the antigen and this is 
believed to contribute to the efficient clearance of pathogens (265,266). In many 
autoimmune diseases, however, this mechanism may contribute to the 







Figure 1-7 Mechanisms of epitope spreading 
(A) A B cell, specific for the epitope 'b', takes up through its B cell receptor (BCR) a complex 
antigen, which consists of multiple epitopes ('a-c'). These multiple T cell-antigenic determinants, 
all arising from one initial complex antigen, are processed by the B cell and presented in the 
context of major histocompatiblily complex (MHC) class II. This way, the anti-b-specific B cell 
can activate, and receive help from, several T cells with different specificities. (B) An activated, 
a-specific Th cell can, in turn, provide help to B cells that can recognise the same determinants 
but are specific for other accessible epitopes of the complex. This can finally lead to generation 





As mentioned earlier, ACPA in RA patients can be detected several years 
before the first symptoms of the disease appear. Interestingly, closer to the 
onset of disease (within 6-12 months), antibody characteristics of ACPA change 
into higher titres, higher number of specificities and an increase in the number 
of isotypes used (267–271). Altogether, these data suggest that progressive 
intra- and intermolecular epitope spreading (as observed by the targeting of 
additional citrullinated epitopes) together with the emergence of subclinical 
inflammation (as evidenced by increases in blood cytokine levels (267)) may 
50 
 
play a central role in the progression of individuals from preclinical to clinical RA 
(256). This notion finds support in other autoimmune conditions like pemphigus 
(272) or SLE (273) where a similar shift in the antigen recognition profile prior to 
clinical onset can be observed. Based on these considerations and examples 
from other autoimmune conditions the hypothesis was therefore made that 
ACPA may initially be non-pathogenic during the preclinical phase and only gain 
arthritogenic properties after the above described changes in antibody 
characteristics (256).  
 
1.3.5.3 Molecular mimicry –link between RA and periodontitis 
It has long been suspected that there may be a link between infections and the 
generation of autoimmune diseases. In 1964, R.T. Damian initially coined the 
term “molecular mimicry” to describe antigen sharing between host and parasite 
and thus provided a mechanistic explanation for this association (274). 
According to the molecular mimicry hypothesis an immune response can be 
caused by a pathogen that shares an immunodominant epitope with a self-
antigen. The conformational structure of the epitope from the self-antigen can 
then be recognised by B cells or linear peptide sequences recognised by T cells 
in the context of MHC molecules. This process is referred to as cross-reactivity. 
The autoimmune reaction against the self-antigen will persist even if the cross-
reacting microorganism has already been eliminated from the body (275). 
There have been several epidemiological and experimental studies 
demonstrating a positive association between RA and periodontitis (PD) (276–
280). PD is a chronic inflammatory disease of the gingiva and underlying 
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connective tissues and affects almost half of the adult population in the UK 
(281). It can cause tooth loss but can also lead to, or associate with, several 
systemic complications (277,282). Historically, it has been considered that three 
main bacterial species are closely associated with disease pathogenesis, 
namely P.gingivalis, T.denticola and T.forsynthia (283). However it is suggested 
that disease is rather caused by an imbalance in the microbial community of the 
biofilm around the gingival margin accompanied by a dysregulation of the host 
immune system. In line with this model, it was demonstrated that P.gingivalis 
was one of the pathogens closely associated with periodontitis in susceptible 
individuals, resulting in inflammatory bone loss (284–286).  
In general, the published association studies regarding the link between PD and 
RA indicate that chronic periodontitis is more prevalent in individuals with RA 
and vice versa. Interestingly, PD and RA share similar pathobiology (278) and 
risk factors such as smoking (287). One explanation for the association 
between these diseases is based on the fact that P.gingivalis has the unique 
capability of expressing a bacterial peptidylarginine deiminase (PPAD) (288). In 
2004, Rosenstein et al. first proposed that citrullinated proteins generated by 
PPAD might become systemic autoantigens in the inflammatory context of PD, 
and ultimately cause autoimmunity in RA (278). This notion was further 
extended by Wegener and colleagues who found that PPAD is not only able to 
citrullinate its own proteins but also host proteins such as human fibrinogen and 
human -enolase, which are known autoantigens in RA (279). Furthermore, 
they discovered that the immunodominant peptide CEP-1 of the human protein 
-enolase shows 82% sequence identity with the region corresponding to CEP-
1 of the bacterial enolase (289). Intriguingly, antibodies to CEP-1 from RA 
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patients also cross-react with in vitro citrullinated enolase from P.gingivalis, 
which suggests a link between the bacterium P.gingivalis and RA based on the 
mechanism of molecular mimicry (290). Interestingly, the link between 
P.gingivalis and RA was supported by two recent and independent animal 
studies: In CIA, but also in CAIA, it was shown that the ability of P.gingivalis to 
exacerbate disease strictly depends on PPAD expression, as mutants lacking 
this enzyme fail to influence disease outcome (291,292).  
Nevertheless, further studies are needed to investigate the link between 
P.gingivalis and/or PD with ACPA-positive RA, since compelling evidence of 
exact molecular mechanisms by which P.gingivalis may induce the loss of 
tolerance to citrullinated proteins is still lacking and a subject of significant 
debate (293–296).  
 
1.3.5.4 Possible effector mechanisms of ACPA 
In order for antibodies to be effective during immune responses, they must in 
general not only bind to their corresponding antigen but also induce immune 
effector mechanisms through the activation of the complement system and the 
engagement of Fc receptors. Depending on the endogenous or exogenous 
nature and location of the antigen, and on the type of immune response 
responsible for the tissue damage, such effector mechanisms in immune-
mediated processes such as allergy and autoimmunity were historically 
categorised into different types of so-called hypersensitivity reactions (297,298).  
One of the most extensively studied murine models of RA to unravel the role of 
antibody induced joint inflammation is the K/BxN mouse model which results 
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from crossing KRN-TCR transgenic mice with NOD mice (23). Notably the F1 
K/BxN offspring develop spontaneous arthritis (299). The antigen recognised by 
the KRN TCR in the context of MHC-II I-Ag7 has been identified as glucose-6-
phosphate isomerase (GPI) a glycolytic enzyme that is widely expressed (300). 
Sera from these mice contain GPI specific antibodies and transferring these into 
healthy as well as in lymphocyte deficient mice, induces joint inflammation. 
Intriguingly, systemic presence of immune complexes together with participants 
of the innate immune system like complement, FcγRIII, mast cells and 
neutrophils induce an inflammatory response reminiscent of the type III 
hypersensitivity (or 'Arthus') reaction, which can theoretically manifest at many 
sites in the body. Why this is manifested particularly in the joints of these mice, 
however, is not well understood. Possibilities discussed include the effect of 
hydrostatic pressure, regionally distinct vascular properties (301) or further 
mechanisms leading to a lack of clearance of ICs from the inflamed joint. In the 
K/BxN model, GPI and associated antibodies have been shown associated with 
the cartilage surface. Similarly, in ACPA positive RA patients, precipitates of RA 
and their immunoglobulin antigens are found on the surface of the cartilage 
(302). The presence of citrullinated proteins has also been observed in 
precipitates on the surface of the synovial lining of RA patients, suggesting that 
these may also involve formation of ICs (248). When immune complexes were 
purified from plasma (303) and the SF of RA patients (304), and analysed for 
the antigens involved, citrullinated proteins were detected. Importantly, these 
ICs may play a critical role, because they can activate macrophages to produce 
cytokines such as TNF-α, which is the driving force in the chronicity of RA (305). 
Interestingly, this TNF-α secretion can even be increased, if RF IgM are 
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incorporated into ICs already containing ACPA, and likely depends on an 
increase in the number of IgG-engaged FcγR (306).  An interaction between 
ACPA and RF has also been suggested due to the fact that RFs preferentially 
interact with hypoglycosylated IgG and that ACPA are hypoglycosylated 
compared with total IgG (179). Experiments using mice deficient in individual 
immunoglobulin receptors revealed that ICs binding to FcγRIII but not to FcγRII 
were necessary for arthritis development (307,308). Furthermore it has been 
shown that the inflammatory response depends on the presence of neutrophils, 
macrophages and the alternative and classical complement pathway (309). In 
vivo inhibition of the CXCR2 receptor led to significant reduction in RA, 
reflecting its important role in neutrophil recruitment (310). In addition, a recent 
report has also shown that expression of Syk, a kinase downstream of the Fcγ 
receptor, specifically in neutrophils is necessary for development of arthritis 
(23,311).  
 
Finally, in addition to the effector mechanisms described above, the pathogenic 
role for the anticitrulline response was recently supported by a study 
demonstrating that ACPA can also affect bone destruction through the 
activation of osteoclasts (312). If these findings are confirmed they would imply 
that ACPA have functional properties in the initiation of RA and may be directly 
pathogenic in contrast to the possibility of just simply enhancing a pre-existing 
inflammation. Additional investigations are therefore needed to elucidate the 





Neutrophils can enter a novel form of cell death known as NETosis, which 
depends on the enzymatic activity of PAD4. The overarching aim of the work 
described in this thesis was to test the hypothesis that enzymatically active 
PADs during NETosis are involved in the generation of citrullinated 
autoantigens in the inflamed joint, and that these antigens are targeted by anti-
citrullinated protein antibodies (ACPA) in RA patients. 
 
In particular, the objectives of this project were: 
 
 To investigate evidence for NETosis in the joints of patients with 
arthritides. 
 To develop a suitable assay to study the release of PADs and 
citrullinated proteins from neutrophils going into NETosis. 
 To relate findings of in vitro NETosis to the in vivo situation in the joints of 
RA patients by measuring PAD activity in the synovial fluid and by 
investigating the composition of proteins in NETs isolated from the 
synovial fluid. 
 To assess the presence of known and novel citrullinated antigens in 
NETs. 
 To examine the antigenicity of NET-associated citrullinated proteins in 




























The following antibodies shown in Tables 2.1-2.3 were used for 
immunofluorescence staining and Western Blotting. 
 





species isotype supplier clone 
product 
number 
anti-PAD4 10.1 mouse IgG2a Abcam 4H5 ab128086 
anti-PAD2 5 rabbit IgG Abcam - ab50257 
anti-CD68 5 mouse IgG2b BD Pharmingen Y1/82A 556059 
anti-CD15 10 mouse IgM Immunotools MEM-158 21270151 
anti-neutrophil 
elastase 
12.5 rabbit IgG Abcam - ab21595 
Western Blotting 






anti-PAD4 3.2 mouse IgG2a Abcam 4H5 ab128086 
anti-PAD2 25 rabbit IgG Abcam - ab50257 
anti-neutrophil 
elastase 
0.15 mouse IgG1 SantaCruz NP57 53388 
anti-modified 
citrulline (AMC) 
2 human IgG1 ModiQuest clone C4 
MQR2.601-
100 
anti-histone H3 0.08 rabbit IgG Abcam - ab1791 
anti-citrullinated 
histone H3 
1.33 rabbit IgG Abcam - ab5103 
*end concentration (concentr.)  
 
 




species supplier product number 
IgG1 * mouse DAKO X0931 
IgG2a * mouse DAKO X0943 
IgG2b * mouse DAKO X0944 
IgG * rabbit DAKO X0936 
IgM * mouse DAKO X0942 











Table 2.3 Conjugated antibodies used 
conjugate description dilution supplier product number 








AlexaFluor 488 donkey anti-rabbit IgG 1:100 Life technologies A21206 


















HRP donkey anti-rabbit IgG 1:10000 Amersham NA934 
HRP sheep anti-mouse IgG 1:10000 Amersham NA931 
 
 
2.2 Quantification of extracellular DNA in SF samples 
(untreated or cell-free)  
Untreated synovial fluid samples were used immediately following aseptic 
aspiration from the joints (see section 2.9) and were diluted with PBS to 1:10, 
1:100 and 1:1000. Levels of free DNA were assessed using SYTOX Green as 
described in section 2.6.1.2. DNA concentrations were calculated using a 
standard curve of purified DNA (placental DNA, Sigma-Aldrich, D4642). To 
obtain cell-free SF, samples were centrifuged for 10 min at 300 x g, the 
supernatants were carefully aspirated away from the cell pellets and used to 
assay DNA concentration. 
2.3 Quantification of cells in SF samples 
Untreated SF samples were obtained immediately after joint aspiration. The 
total cell count and proportion of neutrophils and macrophages within the 
synovial infiltrate was determined using a Neubauer hemocytometer and 
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cytospin preparations after a modified Giemsa staining (Diff-Quick™, Gamidor 
Technical Services, Didcot, UK). To generate cytospins SF cells were re-
suspended in MACS buffer (0.5% BSA and 2mM EDTA in PBS) and 1 x 105 
cells were transferred onto a clean glass slide using a cytocentrifuge, stained 
with modified a Giemsa stain (Diff-Quick, Gamidor Technical Services, Didcot, 
UK) and examined by light microscopy (Axiocam, Ero5S, Zeiss). For this 
purpose slides were fixed for 10 min in methanol (Sigma) and then stained 
according to manufacturer’s instructions. Neutrophils and macrophages were 
identified by their characteristic morphology. Giemsa staining of neutrophils 
showed cells with a multilobed blue-violet nucleus and a pale pink granular 
cytoplasm while macrophages were identified as cells with an irregular 
amoeboid shape and a pale blue and vacuolated cytoplasm (Figure 2-1). The 
ratio of neutrophils or macrophages compared with the total cell number was 
determined in five microscopic fields (40 x 10 original magnification) with a total 
minimum cell number of 200 cells per sample. Finally, the concentration was 
calculated using the ratios and the total cell count in the infiltrate. Other cells 
such as lymphocytes with their high nucleus:cytoplasm ratio or synoviocytes, 
which were usually found in the form of aggregates, were not considered for the 





Figure 2-1 Example image of neutrophils and macrophages in the synovial fluid infiltrate used for 
cell characterisation and quantification 
Cytospin preparation of SF cells from an RA patient stained with Diff-QuickTM. The 
dashed arrow indicates an example of a neutrophil and the solid arrow a macrophage 
(40 x 10 original magnification). 
 
2.4 Isolation of neutrophils from peripheral blood 
Peripheral blood from healthy donors was anti-coagulated with EDTA (Sigma-
Aldrich, E7889) at a final concentration of 1.5 mM and 1 ml of 0.04 mM Dextran 
T-500 (Sigma-Aldrich, 31392) was added per 6 ml blood to sediment 
erythrocytes. The supernatant without erythrocytes was then layered on top of a 
discontinuous Percoll (Sigma-Aldrich, Poole, UK) gradient of 56% Percoll over a 
layer of 80% Percoll and finally centrifuged at 190 x g for 20 minutes at RT with 
the centrifugal brake turned off. Neutrophils were collected at the interface 
between both Percoll layers using a Pasteur pipette and transferred into RPMI 
1640 medium (Sigma-Aldrich) containing 2 mM L-glutamine, 100 U/ml penicillin 
and 100 µg/ml streptomycin (Sigma-Aldrich). The cells were washed by 
centrifugation at 300 x g for 10 min and resuspended in RPMI. Purity of 
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neutrophil isolation was determined by Diff-Quick™ staining of cytospins and 
light microscopy (as described above). Routinely >97% of neutrophils were 
obtained in preparations, with eosinophils being the main contaminating cell. 
Cells were counted using a Neubauer hemocytometer.  
2.5 Induction of necrotic cell death in neutrophils 
Neutrophils were pipetted into 2 ml polypropylene tubes at a cell concentration 
of 1 x 106 ml-1 in 1 ml and subjected to 5 freeze-thaw cycles as has previously 
been described elsewhere (313). After the final freeze-thaw cycle samples were 
centrifuged for 10 min at 300 x g to remove intact cells, supernatants were 
transferred to fresh tubes and centrifuged a second time for 10 min at 16000 x g 
to remove cell debris. The supernatants of unstimulated neutrophils and 
NETotic neutrophils (generated as described in section 2.6) of the same donors 
after 4 h of incubation without or with PMA, respectively, were used as controls. 
Finally, DNA concentration (section 2.6.1.2) and PAD activity (section 2.10) in 
the supernatants was determined. 
 
2.6 Isolation of NETs  
 
2.6.1 Isolation of NETs from neutrophils stimulated with PMA 
(in vitro) 
Isolated neutrophils from healthy donors were seeded in 12-well tissue culture 
plates at a density of 1 x 106 ml-1 (1.7 x 106 cells per well) and were induced to 
form NETs using 25 nM phorbol myristate acetate (PMA) for 4 h at 37°C in a 
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5% CO2 atmosphere (314). To ensure appropriate stimulation of the cells, cell 
morphology was checked following stimulation under light microscopy. 
Unstimulated neutrophils demonstrated a typical rounded shape while 
neutrophils stimulated with PMA became flattened and exhibited a loss of cell 
membrane integrity (Figure 2-2). Supernatants from stimulated (SN) and 
unstimulated neutrophils (SN (unst.)) were harvested and wells were washed 
three times by removing the supernatant and carefully adding 500 μl of fresh 
pre-warmed RPMI into the well. Each wash was incubated for 20 min at 37°C. 
This process was undertaken to remove proteins that do not bind firmly to NETs 
as is previously described (315).  
 
 
Figure 2-2 Example images of cell morphology of unstimulated and PMA-stimulated neutrophils 
(25 nM PMA) after 4h cell culture (20 x 10 original magnification) 
 
Cell-associated NETs were solubilised with 10 U/ml DNase-I (Ambion AM2235, 
Applied Biosystems) for 20 min in 500 μl RPMI and protease inhibitor cocktail 





25 nM for 4 h
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reaction was stopped using a final concentration of 5 mM EDTA. Supernatants 
from all washing steps (W1-3), DNase-I treated NET fraction (+DNase-I) and 
control fractions were collected. The supernatants were centrifuged for 10 min 
at 300 x g to remove intact cells and then centrifuged for 10 min at 16000 x g to 




2.6.1.1 Precipitation of proteins using trichloroacetic acid (TCA) 
Proteins in the supernatants of neutrophils (including the NET fraction) were 
precipitated using a final concentration of 15% w/v trichloroacetic acid (TCA) 
(T6399, Sigma-Aldrich) for 20 min on ice and centrifuged for 10 min at 16000 x 
g. Pellets were washed twice with 500 μl ice-cold acetone (Sigma) and then 
alllowed to air dry on ice. Finally, all protein pellets were solubilised in equal 
volume of SDS loading buffer or prepared for MS identification as described in 
section 2.14.  
 














2.6.1.2 Measurement of DNA concentration in supernatants of neutrophils  
To quantify DNA, 90 µl of each supernatant was incubated with 10 µl of 10 µM 
SYTOX Green (Invitrogen) at a final concentration of 1 µM in a black 96-well 
assay plate (Corning) and incubated for 10 min at RT. Readings were obtained 
at a wavelength of 530 nm using a plate reader (BioTek-Synergy 2). Values 
obtained were compared with a standard curve of purified DNA (placental DNA, 
Sigma-Aldrich, D4642). Differences in volumes were accounted for in the 
calculation of the final DNA concentration. 
2.6.2 Isolation of NETs from synovial fluid of RA patients (ex 
vivo) 
For isolation of NETs from SF samples a modified version of the protocol 
described in section 2.6.1 was applied. Undiluted synovial fluid containing 
infiltrating cells was seeded on poly-L-lysine (Sigma) coated 12-well plates at 
300 µl per well, centrifuged at 300 x g at room temperature to sediment the cells 
and incubated at 37°C in a 5% CO2 atmosphere for 30 min. After removing the 
supernatant 500 μl pre-warmed RPMI were added into each well to gently wash 
the cells eight times so that proteins are removed which are not firmly attached 
to NETs. Each wash was incubated for 10 min at 37°C and the supernatants 
from 1 plate of the last washing step were collected as washing step 8 (W8). 
Subsequently NET-bound proteins from 1 plate were solubilised for 20 min in 
500 μl RPMI with 10 U/ml DNase-I (Ambion AM2235, Applied Biosystems) and 
protease inhibitor cocktail (Sigma-Aldrich) at a dilution 1:200 (+DNase-I). 
Importantly, EDTA at a final concentration of 5 mM, was used to stop the 
activity of DNase-I directly after incubation. A further plate was used as a 
control with RPMI alone and without DNase-I (-DNase-I) to ensure the 
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specificity of NET release. The supernatants were then centrifuged for 10 min at 
300 x g to remove intact cells and again for 10 min at 16000 x g to remove cell 
fdebris. Finally, proteins from each fraction (W8, +DNase-I and -DNase-I) were 
precipitated with TCA (as described in section 2.6.1.1), pellets were dissolved in 
SDS buffer and loaded onto an acrylamide gel (see below). In parallel, DNA 
levels in all supernatants were tracked using SYTOX Green as described in 
section 2.6.1.2.  
 
2.7 SDS-PAGE (Sodium Dodecyl Sulfate- 




Acrylamide gels were prepared at 12% or 15% for the resolving gel and 5% for 
the stacking gel. Gels were placed in a electrophoresis chamber and immersed 
in running buffer (Geneflow). Protein precipitates were solubilised in SDS 
loading buffer (0.35 mM SDS, 2.74 mM Glycerol, 0.04% β-Mercaptoethanol, 
Bromophenol blue powder, 0.1 M Tris, pH 6.8), boiled at 95ºC for 5 min, 
separated on SDS-PAGE gels using tris-glycine SDS-PAGE Tank Buffer 
(Geneflow). Samples were transferred to polyvinylidene difluoride (PVDF) 
membranes (345774, GE Healthcare, Amersham) using Electroblotting Buffer 
Tris-glycin (Geneflow). After blocking with 5% milk powder (Marvel powder) in 
TBS with 0.05% Tween-20 (Fisher BioReagents), membranes were incubated 
overnight at 4°C with primary antibody and developed with HRP conjugated 
secondary antibody and ECL Plus or ECL Prime (GE Healthcare, Amersham). 
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2.7.1 Sample preparation 
Precipitated proteins from pooled supernatants of 4 wells of PMA-stimulated 
neutrophils or from pooled supernatants of 12 wells of synovial fluid cells were 
solubilised in 25 µl SDS buffer prior to loading on a polyacrylamide gel. Intact 
neutrophils and human skeletal muscle tissue were lysed in RIPA-buffer 
(Sigma-Aldrich, R0278) in combination with protease inhibitor cocktail (Sigma-
Aldrich, P8340) first and the protein concentration was determined using the 
BCA protein assay kit (Thermo Scientific) according to the manufacturer's 
instructions. The samples were diluted with 5 x SDS loading buffer prior to 
loading on a polyacrylamide gel. 
2.7.2 Depletion of albumin from the synovial fluid 
Frozen and cell-free SF samples were thawed and albumin was removed from 
supernatants using the ProteoExtract Albumin/IgG Removal Kit, Maxi 
(Calbiochem). Protein concentrations of the eluate were determined using the 
BCA protein assay kit (Thermo Scientific) according to the manufacturer's 
instructions. Twelve µg of each sample was diluted with 5 x SDS loading buffer 
prior to analysis by SDS-PAGE and Western Blotting (section 2.7). 
2.7.3 Relative quantification of protein signal  
Images were captured with the ChemiDoc MP imaging system (Bio-Rad) and 
analysed using Image Lab 4.0 software (Bio-Rad) in the ‘manual band 
quantification’ mode and the ‘Identify Bands’ tool was used to detect individual 
bands. By default, the bands were labelled by band number. The ‘assign 
quantity’ tool was used to assign the brightest or reference band a value of 1. 
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All other band intensities were subsequently given values between 0-1 relative 
to this reference band. An example is shown in Figure 2-4. 
 
Figure 2-4 Relative quantification of protein bands using Image Lab 4.0 software 
Relative quantification of western blot signals was performed using the Image Lab 4.0 
software by Bio-Rad. In this example 8 bands were automatically detected by the 
programme and band 6 was identified as the reference band (in red) with the value 1.0. 
The signals of the other bands were calculated in relation to this reference band. 
 
2.7.4 Detection of citrulline modifications using the AMC-kit 
Citrullinated residues in proteins from neutrophil supernatants blotted on PVDF 
membranes were modified for assay using the protocol described by Senshu et 
al. (316). Briefly, membranes were incubated overnight at 37°C with an end 
concentration of 0.77 mM FeCl3, 1.47 M H3PO4 and 2.25 M H2SO4 in 
combination with 0.25 M C2H4O2, 25 mM 2,3-butanedione monoxime and 6.64 
mM antipyrine. After rinsing with dH2O and blocking with 5% milk powder in 
TBS with 0.05% Tween-20 next day, membranes were probed overnight at 4°C 
with a monoclonal human anti-modified citrulline (AMC) antibody (ModiQuest, 
clone C4) and developed with HRP conjugated goat anti-human antibody 
(Jackson ImmunoResearch Laboratories) and ECL Prime (GE Healthcare, 
Amersham). 









2.7.5 Staining of SDS-PAGE gels or PVDF membranes with 
Coomassie Blue 
Gels were prefixed in 50% methanol (MeOH), 10% acetic acid (HOAc) and 40% 
H2O overnight and stained in the same solution with 0.25% Coomassie Blue (R-
250) for 4 h on the next day until the gel became a uniform blue colour. Finally, 
the gel was destained for 4 h in 5% MeOH, 7.5% HOAC, 87.5% H2O until bands 
began to appear and the background became clear. In comparison, PVDF 
membranes were not prefixed and stained in the above Coomassie Blue 
solution for 30 sec. Destaining of PVDF membranes was undertaken using the 
same solutions and in the same way as that described for gels. 
2.7.6 Generation of gel slices for mass spectrometry 
Proteins of the in vitro isolated NET fractions from 5 donors were separated 
using SDS-PAGE as described above (section 2.7) and thin slices (2 x 4 mm) 
were dissected from the polyacrylamide gel at the molecular weight of 11 kD in 
a ventilation hood to avoid contamination with keratin. In-gel digestion of the gel 
slices followed by mass spectrometry analysis were performed by Jimmy 
Ytterberg at the Karolinska institutet in Sweden. 
 
2.7.7 Generation of PVDF strips and incubation with patient 
sera or antibodies 
Either precipitated proteins from in vitro NET fractions (from the supernatants of 
36 wells) or 3.2 µg recombinant histone protein (New England Biolabs) were 
evenly distributed in one large well on the surface of an acrylamide gel, 
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separated using SDS-PAGE and blotted onto a PVDF membrane. After the 
blocking step, eight strips of PVDF membrane of the same size were dissected 
out of one membrane for the incubation with eight different patient sera or eight 
different antibodies. 
2.8 Immunoprecipitation of PAD4 from the synovial 
fluid 
Initially 100 µl of protein G microbeads (Miltenyi, 130-071-101) were pre-
coupled with 3 µg of an anti PAD4 antibody (abcam, ab128086) in 0.4 ml ice-
cold PBS and mixed for 3 h at 4°C on a rotating table. An isotype-, 
concentration- and species- matched antibody was used as negative control for 
the immunoprecipitation. In the subsequent step, SF samples were pre-cleared 
by addition of 40 µl A/G plus agarose beads (Santa-Cruz, sc-2003) per SF 
sample and incubated for 3 h at 4ºC on a rotating table. After centrifugation at 
800 x g agarose beads were removed and 1.5 µg recombinant human PAD4 
(rPAD4, Cayman, 10500) was added as a positive control in combination with 
the specific antibody. Pre-cleared SF samples were then combined with the pre-
coupled Miltenyi beads and incubated overnight at 4°C with agitation to allow 
the binding of the PAD4 protein to the anti-PAD4 antibodies on the surface of 
the beads. Next day, the immune complexes were loaded on µMACS columns 
(Miltenyi) and allowed to filter through. After washing the columns according to 
the manufacturer's instructions, 20 µl 95°C pre-heated SDS loading buffer was 
added to the columns and the flow-through was discarded. Finally, another 20 
µl 95°C-warm SDS loading buffer was added and the eluate with the protein-
antibody complexes collected and loaded on SDS-PAGE gels (section 2.7). 
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2.9 Patient selection and sample collection 
RA patients studied all fulfilled the 1987 ARA classification criteria (76). At initial 
assessment, the disease activity score in 28 joints (DAS28) was calculated, and 
blood samples were analysed for C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), rheumatoid factor and anti-CCP antibody. 
Seropositivity for anti-ccp antibody was defined as a titre of ≥7 IU/ml and a 
maximum cut-off level of 340 IU/ml. Seropositivity for rheumatoid factor was 
defined as a titre of ≥11 IU/ml. Psoriatic arthritis was diagnosed according to 
established criteria (317). Samples were obtained from patients seen by 
consultant rheumatologists, Prof Karim Raza or Dr Andrew Filer. Synovial fluid 
was aspirated from joints under manual palpation or ultrasound guidance. 
Synovial tissue was obtained by ultrasound guided synovial biopsy (318). 
Ethical approval was obtained and participants gave informed, written consent. 
Clinical details of patients are provided in the appendix (section 8.1). 
2.10 Measurement of PAD activity (ABAP-assay) 
The Antibody Based Assay for PAD activity (ABAP) was purchased from 
ModiQuest Research, MQ-17.101-96. The assay utilises a solid Enzyme-linked 
immunosorbent assay (ELISA) for the determination of PAD enzyme activity 
(197). The wells of a 96-well plate were pre-coated with arginine containing 
peptides (Figure 2-5). After incubation with PAD enzyme-containing solutions, 
arginine residues can then be citrullinated and recognised by a monoclonal 
detection antibody specific for citrullinated arginine. In the final step wells are 
incubated with a HRP-labelled polyclonal anti-mouse immunoglobulin antibody 
which is then developed using the HRP substrate tetramethylbenzidine (TMB) 
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(Sigma) (Figure 2-5). The staining reaction is directly proportional to the amount 
of arginine residues that have been citrullinated. For quantification of the 
measured optical density at a wavelength of 450 nm a standard control PAD 
enzyme diluted in deimination buffer (40 mM Tris-HCl pH 7.5; 5 mM CaCl2; 1 
mM DTT) was used. Synovial fluid samples from patients with RA and OA and 
supernatants from in vitro PMA stimulated neutrophils were diluted in 
deimination buffer according to the manufacturer’s instructions.  
 
 
Figure 2-5 The Antibody Based Assay for PAD activity (ABAP) 
Schematic diagram showing the sequential steps (bottom to top, as described in the 
text) involved in quantifying PAD activity in PAD enzyme-containing solutions using the 



































2.10.1 PAD activity measurement in the supernatants of 
neutrophils (in vitro) 
For analysis of PAD activity released by in vitro stimulated neutrophils, isolated 
cells were seeded at 1 x 106 ml-1 in individual wells of a 12-well plate and 
allowed to sediment for 1 h at 37 °C at 5% CO2 in RPMI 1640 medium (Sigma-
Aldrich). Following sedimentation, the supernatant was replaced either by 1 ml 
pre-warmed RPMI (unstimulated control) or with 1 ml 25 nM PMA in RPMI. 
Following stimulation the supernatants were collected and treated with 1:100 
protease inhibitor cocktail (Sigma-Aldrich) with an additional 3.5 mM 
aminoethylbenzene-sulfonyl fluoride hydrochloride (AEBSF) on ice. 
Supernatants were centrifuged at 4 °C for 5 min at 300 x g to remove residual 
cells and diluted 1:2 with self-prepared deimination buffer (8.58 mM CaCl2, 5 
mM DTT and 40 mM Tris-HCl pH 7.5) which, together with the 0.42 mM calcium 
in RPMI 1640, resulting in a calcium concentration of 4.5 mM. Supernatants 
were transferred to the ABAP-Assay (ModiQuest), incubated for 1.5 h at 37 °C 
and further processed according to the manufacturer’s instructions. 
 
2.10.2 PAD activity assay in synovial fluid  
Frozen, cell-free synovial fluid samples from patients with RA and OA were 
either used non-diluted (at physiological calcium concentration) or diluted 1:100 
with deimination buffer (artifical calcium concentration of 5 mM) before transfer 
of 100 µl onto the ABAP assay plate.  
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2.11 In vitro citrullination 
Human recombinant histones H3.3, H2A and H4 (New England Biolabs), His-
tagged human recombinant vimentin (Sigma, SRP5150) and calf thymus 
histones (Worthington Biochemical Corporation) were used as a substrate for 
the human recombinant PAD4 enzyme (MQ-16.203-2.5, stock concentration 
18.7 mU/µl). For the enzymatic reaction 1 µg of substrate was added to 5 mU of 
PAD4 enzyme and diluted in deimination buffer, which was provided with the 
ABAP assay kit (compare 2.10.1). After citrullination for 2 h at 37ºC proteins 
were diluted with 5 x SDS loading buffer and used for Western Blotting (section 
2.7). 
2.12 Peptide ELISAs 
Citrullinated and non-citrullinated peptides from histone H3.3 were synthesised 
by Innovagen, Sweden. Nunc high-binding 96-well plates (Thermo Scientific, 
442404) were coated overnight with the peptide, which was diluted in carbonate 
coating buffer (Na2 CO3 1,59g/l , NaHCO3 2,93g/l, pH 9.6) at a concentration of 
5 µg/ml. Next day, plates were washed and blocked with 1% bovine serum 
albumin (BSA) in PBS for 1 h and then incubated for 2 h with control and test 
sera, which were previously diluted 1:50 in RIA-buffer (10 g/L BSA, 350 mM 
NaCl, 1% Triton-X-100, 5g/L Na-deoxycholate (0.5%), 0.1% SDS, 10 mM Tris-
HCl pH 7.6). Positive control sera were pooled from four anti-ccp antibody 
positive RA patients and negative control sera were pooled from four healthy 
individuals. 
After washing with PBS and 0.05%Tween, plates were incubated with a 
secondary goat anti-human IgG HRP-conjugated antibody (Jackson 109-036-
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008) at a final concentration of 0.04 µg/ml for 1 h. The HRP substrate 
tetramethylbenzidine (TMB) (Sigma) was diluted in phosphate-citrate buffer with 
sodium perborate (P4922-100) and the reaction stopped by addition of 2 M 
H2SO4. The optical density was measured at a wavelength of 450 nm in a plate 
reader. 
 
2.13 Immunofluorescence microscopy 
All samples were visualised using a Zeiss UV confocal LSM 510 microscope 
(Zeiss, Germany) and captured and processed using Zeiss LSM Image 
Examiner software (Zeiss).  
2.13.1 Immunofluorescence staining of synovial fluid 
preparations and synovial tissue sections 
Synovial fluid slide preparations were generated by pipetting 30 μl synovial fluid 
from patients onto a glass slide and cells were allowed to sediment for 2 min at 
RT. Supernatant was subsequently carefully removed and slides were left to air 
dry and then frozen at -20°C prior to use. Immunofluorescence staining was 
also performed on 5 m frozen synovial tissue sections from RA patients. When 
required, synovial fluid slide preparations and synovial tissue slides were 
defrosted and fixed in 4% paraformaldehyde (PFA) (P-6148, Sigma) for 10 min, 
hydrated in PBS and blocked for 30 minutes with 10% FCS/PBS. Primary 
antibody preparations (CD15, neutrophil elastase or CD68) were incubated for 1 
h at room temperature in PBS supplemented with 10% FCS and then washed in 
PBS. Concentration-, species- and isotype-matched antibodies were used as 
controls. Secondary antibodies (donkey anti-mouse IgM-Dylight 488,  donkey 
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anti-rabbit IgG-Alexa Fluor 647, goat anti-mouse IgG2a-Cy5, respectively) were 
incubated for 30 min at room temperature in the dark, and nuclei were 
counterstained using 10 µg/ml Hoechst S769121 (Life Technologies). Slides 
were mounted with mounting medium (DABCO, in-house).  
2.13.2 Staining of in vitro isolated neutrophils on 
coverslips  
For immunofluorescence staining of in vitro stimulated cells, neutrophils were 
seeded on coverslips and fixed with 4% PFA for 10 min after stimulation and 
incubated overnight at 4oC. Coverslips were rinsed with PBS, blocked for 45 
min with PBS in 2% BSA, 2% goat and/or donkey serum and 0.25% Triton-X-
100 as described (21). Samples were then exposed to primary antibody in PBS 
with 2% BSA and 0.25% Triton-X-100, washed in PBS, revealed using Alexa 
Fluor conjugated secondary antibodies and counterstained with 10 µg/ml 
Hoechst S769121.  
2.13.3 Staining of cytospins of isolated neutrophils and 
synovial fluid cells 
Cytospins of neutrophils from the peripheral blood of six healthy individuals and 
of peripheral blood neutrophils or SF infiltrate cells of five RA patients were re-
suspended in MACS buffer and 1 x 105 cells were transferred onto a clean 
glass slide using a cytocentrifuge. All cytospins were stained using the same 
protocol and the images were acquired with the same settings. Cytospins were 
initially fixed with 4% PFA for 10 min, rinsed with PBS and then blocked for 45 
min with PBS in 2% BSA, 2% goat serum, 2% donkey serum and 0.25% Triton-
X-100. They were then exposed to anti-PAD4 and anti-NE antibodies in PBS 
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with 2% BSA and 0.25% Triton-X-100, washed in PBS, revealed using Alexa 
Fluor conjugated secondary antibodies (Biotin- and Streptavidin-conjugated 
antibodies for anti-PAD4) and counterstained with 10 µg/ml Hoechst S769121. 
2.13.4 Quantification of PAD4 signal in neutrophils  
For the quantification of cytoplasmic PAD4 signal compared with the total PAD4 
signal on the immunofluorescence stainings obtained from cytospins described 
in section 2.13.3, pixel counts per µm2 area were analysed using the ZEN 2010 
software (ZEISS). For this purpose all NE-positive and intact neutrophils (60-80 
cells) from five different fields of vision were isolated using the overlay function 
within the ZEN software as shown in the example provided in Figure 2-6A. The 
Image calculator function was then applied to subtract all PAD4 pixels, which 
overlap with the nuclear DNA signal, from the total PAD4 signal. Importantly, 
when the pixels of the DNA signal were subtracted from the total PAD4 signal, 
only the overlapping pixels were subtracted and not the total DNA signal. The 
histogram function within the software was used to obtain the pixel counts for 
each channel. After the subtraction a separate pixel count was generated for 
the PAD4 channel. Pixel counts of all different intensities (Figure 2-6B) from all 
channels were then exported from the ZEN software into Excel software 
(Microsoft) excluding the first 30 intensities in order to avoid the inclusion of 
intensities, which are artificially high. In the Excel software, the sum of all pixel 
intensities per µm2 area for individual cells was calculated and the average for 
each cytospin determined. The percent of cytoplasmic PAD4 signal was then 
calculated using the following equation:  
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%cytoplasmic PAD4=100×(total PAD4 positive pixels per µm2 area - 
overlapping pixels per µm2 area) /total PAD4 positive pixels per µm2 area 
These values were then plotted graphically to enable identification of 
differences between neutrophils from the synovial fluid and peripheral blood of 





Figure 2-6 Image calculator function of the ZEN 2010 software 
(A) To calculate the cytoplasmic pixel count of the PAD4 signal (green) in channel Ch3-T2 
(Input S1), the Image calculator function in ZEN 2010 (indicated by the arrow) was used. With 
the subtraction of pixels in one channel (DNA signal, Input S2) from another channel (PAD4 
signal, Input S1) only pixels overlapping in both channels are subtracted from the total PAD4 
signal. For this purpose the formula Input S1 - Input S2 was typed into the formula display 
resulting in all pixels in Ch3-T2 without the one overlapping with the DNA signal. (B) Using the 
histogram function within the ZEN software all intensities excluding the first 30 strongest 
intensities (31-286) from each channel were exported into Excel software. Additionally, also the 
pixel intensities in Ch3-T2 (PAD4) excluding the one overlapping with Ch2-T1 (DNA) (not 
shown here) were added into the excel sheet. The sum of all intensities divided by the area 
[µm x µm] was then calculated for each channel separately and the ratio cytoplasmic 




2.14 Mass spectrometry 
All mass spectrometry analyses were performed in collaboration with Jimmy 
Ytterberg at the Karolinska Institutet, Stockholm, Sweden. 
2.14.1 Quantification of proteins in the supernatants and 
NET fractions of activated neutrophils 
Quantitative comparison of protein levels in supernatant directly after PMA 
stimulation (SN) and DNase-I treated NETs (+DNase-I and/or D) were 
undertaken. Supernatant (SN) and DNase-I treated NETs (D) from stimulated 
neutrophils from 7 donors were digested with trypsin, analysed by mass 
spectrometry (4 donors by LTQ OrbitrapVelos ETD and 3 donors by Q 
Exactive), searched against the human complete proteome database and 
quantified by the Quanti software (319). Details are described in the appendix 
section 8.2. The list provided in the appendix (section 8.2.2) shows the 286 
proteins that were quantified in both fractions of all patients. The data from the 
two instruments used for analysis is presented separately. The “PROTEIN ID” 
lists the UniProt accession numbers, the “PROTEIN IDs” lists all the accessions 
sharing peptides with the quantified accession, “log2 (D/SN)” lists the log2 of 
the ratio of medians of the two fractions, the “P (D vs SN)” lists the p-value 
using t-test, the “E” show the expectation value (n x p) together with the number 
of quantified proteins in the dataset. The Bonferroni corrected thresholds for 
significance are p = 1.70E-4 (Velos) and p = 9.01E-5 (Q Exactive) respectively. 
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2.14.2 Qualitative analysis of the presence of citrullinated 
proteins in the supernatants and NET fractions of 
activated neutrophils 
The presence of citrullination in the total SN and DNase-I treated NET (alias 
"D") fractions was investigated by re-searching the data (generated as 
described in section 2.14.1) with the inclusion of citrullination (R) and 
deamidation (N/Q) as variable modifications. Spectra identifying citrullinated 
peptides were validated manually, by verifying that the precursor mass was 
correctly assigned and that the modified site was consistent with observed 
mass shifts in the fragment ions. All peptides identified as citrullinated with a 
Mascot score of at least 20 are shown. A score of 20 is a commonly used 
threshold (320) and is defined as −10 log(P), where P is the probability of a 
random match between the theoretical MS/MS spectra of a peptide and the 
measured MS/MS spectrum. 
 
For the analysis of citrullinated peptides of 11 kD in the NET fractions, bands 
from five donors were excised from 1D-SDS-PAGE, reduced, alkylated and 
digested by trypsin using standard protocols (321). After zip tipping (Merck 
Millipore Ltd, Irland), the peptides were separated using on-line nLC-MS/MS 
(RP C18) and analysed on a LTQ Velos Orbitrap ETD MS (Thermo Fisher 
Scientific, Germany). The following gradient was used for the separation: 5-30% 
B in 35 min and 30-95% B in 5 min (A: 1% formic acid in water; B: 1% formic 
acid in acetonitrile), all at a flowrate of 300 nl/min. 
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2.15  Stimulation of neutrophils with enriched immune 
complexes from the SF of RA patients  
Based on previous protocols published by Robinson et al. (322) and Mathson et 
al. (323) frozen and cell-free SF samples from  RA patients were thawed and 
either pooled or used individually from each patient. Immune complexes (ICs) 
were enriched overnight at 4°C by combining the SF with an equal volume of 
ice-cold 5% polyethylene glycol (PEG) 6000 (Fluka, 03394) with a final 
concentration of 0.1 M EDTA. The following day, precipitates were centrifuged 
at 11600 x g at 4˚C for 10 min and washed twice with sterile PBS (Sigma). The 
precipitate, after centrifugation, was then diluted in the same volume of PBS as 
the original pool of synovial fluid samples. This solution of immune complexes 
(100%) was then further diluted to determine the percentage of 40% immune 
complexes sufficient to show an effect on freshly isolated neutrophils from the 
peripheral blood of healthy donors. For the blocking experiments antibodies 
against CD32a and CD16b (R&D) were used. 
 
2.16 Statistical analyses 
Each experiment was performed at least three times with a minimum number of 
two technical replicates unless otherwise stated. Non-parametric distribution 
was assumed for all assays. Individual tests used are indicated in the figure 
legends. p-values of less than 0.05 were considered statistically significant. 















3 Detection of neutrophil extracellular traps 















A considerable body of work suggests that neutrophils in patients with RA are 
functionally different from those isolated from healthy individuals (116). 
Neutrophils of RA patients, for example, are already primed for ROS production 
(109) and show an increased expression of several different cytokines (118). In 
the inflamed RA joints, these cells are rarely observed in synovial tissue, while 
they are the most abundant cell type in the SF (102). The abundance of 
neutrophils in early stages of disease (324–326) implicates a role in the 
pathogenesis of joint inflammation. This is also supported by several animal 
models of rheumatoid arthritis which depend on the presence of neutrophils 
(121,327,328). 
SF neutrophils in RA patients have been shown to be activated and secrete 
cytokines which activate other immune cells such as B-cells (117,118) and 
promote further neutrophil recruitment from the circulation amplifying the 
inflammatory response (116). Additionally, exposure to immune complexes, 
cytokines and rheumatoid factor in the SF of RA patients can induce neutrophil 
activation and secretion of ROS and proteases (322,329) and may thus lead to 
damage of cartilage and surrounding tissue (330,331).  
Autoantibodies against neutrophils have been described not only in systemic 
vasculitis and SLE but also in RA (332–334). Interestingly, anti-neutrophil 
cytoplasmic antibodies (ANCAs) were found to activate neutrophils causing 
degranulation and tissue damage and their presence was associated with 
higher joint scores in RA (335,336).  
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Recently, a novel cell death mechanism was described in neutrophils, the 
formation of neutrophil extracellular traps (NETs) or ‘NETosis’ (21). NETs are 
composed of chromatin associated with granular proteins and were found to 
primarily capture and immobilise microorganisms. Additionally, these structures 
were also demonstrated to be involved in the pathogenesis of several 
inflammatory conditions such as SLE, small vessel vasculitis, psoriasis or 
crystal arthritis (20–25). 
Based on the above-described significance of neutrophils in RA and  
previous findings of extracellular DNA in the SF of RA patients (26,27) it was 
hypothesised here that neutrophils may contribute through NETosis to the pool 
of extracellular DNA detected in the synovial fluid of RA patients. In this chapter, 
the formation of NETs in the SF and ST in relation to evidence of neutrophil 
infiltration and extracellular DNA levels is investigated.  
 
3.2 Extracellular DNA levels in the synovial fluid of 
patients with inflammatory arthritis correlate with 
neutrophil cell numbers 
 
As described in detail by Fuchs et al. NETosis is characterised by the entire 
fragmentation of the nuclear envelope and the active release of free DNA into 
the extracellular space (24). In order to quantify extracellular DNA that may be 
released during NETosis into the SF the DNA dye SYTOX green was used, 
which has been previously described to be suitable for the staining of NETs due 
to its cell-impermeability (314). Subsequently SF samples were freshly obtained 
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and immediately processed without cryopreservation to exclude artificially 
induced necrosis of cells and thus release of DNA.  
 
Quantification of extracellular DNA in untreated SF of patients with RA, OA and 
other types of inflammatory arthritis confirmed and extended previous findings 
that free extracellular DNA can be found in RA SF. Samples were compared to 
a known DNA standard solution in individual experiments and freshly isolated 
neutrophils from peripheral blood of healthy donors (PB PMNs) were used as 
negative control. Significantly higher DNA levels were found in SF of patients 
with RA compared to patients with osteoarthritis (OA) (p<0.001) and psoriatic 
arthritis (PsA) (p<0.05) (Figure 3-1A). A small number of patients with different 
types of inflammatory arthritis, including gout (n=2), pseudo gout (n=2), 
spondyloarthritis (SpA), reactive arthritis (n=1) or unclassified inflammatory 
arthritis (n=3), showed variable levels of extracellular DNA in the SF (Figure 
3-1B). Validation experiments in which the DNA concentration in untreated SF 
samples was measured before and after centrifugation of cells showed that 
78% (IQR 65-89, n=12) of the signal derived from cell-free SF samples 
suggesting that cells with permeable membranes such as necrotic or late-stage 
apoptotic cells contributed only a small proportion of the DNA signal (Figure 
3-1C). In parallel experiments neutrophils from healthy donors were isolated 
and after inducing NETosis and necrosis the release of free extracellular DNA 
was compared. As shown in Figure 3-1D, a significantly higher amount of 
soluble extracellular DNA is released after NETosis compared with unstimulated 




No statistically significant correlations were observed between DNA 
concentration and clinical parameters such as ESR, CRP, DAS28 (ESR), VAS, 
SJC and TJC (Figure 3-2 A-F). Interestingly, however, levels of free DNA in SF 
samples showed a weak, although significant positive correlation with disease 
duration (r=0.4; p<0.01), which could be increased when excluding patients 






Figure 3-1 Detection of extracellular DNA in the synovial fluid of patients with inflammatory arthritis 
(A) Extracellular DNA was quantified in the synovial fluid (SF) of patients with RA (n=54), 
osteoarthritis (OA) (n=15) and Psoriatic Arthritis (PsA) (n=12) using the cell-impermeable dye 
SYTOX Green. Freshly isolated neutrophils from peripheral blood of healthy donors (PB PMNs) 
(n=6) were used as negative control. (B) Quantification of extracellular DNA in the SF of 
patients with different types of inflammatory arthritis: gout (n=2), pseudo gout (n=2), 
spondyloarthropathy (SpA) (n=2), reactive arthritis (n=1), unclassified inflammatory arthritis 
(unclass. inflam. arthr.) (n=3). (C) Quantification of the DNA signal in 12 SF samples from 
patients with inflammatory arthritis revealed an approximate percentage of 78% (IQR 66-89) of 
the DNA signal derived from the cell-free fraction of SF samples. (D) Release of DNA into the 
supernatant of unstimulated, NETotic or necrotic neutrophils of healthy donors (n=6). To induce 
necrosis, neutrophils were frozen and then thawed and to induce NETosis the cells were 
stimulated with 25 nM PMA. Statistical analysis was performed using a Mann-Whitney test with 

































































































































































Figure 3-2 Relationship between DNA concentration and clinical parameters in RA patients 
(A-F) Scatter plot showing relationship between DNA levels and erythrocyte sedimentation rate 
(ESR) (r=0.07; p=0.7), C-reactive protein (CRP) (r=0.2; p=0.1), DAS28(ESR) (r=0.09; p=0.6), 
visual analogue scale (VAS) (r= -0.2; p=0.3), swollen joint count (SJC) (r=0.1; p=0.4), and 
tender joint count (TJC) (r=0.1; p=0.4). (G) Scatter plot showing relationship between disease 
duration and DNA concentration in patients treated with DMARDs (n=37; r=0.36; p=0.03). (H) 
Scatter plot showing relationship between disease duration and DNA concentration in patients, 
which did not receive DMARDs (n=12; r=0.74; p=0.006). Data were analysed using Spearman’s 
test for correlation. DMARDs= disease modifying anti-rheumatic drugs. 



























































































































































Concentrations of different cell populations including neutrophils in the SF 
infiltrate were determined using cytospins of cells, stained with a Romanowski 
stain (Diff Quick™). Using light microscopy cells were then quantified based on 
cell morphology. Occasionally, cells with decondensed nuclei within neutrophil 
aggregates could be detected suggesting the presence of neutrophils in the 
early stage NETosis (Figure 3-3A). Quantification of different cell populations 
revealed that neutrophils predominate in the synovial fluid infiltrate in most RA 
SF samples (Figure 3-3B). 
 
Levels of free DNA in SF samples of RA patients showed a strong positive 
correlation both with total number of cells in the SF infiltrate (Figure 3-4A) and 
also neutrophil cell counts (Figure 3-4B). In contrast, no correlation between 
macrophage cell counts and DNA levels (Figure 3-4C) was observed. Instead, 
SF samples, in which neutrophil concentrations were higher than macrophage 
concentrations, displayed significantly higher DNA levels compared with SF 
samples, in which macrophages outnumbered neutrophils (Figure 3-4D). 
Additionally, a strong significant negative correlation between DNA levels and 
the proportion of macrophages from the total SF cell infiltrate could be observed 
(Figure 3-4E). Finally, a strong positive correlation between neutrophil numbers 
and disease duration was observed in RA patients when excluding those 
receiving methotrexate (MTX) treatment (Figure 3-4F). 
In conclusion, these results support the notion that neutrophils may be a 
source of extracellular DNA in the SF while macrophages may be potentially 
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involved in the regulation of this DNA release from neutrophils, although 










Figure 3-3 Determination of the cell composition in the RA synovial fluid 
(A) Synovial fluid cells from RA patients were re-suspended in MACS buffer and 1 x 10
5
 cells 
were transferred onto a clean glass slide using a cytocentrifuge, stained with Diff Quick™ and 
examined under light microscopy (40 x 10 original magnification). Representative synovial fluid 
sample with a predominantly neutrophilic infiltrate and cells with decondensed nuclei (indicated 
by arrows) are shown. (B) Comparison of the concentration of different cell populations in the 
SF infiltrate of RA patients. Other cells represent SF cells excluding macrophages and 











































Figure 3-4 Neutrophil cell counts in RA patients correlate with DNA levels and disease duration 
(A) Results are depicted as a scatter plot of DNA concentration (DNA Conc) against cell 
infiltrate and cell counts of different cell populations in SF from 22 patients with rheumatoid 
arthritis. (B) DNA concentration is shown in relation to neutrophil concentrations in SF from 20 
patients with rheumatoid arthritis (n=20, r=0.88, p<0.0001). (C) DNA concentration is shown in 
relation to macrophage concentrations in SF from 20 patients with rheumatoid arthritis (n=20, 
r=0.4, p=0.88). (D) Significantly higher DNA levels are detected in RA SF samples with more 
neutrophils than macrophages (ratio Neutr./Macr. > 1) compared with SF samples, in which 
neutrophils are outnumbered by macrophages (ratio Neutr./Macr.< 1). Statistical analysis was 
performed using the Mann-Whitney test and horizontal bars represent median values (n=20; 
**indicates p<0.01). (E) Relationship between DNA concentration and the proportion of 
macrophages from the total number of cells in the SF infiltrate of RA patients (n=18, r=-0.7, 
p=0.001). (F) Neutrophil concentrations are shown in relation to disease duration in RA patients 
excluding those receiving methotrexate (MTX) treatment (n=9, r=0.74, p=0.2). Relationships 
between two variables were analysed using Spearman’s test for correlation. 
































40 r = 0.9; p < 0.0001































































































r = - 0.72; p < 0.001















3.3 Visualisation of NETs in the synovial fluid and 
tissue of RA patients 
 
Neutrophils are considered to be the most abundant cell type in the synovial 
fluid and show evidence of having initiated ROS generation in vivo (110), which 
is an absolute requisite for the induction of NETosis (24). Based on our findings 
of extracellular DNA in the SF and its strong correlation with neutrophil cell 
counts we hypothesised that the source of measured extracellular DNA may be 
NETs released from activated neutrophils in the joint. Therefore we sought to 
examine the neutrophil population in the joints of RA patients in more detail 
using confocal laser-scanning microscopy. To avoid NET disruption, synovial 
fluid was pipetted onto a glass slide and cells were allowed to sediment for 2 
min. Subsequently the supernatant was carefully removed and slides were 
allowed to air dry. As shown in Figure 3-5, immunostaining of preparations of 
RA SF revealed a network of extracellular DNA strands similar to that reported 
for NETs in a range of studies. DNA co-localised with neutrophil elastase 
(Figure 3-5), a protein, which is tightly associated with NETs and currently 
widely accepted to represent a marker for NETosis (39,342). The majority of 
cells detected within this meshwork of DNA fibres were neutrophils, but also 
some macrophages were observed (Figure 3-6). 
 
In frozen sections of synovial tissue, neutrophil aggregates were observed on 
the surface of the synovial lining, facing the joint cavity (Figure 3-7A). In 
agreement with the literature, relatively few neutrophils were detected within the 
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synovial tissue. As shown in Figure 3-7B, DNA staining revealed extracellular 
DNA associated within these aggregates. 
 
 
Figure 3-5 NETs can be detected in the synovial fluid of RA patients 
Synovial fluid preparations from RA patients were stained for DNA (grey) and Neutrophil 
Elastase (green). Lower panel shows concentration and isotype matched control staining. 
Immunofluorescence staining was visualised using a confocal microscope and viewed at a final 










Figure 3-6 Neutrophil and macrophages staining in SF infiltrate 
Confocal laser-scanning microscopy images of synovial fluid preparations (63 x 10 original 
magnification). Upper panel shows specific staining and lower panel concentration and isotype 
matched control staining. DNA is revealed with Hoechst dye (blue). CD15 is shown in green; 
CD68 is shown in violet. CD15-positive neutrophils and CD68-positive macrophages were found 
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Figure 3-7 NETs within neutrophil infiltrate attached to synovial tissue of RA patients 
(A) Confocal laser-scanning microscopy (10 x 10 original magnification) imaging revealed 
presence of neutrophil aggregates attached to synovial lining layer (n=3) (NE is shown in green 
and nuclear counterstain in grey). (B) 63 x 10 original magnification of neutrophils and 
extracellular DNA (indicated by arrows) attached to the surface of synovial tissue of RA patients 




















3.4 Antibodies as potential triggers of NETosis in the 
synovial fluid of RA patients 
 
The amount of extracellular DNA detected in the synovial fluid of RA patients 
suggests that the RA SF may represent an environment which promotes cell 
death. According to this scenario, studies were undertaken to determine 
whether NETosis of neutrophils could be induced after recognition of immune 
complexes by Fc receptors, especially as the induction of NETosis by 
autoantibodies such as ANCA or anti-ribonucleoprotein antibodies has been 
shown in SLE and small-vessel vasculitis (33,65). Although RF levels and 
ACPA levels above (7 units) and below (340 units) the threshold of detection in 
ACPA positive RA patients did not correlate with DNA levels in the SF (Figure 
3-8A-B), a small but statistically significant difference in DNA levels of ACPA 
positive (n=34) compared with ACPA negative patients (n=12) could be 
observed (p=0.04) (Figure 3-8C), which could not be seen with RF levels 





Figure 3-8 Influence of serum antibody levels on DNA levels in the SF 
(A) DNA concentration is shown in relation to anti-citrullinated protein antibodies (ACPA) levels 
in the serum of 23 ACPA positive (ccp level >7 units) RA patients (r=0.1, p=0.6). Anti-ccp values 
above the detection limit of 340 units were excluded from the calculation. (B) DNA 
concentration is shown in relation to rheumatoid factor (RF) levels (r=-0.02, p=0.9) in 38 RA 
patients. (C) Statistically significant difference (p=0.04) of SF DNA levels between ACPA 
positive (anti-ccp value >7 units, including levels >340 units, n=34) and ACPA negative patients 
(anti-ccp vlaue <7 units, n=12). (D) Comparison of SF DNA levels between RF positive (n=37) 
and RF negative (n=9) RA patients (p=0.13). Statistical analysis was performed using Mann-















































































































To investigate the influence of antibodies in the synovial fluid of RA patients on 
neutrophils we enriched immune complexes (IC) based on previously reported 
protocols using precipitation with polyethylene glycol (PEG) (323,343). The 
synovial fluid of 8 ACPA positive and negative RA patients was pooled together 
and the immune complexes were enriched with PEG overnight. Subsequently 
the precipitate was centrifuged and diluted in the same volume of PBS as the 
original pool of synovial fluid samples. This solution of immune complexes 
(100%) was then further diluted to determine the percentage of immune 
complexes that is sufficient to show an effect on freshly isolated neutrophils 
from the peripheral blood of healthy donors. Validation experiments also 
excluded the possibility that PEG itself activates neutrophils (data not shown). 
As indicated by the co-staining of DNA and neutrophil elastase, a 40% IC 
solution was able to induce NETosis of neutrophils after only 30 min stimulation 
(Figure 3-9). In comparison, unstimulated neutrophils did not show any 
detectable signs of NETosis even at 240 min of culture (Figure 3-9). These 
findings were also confirmed using SYTOX green staining, which revealed 
significantly increased DNA levels in the supernatants of stimulated cells 
compared with unstimulated cells after only 30 min of stimulation, which could 
not be observed after 30 min of stimulation with 25 nM PMA, a well-described 
stimulant for NETosis (314) (Figure 3-10A). At 240 min, however, a comparable 
amount of DNA could be detected in immune complex-stimulated neutrophils 
compared with PMA-stimulated neutrophils (Figure 3-10A). 
 
To investigate further whether the observed activation and NET release of 
neutrophils is influenced by the presence of ACPA within immune complexes, 
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neutrophils were separately stimulated with IC enriched from SF samples of 
ACPA negative (n=8) and ACPA positive (n=10) patients. Compared with 
neutrophils, which were stimulated with IC enriched from ACPA negative 
samples, a trend towards a higher DNA signal in the supernatant of cells, which 
were stimulated with IC enriched from ACPA positive SF samples could be 
observed (Figure 3-10B), although no statistically significant difference was 
detected (Figure 3-10C). Similarly, no statistically significant difference was 
observed when comparing RF positive and negative samples (data not shown). 
Additionally, to assess whether the induction of NETosis is mediated through Fc 
receptors, the two main Fc receptors, FcγRIIA (CD32a) and FcγRIIIb (CD16b), 
present on neutrophils were blocked. To exclude the possibility that the blocking 
antibodies themselves could activate neutrophils, unstimulated neutrophils were 
incubated with the same concentration of blocking antibodies as the stimulated 
cells, respectively. No reduction of NETosis, as induced by 40% IC, was 







Figure 3-9 Immune complexes enriched from RA SF induce NETosis 
Synovial fluid from 8 RA ACPA positive and ACPA negative patients were pooled; immune 
complexes (IC) were precipitated and used at a concentration corresponding to 40% of the 
original volume SF. Neutrophils were isolated from peripheral blood of healthy donors and left 
to adhere for 30 min before stimulation. Confocal laser-scanning microscopy analysis of 
neutrophils from healthy donors (63 x 10 original magnification). Cells were either left 
untreated for 240 min (unstimulated) or stimulated with 40% IC for 30 min, 120 min and 240 
min. Upper panel on the right shows concentration and isotype matched control staining of 
unstimulated neutrophils at 0 min (isotype control). To exclude a possible enrichment of NETs 
within the added immune complexes, cells were fixed immediately after adding 40% IC (40% 
IC background) as a control (bottom panel on the right). Neutrophil elastase is shown in red 
and nuclear counterstain in grey. One representative experiment out of three independently 
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Figure 3-10 Influence of enriched immune complexes from RA synovial fluid on neutrophils 
Release of extracellular DNA after stimulation with 40% IC is measured in arbitrary fluorescence 
units at 530 nm (AFU (530 nm)) using SYTOX green. (A) Time course study of release of 
extracellular DNA from neutrophils stimulated with 40% IC enriched from the pooled SF of 8 
ACPA positive and negative patients in 5 independently performed experiments. 25 nM PMA 
was used as a positive control for the induction of NETosis and unstimulated neutrophils as a 
negative control. Statistical significance was determined by paired Student's t-test (*p<0.01). (B) 
Neutrophils were stimulated for 1 h separately with 40% IC isolated from the SF of 8 ACPA 
negative (1-8 ACPA neg) and 10 ACPA positive RA patients (9-18 ACPA pos). 25 nM PMA was 
used as positive control for the induction of NETosis (PMA). Horizontal broken line indicates 
background level of extracellular DNA in the supernatant adjusted to unstimulated neutrophils 
after 1 h in cell culture (unst.). One experiment out of 4 independently performed experiments is 
shown. (C) Statistical analysis of difference in DNA levels shown in (B) using Mann-Whitney test 
with horizontal bars representing median values (p=0.9). n.s.=non-significant. (D) Neutrophils 
were either stimulated with 40% ICs from pooled SF samples (40% IC) or left untreated (unst.) 
for 1 h in the presence of 20 µg/ml or 60 µg/ml receptor blocking antibodies against the Fc 
receptors FcγRIIA (CD32a) and FcγRIIIb (CD16b). One representative experiment out of two 









































































































































This chapter addresses the question as to whether neutrophils could contribute 
through NETosis to the pool of extracellular DNA detected in the synovial fluid 
of RA patients. Previous findings of free DNA in the synovial fluid of RA patients 
were confirmed and found to be not only strongly correlated with neutrophil cell 
numbers in the RA SF but also with disease duration. Extensive NET formation 
in the joints of RA patients were visualised using confocal microscopy and 
NETosis of neutrophils from the peripheral blood of healthy donors could be 
induced with immune complexes enriched from the synovial fluid of RA patients. 
 
The presence of free DNA in the synovial fluid and serum of patients with 
arthritis has already been described by Leon et al. in 1981 (340). In agreement 
with our findings, this study reported significantly increased levels of DNA in RA 
SF compared with DNA levels in the SF of OA patients. The same results were 
confirmed in a more recent study, which in addition also found a correlation 
between DNA levels in the synovial fluid and SF leukocytes (341). This is 
similar to our observations which demonstrate a strong correlation with the total 
population of synovial fluid cells and, more precisely, neutrophil cell counts. 
 
Several previous studies have reported the presence of NETs at the site of 
inflammation. Although NETs were originally shown to be involved in the 
immobilisation and killing of microbes due to the concentrated presence of 
antimicrobial agents within NETs (24,36,315), their presence was recently also 
described in sterile inflammation (339,344). Confocal microscopy analysis used 
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in this study revealed the presence of a meshwork of DNA fibres co-localised 
with neutrophil elastase and associated with neutrophils and occasionally 
macrophages in the joints of RA patients, but also patients with other forms of 
inflammatory arthritis (data not shown). They were not only found in the SF but 
were also attached to the surface of the synovial lining facing the joint cavity 
and resembled the appearance of NETs reported in a range of studies. These 
results are therefore consistent with the concept that extracellular DNA is 
associated with the localisation and number of neutrophils present in the SF of 
patients with inflammatory arthritis and likely to be a result of extensive NET 
formation in the inflamed joint. These results are also in line with a recent study, 
in which NETs were generated upon activation of neutrophils by MSU or CPPD 
crystals in gout and pseudo gout patients, respectively (339,345), which indicate 
the different mechanisms for the induction of NETs in different types of 
inflammatory arthritis. 
 
Whereas in chronically inflamed synovial tissue only relatively low numbers of 
neutrophils are observed, these cells are in general known to be the most 
abundant cell type present in the SF of patients with RA (103,116). In light of 
the high abundance of neutrophils, the strong correlation with DNA levels and 
the observed NET formation, these data suggest that NETosis may be a source 
of extracellular DNA in the synovial fluid. Interestingly, this notion is also 
reinforced by the finding of significantly lower DNA levels in psoriatic arthritis 
patients, in which a trend of decreased neutrophil cell counts was detected 
compared to RA SF samples. Nevertheless, this study cannot exclude the 
possibility that cells other than neutrophils contribute to the levels of DNA in RA 
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SF. As noted, macrophages can also account for a large proportion of the 
cellular infiltrate. Furthermore, cells such as eosinophils, mast cells or 
macrophages can release their chromatin in a process similar to NETosis 
(28,346,347). However, eosinophils and mast cells are present in only relatively 
low numbers in RA SF in a small proportion of RA patients (28). In addition, 
macrophage cell counts in this study showed no significant correlation with 
levels of extracellular DNA. Instead, SF samples, in which macrophages 
outnumbered neutrophils, showed significantly lower DNA levels compared with 
SF samples, in which neutrophils outnumbered macrophages in the SF 
infiltrate. As macrophages are one of the main professional phagocytes 
participating in the removal of dead cells (348,349), it is therefore conceivable 
that SF macrophages are involved in the removal of cellular debris derived from 
neutrophils. With regard to clearance mechanisms of dead cells it was also 
interesting to find that the only clinical parameter that DNA levels in the RA SF 
correlated with was disease duration. At the same time, a strong correlation 
between neutrophil but not macrophage numbers and disease duration could be 
found when excluding patients receiving treatment with methotrexate. There 
could be several possible explanations for this association between DNA levels 
in the SF with disease duration. One possibility is that the equilibrium between 
influx in, and removal of, neutrophils from the SF becomes disturbed over time 
due to changes in neutrophil recruitment or clearance defects. Another 
possibility, however, could also be that changes in the disease phenotype over 
time lead to an increased rate of cell death in the SF with disease duration. In 
support of this view and in the context of NETosis it was shown in SLE patients 
that complement protein C1q appears to protect NET DNA from DNase I 
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degradation, and that an increased binding of autoantibodies over time further 
increased C1q deposition which resulted in decreased NET degradation (64). 
Similar processes are also possible in RA, but would need to be proven 
experimentally in future studies. Additionally, it was interesting to observe that a 
much weaker correlation between DNA levels and/or neutrophils and disease 
duration was observed when patients receiving methotrexate or other DMARDs 
were included. This would indicate that neutrophil cell death could potentially be 
influenced by DMARDs and, more precisely, methotrexate. In this context it was 
reported that low doses of methotrexate can enhance adenosine release from 
connective tissue cells which inhibits neutrophil adherence to these cells 
(350,351). In view of these data, patients treated with methotrexate may 
therefore show decreased levels of neutrophil recruitment into the synovial fluid 
and neutrophil cell death, which could explain the observed weaker association 
of DNA levels and/or neutrophil concentrations with disease duration when 
including these patients in the statistical analysis. 
 
In search of an answer to the question as to how neutrophils are possibly 
activated to enter into NETosis in the RA SF we hypothesised an influence of 
autoantibodies, as ANCA and anti-DNA antibodies in SLE and ANCA-
associated vasculitides have been shown to induce NETosis (33,66). The exact 
molecular mechanism, as to how this may happen, still remains elusive. In 
addition, immune complexes in RA have long been proposed to play a role in 
neutrophil activation primarily based on data generated from murine arthritis 
models such as the K/BxN model (300,311). In humans, immune complexes 
(IC) have also been found in the SF and ACPA in the SF were shown to be 
106 
 
enriched compared to the peripheral blood (352). Recently, rheumatoid factor 
was reported to activate neutrophils via Fcγ receptors on neutrophils in arthritis-
associated vasculitis (331). In view of these studies it was interesting to find that 
indeed PEG enriched immune complexes from SF of RA patients induced 
NETosis in neutrophils. PEG precipitation is a well-recognised technique for the 
isolation of high-molecular-weight ICs. However, earlier investigations showed 
PEG-precipitated sera to contain uncomplexed immunoglobulins, C3 (353) and 
a number of serum proteins including fibronectin and albumin (343). Therefore 
PEG precipitates are not only composed of ICs. This may explain why the rate 
of NETosis is not decreased by pre-incubating the cells with blocking antibodies 
against the Fc receptors FcγRIIA (CD32a) and FcγRIIIb (CD16b). This would 
suggest that other factors, which were co-enriched by PEG, are possibly also 
involved in the induction of NETosis. 
 
In agreement with an ACPA-dependent induction of NETosis, a trend of 
increased release of extracellular DNA could be detected when stimulating 
neutrophils with IC enriched from the SF of ACPA positive patients compared 
with ACPA negative patients. Additionally, a small but statistically significant 
difference in DNA levels in the SF of ACPA-positive compared with ACPA-
negative RA could be detected. However, it can be assumed that this study 
currently does not have sufficient statistical power to reveal the influence of 
ACPA on DNA levels in the SF. Additionally, due to the low number of available 
samples, in which the cell number could be determined, it could not be identified 
as to whether the difference in DNA levels arises because of a difference in 
neutrophil numbers between ACPA positive and negative RA patients or 
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whether other factors are involved. Interestingly, in the previously mentioned 
work of Leon et al., in which a larger sample number of 106 patients was 
studied, a statistically significant difference between seropositive and 
seronegative samples could be measured (340). Nevertheless, since no 
sufficient knowledge about ACPA was available at that time no further details 
can be drawn from this report. More recently, two publications reported on the 
association of NETosis with ACPA (120,354). In agreement with the IC 
experiments in this thesis, Khandpur et al. detected induction of NETosis in 
control and RA peripheral blood (PB) neutrophils upon exposure to sera and SF 
from RA patients. Interestingly, they also found a correlation between NET 
formation by peripheral blood (PB) neutrophils from RA patients and the titre of 
ACPA, but no correlation with disease duration. In this regard, our data 
therefore do not overlap with these results, however, due to missing information 
with regards to the number of experiments and samples included in  their study 
it was difficult to make direct comparisons with the experiments presented here 
and ultimately draw definitive conclusions. With regard to additional stimuli that 
may induce NETosis in RA patients, Khandpur et al. also reported that the 
presence of TNF-α and IL-17 triggered NETosis in a ROS-dependent manner 
supporting our view of further antibody-independent ways of inducing NETosis 
in RA. Nevertheless, the exact explanation as to how this induction may occur 
remains elusive, as it is still unknown how neutrophils are activated by IL-17 
since studies suggest that these cells do not express the IL-17 receptor C which 
forms a multimeric complex with IL-17 receptor A and is required for IL-17 
receptor signal transduction (355,356). Others also report about the induction of 
NETosis by the alarmin HMGB1 (344) or GM-CSF in combination with the 
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complement factor 5a (C5a) (357). Taking into account that the concentrations 
of GM-CSF (358) and C5a (309) are much higher in the SF of RA patients, and 
considering the fact that we found macrophages which are known to produce 
GM-CSF in high amounts associated with neutrophils and NETs on SF 
preparations, these mediators could possibly be of great importance for NET 
formation. Moreover, findings in mouse models of inflammatory arthritis have 
revealed that C5a is critically involved in inflammatory joint damage and that 
anti-C5a antibodies have been proven effective in the prevention of the disease 
in these mice (359,360). 
 
Although the in vitro experiments presented here demonstrate less DNA release 
from necrotic neutrophils compared with NETotic neutrophils and although 
attempts were made to exclude the measurement of DNA derived from SF cells 
with permeable membranes in our assays, it is still difficult to certain as to which 
type of cell death precisely contributed to the pool of extracellular DNA in the SF 
of patients with inflammatory arthritis. Indeed NETosis may well be not the only 
source of extracellular DNA in the joints of patients with inflammatory arthritis. 
Additionally, caution has to be taken with respect to the significance of NETosis 
for the RA pathogenesis compared with other cell death mechanisms in the RA 
joint since different types of cell death were reported to have either pro- or anti-
inflammatory effects on macrophages (349,361). 
 
Nevertheless, the discovery of NETosis in the joints of patients with 
inflammatory arthritis, no matter at what proportion, not only implies a possible 
pathogenic role due to cytotoxicity of NETs but also suggests an important role 
109 
 
for neutrophils in the supply of intracellular autoantigens. This concept 
associates with the widely-accepted hypotheses linking cell death to the 
initiation of systemic autoimmunity (361–363). This aspect will further be studied 


































4 Peptidylarginine deiminase activity in the 















Citrullination (or deimination) is a post-translational modification, in which 
arginine residues are converted into citrulline. This calcium-dependent 
enzymatic reaction is catalysed by peptidylarginine deiminases (PADs) and 
leads to a change in protein structure. The family of PADs consists of five highly 
homologous and functionally similar isoenzymes, but these enzymes differ in 
their expression pattern throughout organ systems and cell types (185,186). 
Activation of PAD isoforms is relevant to RA, as specific autoimmunity to 
citrullinated proteins can be observed in approximately 60% of RA patients 
(171,364) and their presence defines a group of patients with more aggressive 
disease and distinct genetic associations. Anti-citrullinated protein antibodies 
(ACPA) are enriched in the synovial fluid of RA patients compared with serum 
(352,365) and local B cell responses to citrullinated proteins have been 
observed in the rheumatoid joint (235). Although citrullination of intra- and 
extracellular proteins can be found in the synovial tissue and synovial fluid of 
RA patients (248,249,254), it is a general inflammation-dependent process and 
not specific for RA (251,252). 
Neutrophils express PAD2, which is ubiquitously expressed, and PAD4 which is 
mainly expressed by myeloid cells. Recently, PAD3 expression in human 
primary neutrophils has also been described (203). PAD4 is the only PAD 
isoform with a nuclear localisation signal and its activity was described to be 
essential for NET formation (44,46).  
Our observation of NETosis in arthritic joints raises the possibility that 
enzymatically active PADs are released into the SF during NET formation, and 
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thus implicates a central role for neutrophils in the generation of autoantigens 
for the local inflammatory response. In the work described in this chapter the 
development of an in vitro assay will initially be reported and the release of 
PADs from neutrophils entering into NETosis and the localisation of PADs in 
these cells is investigated. Furthermore levels of PAD activity in SF in relation to 
the observed neutrophil infiltration will be examined and lastly, possible 
additional PAD release mechanisms will be discussed. 
 
4.2 Method development for the in vitro isolation of 
NETs 
Since NETosis leads to the release of intracellular proteins, firstly it was sought 
to determine whether, and how, neutrophils undergoing NETosis release PADs 
into the extracellular space. If neutrophils in the SF contribute to the pool of 
available extracellular PADs it is important to know whether PAD isoforms 
during NETosis are released attached to the DNA/protein complex of the NETs 
or whether they diffuse freely. If PADs remain tethered to NETs, this would 
potentially limit the role of neutrophil-derived PADs to the SF. For this purpose, 
an in vitro assay of NET isolation and detection was developed based on a 
previously published method (315). Initially, to determine an optimal time point 
for the isolation of NETs, a time course after stimulation of neutrophils with 25 
nM PMA was performed using SYTOX green in order to monitor DNA levels in 
the supernatants. As shown in Figure 4-1, a statistically significant difference 
between the release of extracellular DNA in stimulated and unstimulated 
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neutrophils could be observed 240 min after stimulation with 25 nM PMA. This 













Figure 4-1 In vitro time course analysis of DNA release post-stimulation with PMA 
Neutrophils were isolated from peripheral blood of healthy subjects and stimulated with 25 nM 
PMA. Significantly higher DNA levels were found in the supernatant after 4 h of stimulation with 
PMA compared with non-stimulated cells (Wilcoxon matched-pairs signed rank test, n=8; n.s.: 











































For the study of NET-associated proteins it is essential to avoid contamination 
with unbound proteins that are released freely into the extracellular space 
during NETosis. The method developed therefore took advantage of the 
capacity of activated neutrophils to attach firmly to the bottom of tissue culture 
plates. For this purpose, peripheral blood neutrophils were isolated from healthy 
donors and seeded in 12-well plates. After stimulation of 4 h with 25 nM PMA 
neutrophils were washed three times to remove unbound proteins. At this stage, 
the majority of the NETs remained associated with activated neutrophils at the 
bottom of the plate. In the final step DNase-I was used to release NETs from 
the cells into the supernatant. To verify the purification procedure, DNA levels in 
the supernatants generated during NET isolation were tracked using SYTOX 
green. As shown in Figure 4-2, only a small proportion of DNA was detectable 
in the supernatant of stimulated neutrophils (SN) indicating that NETs remain 
largely attached to the neutrophil-layer at this stage. After 3x washing (W1-W3) 
DNase-I treatment released a fraction containing significantly higher levels of 
DNA (+DNase-I) compared with fractions derived from stimulated neutrophils 
incubated without DNase-I (-DNase-I) or non-stimulated neutrophils treated with 
DNase-I (+DNase-I (unst.)) (Figure 4-2). Importantly, all supernatants were 
centrifuged once at 300 x g to remove cells and a second time for 16 000 x g to 







Figure 4-2 DNA levels in supernatants generated during in vitro NETosis 
Supernatants of unstimulated (SN (unst.)) or stimulated neutrophils (SN) were collected. After 
stimulation, cells were washed 3 x with RPMI (W1-W3) and subsequently incubated with or 
without DNase-I (+DNase and –DNase). Non-stimulated cells were treated with DNase-I 
(+DNase (unst.)) as control. NETs could be specifically enriched in the supernatant of 
stimulated neutrophils treated with DNase-I (+DNase-I = NET fraction) compared with control 
fractions (Wilcoxon matched-pairs signed rank test, n=7; * indicates p<0.05). All fractions were 
centrifuged to remove cells and cell debris. Release of NETs was detected using SYTOX 
















































































4.3 Analysis of PAD release during in vitro NETosis 
Having established and validated a method for the isolation of NETs, the protein 
composition in the different fractions of the in vitro model were determined, as 
described in 4.2. The supernatants were precipitated using trichloroacetic acid 
(TCA) and western blotting was performed with each of the fractions. 
Importantly, anti-PAD2 and anti-PAD4 antibodies were assayed for cross-
reactivity using human recombinant PAD4 and human skeletal muscle tissue, 
which is known to specifically express just the isoform PAD2, but not PAD4. As 
shown in Figure 4-3A, the antibodies did not show any cross-reactivity between 
different PAD isoforms. Using these antibodies it was then demonstrated that 
both PAD2 and PAD4 can be detected in the SN and in the NET fraction 
(+DNase-I), suggesting that PAD2 and PAD4 are both freely diffusible as well 
as released attached to NETs (Figure 4-3B). Neutrophil elastase, which was 
already shown to be one of the most abundant NET-associated proteins, was 
used as an additional control. As expected it was found to be associated with 
the NET fraction in this approach. Additionally, in accordance with the 
previously shown STYOX green assay (Figure 4-2) for DNA release, histone H3 
could be detected both in the SN and the chromatin-rich NET fraction.  
 
To validate these results quantitative proteomics after trypsin digestion was 
performed. In agreement with Urban et al. a small number of mainly granular 
and nuclear proteins were confirmed to be enriched in the NET fraction (315) 
(Table 4-1). In comparison, a wide range of proteins were found to be released 
into the supernatant during NETosis, which were either enhanced in the SN 
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fraction or present in both fractions (listed in Appendix, Table 8.5). In agreement 
with the western blotting data, PAD2 and PAD4 were detected both in the 
supernatant and in the DNase-I treated NET fraction from seven patients in two 
different analyses: while PAD2 was more abundant in the SN fraction, PAD4 
was more abundant in the NET fraction (listed in Appendix, Table 8.5). 
 
Furthermore, to test whether the PAD2 and PAD4 enzymes that are released 
into the supernatant during in vitro NETosis are enzymatically active, PAD 
activity was determined using a recently developed assay (19). Firstly, 
increased PAD activity with the addition of protease inhibitors was observed 
(Figure 4-4A). This is not potentially surprising, as enzymatically active PADs 
are known to be autocitrullinated (199,200) and citrullinated proteins have been 
reported to be more susceptible to proteolysis due to citrullination-induced 
protein unfolding (185,191,193). Additionally, enzymatic PAD activity in 
supernatants from neutrophils could be increased by diluting the supernatants 
1:2 with calcium concentrations of up to 8.58 mM resulting in a final 
concentration of 4.5 mM calcium (Figure 4-4B). At final calcium concentrations 
at 10 mM and higher, however, no PAD activity could then be detected (Figure 
4-4B). PAD activity in RPMI, which contains a physiological calcium 
concentration of 0.42 mM, was therefore minimally detectable but could be 
increased at non-physiological calcium concentrations in agreement with 
previous reports (48). Using a final calcium concentration of 4.5 mM together 
with protease inhibitors, the PAD activity assay could be optimised in a way that 
revealed significantly higher levels of PAD activity in the supernatants of in vitro 
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stimulated neutrophils compared with non-stimulated cells after 2.5 h of 






Figure 4-3 Identification of PADs released during NETosis in vitro 
(A) Immunoblotting using human recombinant PAD4 (250 ng) and PAD2-expressing human skeletal muscle tissue lysate (7 or 15 
µg). To demonstrate the absence of cross-reactivity, membranes were incubated with anti-PAD2 and two anti-PAD4 antibodies 
(Abcam and Novus Biologicals). (B) Proteins were precipitated from supernatants as described and their presence analysed by 
western blotting using antibodies against the proteins histone H3, neutrophil elastase, PAD4 and PAD2. One representative blot out 


























Histone H2B type 2-E 
Histone H2A (fragment) 
Histone H2A type 3 
Histone H2B 
MNDA 
Cytoskeleton Cytokeratin 10 
other 
Eosinophil cationic protein 
Complement C3 
 
Table 4-1 Proteins enriched in the NET fraction 
268 proteins from 3 matched SN and DNase-I treated NET fractions were quantified using 1% 
FDR and 2 peptides per protein. Abundance of proteins in D compared to SN was calculated 
using t-test (cut-off p<0.05). 14 proteins were found to be enhanced in the NET fraction of all 3 











Figure 4-4 PAD activity in the supernatants of in vitro stimulated neutrophils entering into NETosis 
PAD activity was determined in the supernatant of unstimulated neutrophils and neutrophils 
stimulated with 25 nM PMA. (A) PAD activity in the supernatant of neutrophils after 4 h 
stimulation was increased by adding protease inhibitor cocktail (PI-Mix). (B) PAD activity was 
increased when diluting the supernatant of neutrophils after 2 h stimulation 1:2 with a 5.58 or 
8.58 mM calcium concentration, whereas activity was abolished over a 19.58 mM calcium 
concentration. (C) PAD activity in the supernatant of neutrophils after 2.5 h stimulation (SN) 
compared with unstimulated controls (SN (unst.)). Statistical significance was determined by 





































































































































Furthermore, in order to visualise the time point of PAD2 and PAD4 release in 
relation to NETosis in vitro, immunofluorescence staining was performed. Since 
the localisation of PAD4 is still under debate, it was interesting to find that PAD4 
localisation in unstimulated peripheral blood neutrophils from healthy donors 
was restricted to the nucleus (Figure 4-5) in agreement with Nakashima et al. 
(196) while PAD2 was largely restricted to the cytosol. Upon stimulation, at 120 
and 240 min a proportion of the cells had changed their nuclear morphology. 
Nuclei appeared rounded and decondensed indicating a stage of NETosis 
directly preceding DNA release (Figure 4-5). PAD2 staining was reduced within 
30 min of stimulation, while PAD4 staining was lost from the nuclei after DNA 
decondensation. Surprisingly, in contrast to our western blotting and mass 
spectrometry data, the association of PAD4 with NETs could not be confirmed. 
This could, however, be explained by the absence of protease inhibitors in the 
neutrophil cell culture. As previously mentioned, active autocitrullinated PAD4 







Figure 4-5 Time course of PAD2 and PAD4 release during in vitro NETosis 
Confocal microscopy reveals that part of the cells begin entering NETosis after 120 min of 
stimulation. While PAD2 is only seen in the cytosol, in resting neutrophils PAD4 is localised in 
the nucleus. PAD2 levels decrease after 30 min and PAD4 is not detected in the nuclei of cells 
undergoing DNA decondensation (DNA is shown in blue, PAD2 in green, PAD4 in red and co-
labelled with neutrophil elastase (NE) in green). No PAD4 signal was detected after 240 min of 




4.4 Peptidylarginine deiminases in the SF of RA 
patients 
After having demonstrated the release of extracellularly active PADs after 
NETosis in vitro, the presence and enzymatic activity of PADs in the synovial 
fluid of RA patients was assayed. In agreement with Kinloch et al. (249), PAD2, 
PAD4 and neutrophil elastase  were detected in the cell-free SF of patients with 
RA (Figure 4-6A). Whereas PAD4 varied considerably in its expression level 
between patients, the amount of PAD2 was found to be more consistent. In 
preliminary experiments, attempts were made to immunoprecipitate 
endogenous PAD4 from the SF of RA patients using a purified mouse anti-
human PAD4 antibody raised against the recombinant full length protein, 
corresponding to amino acids 1-663 of human PAD4. The same antibody was 
successfully used for immunofluorescence staining in the previously shown 
results (see Figure 4-5). In addition, the SF was spiked with recombinant human 
PAD4 to validate the method. Interestingly, similar to results of PAD4 in 
activated neutrophils in a publication by Andrade et al. (199), endogenous 
PAD4 from the SF could not be immunoprecipitated, whereas the spiked 
recombinant PAD4 was detected (Figure 4-6B). This would indicate that 
although this antibody recognises both denatured recombinant and denatured 
endogenous PAD4 in immunoblotting, it is unable to immunoprecipitate native 
endogenous PAD4 from the SF of RA patients in contrast to native recombinant 
PAD4 protein. Since it was previously reported that PAD4 can autocitrullinate 
itself during activation (199,200) and that citrullination leads to changes in 
protein structure (190), it is therefore likely that endogenous PAD4 in the SF is 
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in an autocitrullinated state, which alters its structure and recognition by 
antibodies generated against non-citrullinated PAD4 and suggests that the SF 
seems to provide high enough calcium concentration to enable enzymatic PAD4 
activity. Indeed, PAD activity in the SF of RA patients could be detected using 
the previously described PAD activity assay. To assess, whether the variable 
citrullination efficiency in the samples can be related to the abundance of PAD2 
and/or PAD4 in the RA SF samples and thus the signal strength on the 
immunoblot shown in Figure 4-6A, relative quantitation of the PAD2 and PAD4 
signal was performed using the Image Lab 4.0 software by Bio-Rad. An 
exposure time below the saturation level of the signal was used. The band with 
the highest intensity was used as reference band and assigned a value of 1.0. 
The intensity of the remaining bands on the blot were then calculated by the 
software in relation to this reference band. Surprisingly, no correlation between 
citrullination efficiency and PAD2 or PAD4 signal strength on the immunoblot 
was deteted. This suggests that the efficiency by which the substrate in the 
assay was citrullinated by the PADs present in the SF of these patients cannot 
be exclusively explained by the quantity of PAD2 and/or PAD4 protein present 
in the samples (Figure 4-6C-D). 
As shown in Figure 4-7A, PAD enzymatic activity was significantly higher in the 
SF of RA patients than in that of OA patients at the supraphysiological calcium 
concentrations used in the assay (p<0.05). Variable amounts of PAD activity at 
supraphysiological calcium levels could also be detected in the SF of patients 
with different forms of inflammatory arthritis (Figure 4-7B). Interestingly, the 
difference between RA and OA could also be observed with non-diluted SF 
samples at their native calcium concentration, however this was at ~140-fold 
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lower median value of PAD activity in the RA SF samples when accounting for 




Figure 4-6 Presence of PAD2 and PAD4 in the synovial fluid of RA patients 
(A) Immunoblotting of albumin depleted SF samples from 8 RA patients incubated with 
antibodies against neutrophil elastase (NE), PAD4 and PAD2. (B) Immunoprecipitation (IP) of 
PAD4 from SF of an RA patient using mouse anti-human PAD4 antibody (ab128086) (lane 1) 
and mouse anti-human IgG2a isotype control (lane 2). In lane 3, SF was spiked with 
recombinant human PAD4 protein (r hu PAD4) and the same amount of specific mouse anti-
human PAD4 antibody was added as in lane 1. All lanes are probed with mouse anti-human 
PAD4 antibody (ab128086). As secondary antibody an anti-mouse IgG, HRP-linked antibody 
was used. (C,D) Relationship between citrullination efficiency (expressed as PAD activity 
measured with the PAD activity assay) and PAD2 or PAD4 signal strength (relative 
quantification) calculated from blot shown in (A). Relative quantification was performed using 
the Image Lab 4.0 software by Bio-Rad and the reference band with the highest intensity was 
assigned the value 1.0. The intensity of all other bands was then calculated by the software in 
relation to this reference band. Data were analysed using Spearman’s test for correlation. 
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Figure 4-7 PAD activity at physiological and supraphysiological calcium levels 
(A) Comparison of PAD activity in RA patients and OA patients. SF samples were diluted 1:100 
with deimination buffer. Data were analysed using Mann-Whitney test. (B) Comparison of PAD 
activity in RA patients and patients with different forms of inflammatory arthritis. (C) PAD activity 
in SF samples, which were either diluted 1:100 in deimination buffer with 5 mM calcium 
concentration (supra-physiological) or were used undiluted (physiological). Significantly higher 
PAD activity could be observed in RA patients (n=6) compared to osteoarthritis (OA) patients 



























































































































Furthermore, PAD activity strongly correlated not only with the level of 
extracellular DNA in the SF (r = 0.8; p < 0.001) (Figure 4-8A) but also with total 
cell counts (Figure 4-8B) and neutrophil cell counts (r = 0.8; p = 0.002) (Figure 
4-8C) in untreated, fresh SF samples. Interestingly, whereas a statistically 
significant difference in DNA levels between ACPA positive and ACPA negative 
RA patients could be detected (chapter 3.4), no statistically significant 
difference in PAD activity between ACPA positive and ACPA negative RA 
patients could be observed (Figure 4-8D). However, PAD activity was found to 
correlate with disease duration similar to the DNA levels in SF samples shown 





Figure 4-8 Correlation of PAD activity with DNA levels, neutrophil numbers and disease duration 
(A) PAD activity correlates significantly with DNA levels in the SF of RA patients (n=22; r=0.8, 
p<0.0001). Data were analysed using Spearman’s test for correlation. (B) PAD activity 
correlates significantly with the total cell count in untreated synovial fluid of RA patients (n=15; 
r=0.72, p=0.002). Data were analysed using Spearman’s test for correlation. (C) PAD activity 
correlated significantly with neutrophil cell counts in the synovial fluid of RA patients (n=13; 
r=0.8, p=0.002). Data were analysed using Spearman’s test for correlation. (D) Comparison of 
PAD activity in ACPA positive and ACPA negative (p=0.47) and/or rheumatoid factor (RF) 
positive and negative patients (p=0.9), respectively. Data were analysed using Mann-Whitney 
test. (E) Relationship between PAD activity and disease duration. Data were analysed using 
Spearman's test for correlation (n=21; r=0.44, p=0.04).  
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4.5 Localisation of PAD4 in neutrophils from RA 
patients 
After having studied localisation and PAD release mechanisms in in vitro 
stimulated neutrophils and having detected PAD activity in the SF of RA 
patients, we were also interested in visualising the localisation of PAD4 in 
neutrophils from RA patients. Similar to unstimulated neutrophils, PAD4 
localisation was found to be restricted to the nucleus. Unexpectedly, however, a 
proportion of neutrophils within the synovial fluid infiltrate of RA patients 
displayed an additional cytoplasmic localisation, whereas at the same time a 
reduced co-localisation between PAD4 and the DNA signal was detected in 
these cells (Figure 4-9) suggesting a potential translocation of the protein from 
the cell nucleus to the cytoplasm. The amount of cells displaying a cytoplasmic 
PAD4 localisation varied between the analysed 5 RA patients; this needs to be 
further confirmed and studied in more detail due to the low number of available 
samples. Interestingly, the cytoplasmic PAD4 staining displayed a granular 
pattern and would suggest a possible release mechanism via degranulation. 
Which of the four types of granules are involved, however, needs to be a target 
of further investigation. 
To determine whether the increased cytoplasmic PAD4 staining can be 
explained by the translocation of the enzyme from the cell nucleus to the 
cytoplasm, the percentage of cytoplasmic PAD4 signal compared with the total 
PAD4 signal in each cell was calculated based on pixel count per µm2 area 
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using the histogram function and the image calculator function of the ZEN2010 
software (details are provided in the Materials and Methods Chapter 2). 
Importantly, all intact neutrophil elastase positive neutrophils on a cytospin from 
a patient sample were included into the calculation (Figure 4-10A). Each data 
point in Figure 4-10B therefore represents the average percentage of 
cytoplasmic PAD4 pixel count of the total PAD4 pixel count in neutrophils in one 
RA patient sample. As shown in Figure 4-10B, a significantly increased 
percentage of cytoplasmic PAD4 in neutrophils within the SF infiltrate of RA 
patients (RA SF) was found compared to the signal in peripheral blood 
neutrophils of RA patients (RA PB) and peripheral blood neutrophils of healthy 
controls (HC PB) (Figure 4-10B). These data therefore indicate that there may 
be a role for cytoplasmic PAD4 expression in the SF of RA patients.  
At this stage, no correlation of cytoplasmic PAD4 expression with DNA levels, 
PAD4 activity or any clinical parameters could be assessed due to the small 
number of analysed samples, however, cytoplasmic PAD4 expression was 
present in both ACPA positive and ACPA negative RA patients. No information 
can also be provided with regard to the presence of cytoplasmic PAD4 in 
patients with different types of inflammatory arthritis. In light of the importance of 
anti-citrulline immunity in RA, however, these preliminary observations are 





Figure 4-9 Cytoplasmic localisation of PAD4 in a population of SF neutrophils from RA patients 
Immunofluorescence of cytospins from cells of the SF of RA patients. Cells were stained for 
DNA (grey), PAD4 (green) and neutrophil elastase (NE) (red). Lower panel shows concentration 
and isotype matched control staining. Immunofluorescence staining was visualised using a 
confocal microscope and viewed at a final magnification of 63 x 10 original magnification. 
Images are representative of 5 SF samples from RA patients. 
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Figure 4-10 Quantification of percentage of cytoplasmic PAD4 signal of total PAD4 signal in 
neutrophils using the ZEN 2010 software 
(A) Immunofluorescence staining of a cytospin from SF cells taken from an RA patient. The 
cytospins were stained with antibodies specific for PAD4 (green) and neutrophil elastase (NE) 
(red). Nuclei were counterstained using Hoechst 33258 (blue). Cytospins were stained 
alongside isotype- and concentration-matched controls, which were negative. Images were 
taken at x 630 total magnification using a Zeiss confocal LSM 510 microscope. To perform the 
analysis, neutrophil elastase positive neutrophils were selected (drawn around) using the 
overlay function within the ZEN software. (B) Percentage of cytoplasmic PAD4 of total PAD4 
pixel count was determined using the method described in (A). Significantly increased 
percentage of cytoplasmic PAD4 in relation to the total PAD4 signal in neutrophils within the SF 
infiltrate of RA patients (RA SF) was compared with the signal in peripheral blood neutrophils of 
RA patients (RA PB) and peripheral blood neutrophils of healthy control subjects (HC PB). 
























































The mechanisms behind the activation of PADs in RA patients, as well as the 
sites and circumstances of citrullination of autoantigens in RA remain unknown. 
In this chapter an in vitro assay for NETosis was established which 
demonstrates that NETosis provides a source of freely diffusible enzymatically 
active PADs. Importantly, significantly increased PAD activity in the SF of RA 
patients compared with OA patients was shown and found to strongly correlate 
with neutrophil numbers. Together with these findings regarding NETosis in 
arthritic joints these results therefore indicate NET formation as one possible 
source of PAD activity and thus a prerequisite for the generation of citrullinated 
autoantigens in ACPA positive RA. 
 
In line with the in vitro findings demonstrating the presence and activity of PADs 
in the supernatants of neutrophils stimulated to go into NETosis, the presence 
and activity of PADs could also be demonstrated in the SF of RA patients. 
These findings are in agreement with previous reports demonstrating the 
presence of PAD2, PAD4 and citrullinated proteins in the joints of RA patients 
(249,250). Kinloch and colleagues showed that PAD4 protein is present in SF 
samples of OA patients, although at lower levels than in SF samples of RA and 
SpA patients. Presence of PAD2 and citrullinated proteins, however, could only 
be detected in RA and SpA SF samples but not in OA SF samples, 
subsequently the hypothesis was proposed that it may be mainly the PAD2 
enzyme that is responsible for the extracellular citrullination of synovial fluid 
proteins in patients with inflammatory arthritis (249). The assay for the detection 
of PAD activity used in the experiments presented here however cannot 
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distinguish between different isoforms of PADs. This hypothesis can therefore 
not be tested here, although indeed significantly higher PAD activity in RA 
patients and in patients with other forms of inflammatory arthritis was found 
compared with OA patients. Interestingly, however, it has to be noted that even 
though no presence of PAD2 protein in OA SF samples was found by Kinloch et 
al., the PAD activity assay in our experiments revealed a low, but still existing 
activity of up to 0.3 mU in some OA patients, suggesting that the enzymatic 
activity of PAD isoforms other than PAD2 should not be discounted. 
Furthermore, it should be considered that the measured PAD activity in cell 
lysates or SF only reflects the efficiency with which moles of substrate are 
converted in a given time. Not only the PAD isoform but also the quantity of 
enzyme as well as the state of activity of the enzymes within the samples are, 
however, unknown factors. PAD activity in the SF of RA patients may therefore 
not only be based on the quantity of enzymes alone but could also be 
influenced by additional factors such as endogenous PAD activators or 
inhibitors. In support of this idea data presented here indeed revealed no 
significant correlation between the intensity of PAD2 and/or PAD4 protein signal 
on immunoblots and measured PAD activity. Although this would suggest that 
the general citrullination efficiency in the SF does probably not increase with 
higher abundance of the enzymes, these data have to be interpreted with 
caution due to the small number of analysed samples. In this context, Darrah 
and colleagues suggested in a recent study that PAD4 activity can be regulated 
by PAD3/PAD4-cross-reacting autoantibodies binding to and changing the 
protein structure of PAD4 (366), which is itself known to be an autoantigen in 
ACPA positive RA (199,367,368). This change in protein structure strikingly 
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increased the catalytic efficiency of PAD4 by decreasing the enzyme’s 
requirement for calcium in vitro. Patients with these antibodies displayed a 
higher likelihood of radiographic progression compared with individuals who 
responded negatively for these antibodies (369). Interestingly, these cross-
reacting autoantibodies are only present in a subpopulation of anti-PAD4 
antibody positive individuals, which themselves are known to be strongly 
associated with anti-ccp antibodies (368). This may also explain why no 
statistically significant difference in PAD activity levels was detected here when 
comparing ACPA positive with ACPA negative RA SF samples. A comparison 
between patients positive and negative for PAD3/PAD4-cross-reactive 
antibodies in this study would have been potentially interesting in order to 
determine whether the in vitro observations by Darrah et al. could be confirmed 
in vivo. 
 
The above mentioned study by Darrah et al. is also interesting in another aspect 
as it provides a potential mechanism for the well-known mismatch between the 
in vitro and in vivo calcium requirements for PAD4 activity (47,48,369). PAD 
enzymatic activity depends on the presence of calcium and intracellular calcium 
levels are reportedly below the level needed for in vitro PAD activity. Whereas 
most in vitro citrullination assays including the ABAP assay used in this study 
utilise calcium concentrations of 5-10 mM calcium to achieve maximal PAD 
activation (47,48,197), cytosolic levels of free Ca2+ are known to increase in 
activated cells only up to 10 µM. Under pathological conditions these levels can 
further rise up to 100 µM for a short time, but need to return to original levels to 
ensure cell survival (370). In comparison, calcium levels in the extracellular 
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space are estimated to range between 1.1-1.3mM in plasma and 0.49-0.98mM 
in SF (369,371). In line with these observations it was interesting to see that 
PAD activity in RA SF samples measured at 5 mM calcium concentration 
decreased ~140-fold when measuring PAD activity at physiological calcium 
levels and accounting for the dilution factor. This indicates that PAD enzymes in 
the SF appear to possess a “general fitness” of increased activity towards the 
substrate used in the assay when they come into contact with higher calcium 
concentrations. Although it is in general possible that a PAD activity below the 
theoretical potential activity is still sufficient for citrullination of synovial fluid 
proteins at the heightened calcium levels in the extracellular space, it is, 
nevertheless, imaginable that additional factors such as cross-reactive 
antibodies or other modulators regulate PAD activity in vivo.  
 
Other possible factors suggested to modulate PAD activity are proteolysis and 
citrullination itself. Although Andrade et al. described in 2010 that 
autocitrullination of PAD4 at several sites of the enzyme inactivates its function 
(199), this finding could not be confirmed in a more recent study by Slack and 
colleagues (200). Interestingly, the main difference in Andrade’s data was that 
citrullinated and native PAD4 was incubated with lysates from HL-60 cells 
whereas highly purified substrates were used by Slack et al. It is therefore 
possible that factors present in the lysate could have inactivated specifically the 
citrullinated form of the enzyme. Although enzyme degradation was excluded by 
Andrade et al., it is surprising that in the studies presented here PAD activity in 
the supernatant of activated neutrophils was only detectable in the presence of 
a protease inhibitor cocktail containing components such as AEBSF, E-64 and 
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Pepstatin A. Indeed, citrullination of proteins is known to lead to their 
degradation by proteases. For example, Hsu et al. reported that citrullination of 
human fillaggrin-2 by PAD1, PAD2 and PAD3 promotes its proteolytic 
degradation by calpain-1 (191). Since citrullination induces a decrease in 
positive charge of the protein, the conformation is changed and makes the 
protein more susceptible to proteolysis (185). 
 
As the assay used for measuring PAD activity does not distinguish between 
different PAD isoforms, it has to be considered that a contribution to the total 
PAD activity by PAD2, PAD3 and PAD4 is possible. Interestingly, mass 
spectrometry data did not identify any unique peptides matching PAD3 as being 
present in neutrophils. Identification of PAD isoforms that are responsible for the 
observed PAD activity is of interest as it was recently reported that different 
PAD enzymes display distinct substrate specificities (203) and could therefore 
lead to the citrullination of different autoantigens. Interestingly, Darrah et al. also 
showed that the citrullination activity of each PAD isoform appears to be specific 
and directed preferentially against distinct substrates, independent of their 
cellular localisation. Indeed this substrate preference becomes even more 
evident when the enzymes are exposed to a larger number of substrates. For 
example, in cell lysates, actin and histone H3 are only citrullinated by PAD2 and 
PAD4, respectively, which means that although actin and histone H3 can be 
citrullinated by all PAD isotypes, each enzyme has a clear, intrinsic substrate 
preference. These results are also in agreement with data from Nakayama-
Hamada et al. who demonstrated that human rPAD2 citrullinates purified 
fibrinogen and filaggrin more efficiently than human rPAD4 (372). In this context 
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different PAD isoforms may have different citrullination efficiency towards the 
substrate used in the PAD activity assay presented here. 
 
In relation to the presence of extensive NET formation in the joints of RA 
patients it was interesting to observe that the PAD activity in the SF of RA 
patients showed, in general, very similar properties compared with DNA levels 
described in Chapter 3: PAD activity was significantly increased in RA patients 
compared with OA patients, it was present in the SF of patients with different 
forms of inflammatory arthritis and also correlated strongly with neutrophil 
numbers. Intriguingly, PAD activity also increased with disease duration. A 
decrease of regulatory factors over time may lead to increases of both DNA 
levels and PAD activity with disease duration and/or degradation and removal of 
the products of NETosis may be affected. Interestingly, Makrygiannakis et al. 
published in a recent study that intra-articular injection of glucocorticoids, and 
not oral methotrexate, resulted in a reduction in synovial inflammation, 
intracellular citrullination, and PAD expression (373). In this study, we could not 
see a significant difference between PAD activity levels in the SF of patients 
taking methotrexate compared with patients taking other medication (data not 
shown). Additionally, no difference between patients taking oral prednisolone 
was found, although the number of analysed samples was relatively small. In 
the future it would be interesting to determine whether the results published by 
Makrygiannakis could be confirmed when examining PAD activity levels in the 




Citrullination of histones H2A, H3 and H4 is catalysed by PAD4 and was shown 
to be an important step in the decondensation of DNA and NET formation 
(34,44), however, the exact mechanism through which PAD4 is involved in the 
unwinding of chromatin is still unclear. Additionally, PAD4 was reported to have 
a crucial role in gene regulation by citrullinating arginine residues on histones 
and thus counteracting arginine methylation that coincides with the 
transcriptionally active state (194). It was therefore not unexpected to find PAD4 
localised in the cell nucleus of unstimulated neutrophils and in the NET fraction 
of in vitro stimulated neutrophils. In contrast, the significantly increased 
percentage of cytoplasmic staining in neutrophils from RA patients compared 
with healthy controls was a novel and unexpected finding. Few studies have so 
far attempted to visualise PAD4 in cells using confocal microscopy due the lack 
of specific and non-cross-reactive antibodies. In a study by Asaga et al. in 2001 
it was initially reported that PAD4 could be localised in myeloperoxidase-
negative neutrophil granules (45), however, the same group published a year 
later results which questioned their previous observations (196). The 
cytoplasmic staining in the previous study was explained by overfixation which 
masked nuclear antigens within the nucleus. Interestingly, in a third study, after 
examining synovial tissue from RA patients it became apparent that whereas 
PAD2 localisation was restricted to the cytosol, PAD4 appeared to be present in 
both cytosol and nucleus (372). Since then no other studies have examined 
PAD4 localisation using immunofluorescence, however, Lominadze et al. 
detected PAD4 in gelatinase as well as specific granules of unstimulated human 
neutrophils using mass spectrometry (374). Interestingly, the cytosolic 
localisation of PAD4 in granules was confirmed by the group of Niels 
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Borregaard in 2013 using proteomics, however, PAD4 was this time found to be 
enriched in secretory granules (13) of unstimulated human neutrophils. Similar 
to previous publications in mouse and human oligodendroglial cell lines 
stimulated with TNF-α (240), translocation of PAD4 from the cytoplasm to the 
nucleus upon stimulation was also speculated to be present in neutrophils from 
RA patients (354). However, no experimental data were provided in this study to 
confirm the theory of PAD4 redistribution, and therefore, in summary, it can be 
concluded that there does not seem to be agreement in the literature with 
regard to cytoplasmic PAD4 localisation. Since cytoplasmic PAD4 expression 
could not be induced with PEG-enriched immune complexes from the SF of RA 
patients (data not shown), it is concluded here that the stimulus inducing 
cytoplasmic PAD4 expression can either not be enriched with PEG and 
therefore present in the discarded SF fraction or it is based on cell-cell contact 
with cells present in the SF.  
 
As previously discussed in Chapter 3, the study presented here cannot exclude 
the possibility of cells other than neutrophils contributing to the extracellular 
DNA concentration and PAD activity in the SF of RA patients. In addition, 
NETosis may also not be the only source of citrullinated proteins in the joints of 
patients with inflammatory arthritis. Intracellular citrullination was reported in 
several cell populations in the synovium (250,251) and in SF cells (53) and 
further studies are required to examine mechanisms underlying the initial 




Nevertheless, in agreement with our findings on PAD activity in the SF, several 
studies have already described the presence of citrullinated proteins in the SF 
of patients with inflammatory arthritis (249,375). The view that NETosis 
contributes to citrullination is also supported by data from De Rycke et al. who 
observed localisation of citrullinated proteins within extra-synovial deposits of 
polymorphonuclear cells on the surface of the lining layer in RA patients (248). 
Understanding the mechanisms that generate citrullinated antigens in ACPA 
positive RA may identify unique pathways that regulate antigen drive in this 
disease, which might be relevant to the development of novel therapies. In the 
following chapter, the generation of citrullinated antigens during NETosis will be 





























5 Investigation into the antigenicity of NETs 















Rheumatoid arthritis is characterised by the presence of a range of 
autoantibodies of which rheumatoid factor (RF) and anti-citrullinated protein 
antibodies (ACPA) are best characterised and used clinically for patient disease 
classification (158,233,376,377). Whereas RF and other autoantibodies can 
also occur in healthy individuals or patients with other inflammatory conditions, 
ACPA represent the most specific autoantibodies in RA discovered to date  and 
can be detected in 60-70% of RA patients (69,377,378). ACPA can be detected 
several years before the onset of clinical symptoms (81,151) and their presence 
is associated with more erosive disease (205). Additionally, several 
environmental (214) and genetic (210,379,380) risk factors are associated 
specifically with the ACPA positive subtype of RA patients. For the above-
mentioned reasons it was therefore proposed that ACPA positive and negative 
RA are regarded as two different disease entities (168) and a test for ACPA, the 
anti-ccp antibody test, was included into the ACR criteria in 2010 (77). ACPA 
target a wide range of citrullinated proteins with the best characterised 
autoantigens being fibrinogen, vimentin, α-enolase, and type II collagen (CII) 
(70,178) with others awaiting further characterisation. 
Key questions regarding the observed autoimmunity against citrullinated 
proteins that have still remained unanswered are whether ACPA are causally 
related to the disease or whether they are just a consequence of the condition. 
Furthermore, it is not known where autoimmunity to citrullinated proteins is 
initiated and whether there is a single or restricted group of antigens 
responsible for the breakdown of tolerance. Since several studies suggest the 
absence of synovial inflammation in individuals who have pre-existing ACPA 
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and joint pain but no clinically apparent joint swelling (85,87,88), the concept 
was proposed that the initiating event leading to ACPA production is more likely 
to be located outside the joint. Examples for such extra-articular locations that 
are currently being discussed are the periodontal tissues  (276,278), the lungs 
(381) and the gut (80). In view of this concept it was therefore proposed that an 
unrelated “second-hit” could represent an episode of otherwise self-limiting 
synovial inflammation resulting in an exacerbation and perpetuation of the 
synovitis in ACPA positive individuals (168). 
In the previous chapters the presence of NETs and enzymatically active PADs 
in the SF of RA patients has been demonstrated. The following chapter reports 
on the identification of citrullinated proteins that are potentially generated during 
NETosis. Since NETs provide an explanation for how otherwise intracellular 
proteins could be released into the extracellular space and exposed to the 
immune system, it was of interest to determine whether NETs contain already 
known intracellular candidate autoantigens such as vimentin or α-enolase. 
Additionally, the analysis of further citrullinated targets was planned using mass 
spectrometry. Finally, it was aimed to determine whether citrullinated proteins in 
NETs isolated from in vitro stimulated neutrophils, but also isolated ex vivo from 






5.2 Citrullinated proteins are released during NETosis 
in vitro 
In the work presented in Chapter 4, a method for the isolation of NETs from in 
vitro activated neutrophils was established in order to study the release of 
enzymatically active peptidylarginine deiminases. In this chapter the same 
assay was applied to assay whether the process of NETosis would result in the 
generation of citrullinated proteins. Briefly, peripheral blood neutrophils from 
healthy volunteers were stimulated for 4 h with 25 nM PMA, washed and finally 
incubated with DNase-I to release NETs from the cells and into the supernatant. 
All generated culture supernatants were centrifuged to remove intact cells and 
cell debris and the proteins precipitated and modified according to the Senshu 
protocol (316) (see Chapter 2 for details). Modified citrullinated proteins could 
then be detected using an anti-modified citrulline antibody (AMC) on western 
blots. As shown in Figure 5-1A, a large number of citrullinated proteins were 
released from stimulated neutrophils into the supernatant after 4 h of stimulation 
(SN) compared to only a relatively small number of citrullinated proteins being 
present in the DNase-I treated NET fraction (+DNase-I). One prominent band 
was detected at 11 kD and, interestingly, a band of the same size was also 
detected using an antibody, which was raised against a synthetic peptide 
corresponding to human histone H3, aa 1-100 and citrullinated at the arginine 
residues 2, 8 and 17 (Figure 5-1A). The presence of this 11 kD band was 
further confirmed in the NET fraction of several donors (Figure 5-1B). 
Additionally, some other citrullinated proteins of a size ranging between 48 and 
75 kD was detected in some of the donors. 
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The detection of an 11 kD band with the anti-citrullinated histone antibody was 
unexpected as the predicted molecular mass for histone H3 is 15.2 kD. It was 
therefore subsequently decided to test for potential cross-reactivity of this 
antibody. For this purpose recombinant histones were first in vitro citrullinated 
with PAD4 enzyme. Histones H2A, H3 and H4 were selected, as these are well-
known targets of PAD4 (50,194,196,382) in contrast to histone H2B, which has 
not been reported to be citrullinated by PAD4 yet. As shown in Figure 5-1C, 
indeed only citrullinated histone H3 was recognised by the anti-citrullinated 
histone H3 antibody confirming its specificity. Interestingly, Urban et al. have 
reported a specific reduction in the molecular weight of histones, but not of 
other proteins, in NETs compared with proteins found in unstimulated 
neutrophils following SDS-PAGE analysis (315). The authors proposed that 
post-translational modifications may be responsible for this phenomenon. 
Indeed, the same mass shift when comparing citrullinated with native forms of 
recombinant histones H2A, H3 and H4 using coomassie blue staining was 
observed (Figure 5-1C). Importantly, the staining did not appear equal as each 
histone type is known to have a different affinity for Coomassie blue (383). To 
conclude, these data indicate that the citrullination of histones results in an 
increased mobility of these proteins during reducing SDS-PAGE, which could 
explain their apparent decreased molecular weight of citrullinated histone H3. 
 
Mass spectrometry data presented here potentially indicated a significant 
enrichment of histones H2A, H2B and H4 but not H3 in the NET fraction 
compared with the supernatant fraction (SN) (refer to Table 4-1 in Chapter 4 
and Figure 8.1 in the Appendix). Indeed, total histone H3 protein was also found 
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to be present in both fractions on immunoblot (Chapter 4, Figure 4.3). These 
findings therefore suggest that the enrichment of citrullinated histone H3 cannot 
be explained by its overall increased abundance within NETs. Instead the 
citrullinated form of histone H3 appears to be specifically associated with NETs 
as reported in several previous publications (34,44).  
 
Importantly, to validate the method of detection of citrullinated proteins, the 
specificity of the anti-modified citrulline antibody for citrullinated proteins after 
Senshu modification was demonstrated using concentration and isotype-
matched control antibody (Figure 5-2A). Additionally, it was aimed to establish 
whether the citrullinated proteins that are released during in vitro NETosis are 
generated de novo during activation or whether they are already present in 
unstimulated neutrophils. For this purpose, lysed unstimulated neutrophils were 
assessed for the presence of citrullinated proteins. As shown in Figure 5-2B, 
even with double the amount of protein loaded from lysed unstimulated 
neutrophils compared with supernatants of stimulated neutrophils from matched 
donors along with an increased exposure time, no citrullinated proteins were 
detected in unstimulated neutrophils (Figure 5-2B). These data therefore 
suggest the specific generation of citrullinated proteins during NETosis and the 








Figure 5-1 Release of citrullinated proteins from neutrophils undergoing NETosis 
The supernatants of unstimulated (SN (unst.)) or PMA stimulated neutrophils (SN) were 
collected. After stimulation cells were washed 3 x with RPMI (W1-W3) and subsequently 
incubated with or without DNase-I (+DNase and –DNase). Non-stimulated cells were treated 
with DNase-I (+DNase (unst.)) as control. Proteins were precipitated from supernatants and 
analysed by western blotting.  Citrullinated proteins (cit.prot.) on western blots are detected 
using the previously described Senshu method (316) and a monoclonal human anti-modified 
citrulline antibody from ModiQuest. (A) Western blots from all supernatants were probed with a 
monoclonal human anti-modified citrulline antibody after Senshu-modification and an anti-
citrullinated histone H3 antibody. One representative blot out of at least 3 independent 
experiments is shown. (B) Detection of citrullinated proteins in +DNase-I treated NET fractions 
from four different donors out of six independent experiments are shown. (C) To demonstrate 
specificity of the human anti-citrullinated histone H3 antibody, western blots from non-
citrullinated and citrullinated recombinant histones H3.3, H2A and H4 (expected size of 15.2 kD, 
14 kD and 11.2 kD, respectively) were incubated with anti-citrullinated histone H3 antibody. 
Coomassie blue staining of the SDS-PAGE gel is also shown in the bottom panel. One 




Figure 5-2 Demonstration of specific detection of citrullinated proteins  
Neutrophils from 4 donors were purified and immediately lysed in RIPA buffer after purification 
(unst.). In parallel, neutrophils from the same 4 donors were stimulated for 4 h with PMA and 
the supernatants were collected (SN). Both supernatants and lysed neutrophils were 
centrifuged at 300 x g and a second time at 16 000 x g to remove intact cells and cell debris. 
Proteins were precipitated from the supernatants of stimulated neutrophils and the protein 
amount was determined for both fractions (SN and unst.). Citrullinated proteins (cit.prot.) are 
detected using the modified Senshu method. (A) To demonstrate specificity of the human anti-
modified citrulline antibody (specific ab), the same blot was incubated after chemical 
modification with a concentration- and isotype-matched control antibody, human IgG (hu IgG). 
Coomassie blue staining of the PVDF membrane is shown in blue below to test equal protein 
loading (20 µg per lane). (B) Comparison of the amount of citrullinated proteins in lysed, 
unstimulated neutrophils from 4 donors (unst. donor 1-4) and the SN fractions of the same 
donors (SN donors 1-4) using immunoblotting after Senshu modification. Blots were developed 
with a short exposure time of 1 sec and a longer exposure time of 10 sec. Twenty μg of 
supernatant proteins and 40 μg of lysed neutrophils were loaded per lane. Coomassie blue 













































5.3 Qualitative analysis of protein composition of NETs 
using mass spectrometry 
 
To determine the origin of the citrullinated 11 kD band in PMA-generated NETs, 
mass spectrometry was kindly performed by Jimmy Ytterberg from the 
Karolinska Institutet in Stockholm, Sweden. In an initial approach, the total 
DNase-I treated NET fraction (NET) and the supernatant fraction after 4 h of 
PMA stimulation (SN) from two different data sets were analysed and data  is 
presented in tables 5-1 and 5-2: Two different donor groups (different patients 
on two different days) were analysed on two different instruments (Q Exactive 
MS and LTQ Velos Orbitrap ETD MS) but with otherwise same search 
parameters (for details refer to Chapter 2.14.2). In light of the immunoblotting 
data, it was not unexpected to find a wide range of citrullinated peptides in the 
SN fraction, although the variability between donors was very high and many 
citrullinated peptides, which were present in one donor group, were not 
detected in the other. Nevertheless, two different peptides from coronin-1A were 
identified using both approaches and were present in both the SN as well as the 
NET fraction (compare Table 5-1 and 5-2). Interestingly, one of these peptides, 
which was present in NETs, has also been reported to be present in the SF of 
RA patients (375). Additionally, two previously published citrullinated peptide 
sequences derived from vimentin (375,384,385) and myeloid cell nuclear 
differentiation antigen (MNDA) (375) were detected in the NET fraction of one 
donor, respectively. Furthermore, a peptide sequence which is shared by 
histone H3.1 and H3.2 was detected in the NET fraction of one donor using the 
Q Exactive MS instrument (Table 5-1). It is interesting to note that the 
citrullinated arginine in this peptide was immediately next to a dimethyl-
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modification of a lysine and that the same peptide was also detected after in-gel 
digestion of an 11 kD gel slice in two out of five donors from a separate analysis 
(Table 5-3). The data generated from the in-gel digestion of the 11 kD gel slices 
not only demonstrated the presence of this peptide but also of an additional 
peptide from histone H3 in one of the donors (Table 5-3). This peptide was 
shared between all histone H3 subtypes and was derived from the N-terminus 
of histone H3 (Figure 5-3). In contrast, neither peptide was detected in the SN 
fraction. This finding was unexpected with regard to the previously used anti-
citrullinated histone H3 antibody purchased from Abcam, which reacted strongly 
with the in vitro generated NET fractions. Since this antibody was raised against 
a synthetic peptide containing citrullinated arginines at the positions 2, 8 and 17 
in histone H3, it should theoretically also react with a peptide sequence 
corresponding to the immunogen peptide sequence. Such a sequence, 
however, was neither detected in the total NET fraction nor in the 11 kD gel 
slices. It is therefore possible that the antibody also cross-reacts with additional 
epitopes in histone H3 such as the two sequences that have been detected 
using mass spectrometry analysis. To conclude, these data suggest that the 
citrullinated protein detected at the molecular weight of 11 kD on immunoblots 
from NET fractions of in vitro stimulated neutrophils is likely to be citrullinated 
histone H3, especially as no other citrullinated peptides from histones in the gel 
slices of the five analysed donors could be detected using the mass 
spectrometry approach. As mentioned previously, the difference between the 
expected molecular weight of 15 kD for histone H3 and the actual presence of 
citrullinated H3 peptides at 11 kD in SDS-PAGE analysis may be explained by 
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the presence of post-translational modifications such as citrullination or 
methylation. 
 
Table 5-1 Citrullinated proteins released from neutrophils undergoing NETosis – Q Exactive MS 
Neutrophils from 3 different donors were stimulated to enter into NETosis and after 4 h 
supernatants were collected (SN1-3). After stimulation cells were washed 3 x with RPMI and 
subsequently incubated with DNase-I to generate the NET fraction (NET1-3). All fractions were 
centrifuged and subsequently precipitated with TCA. After trypsinisation samples were 
processed and analysed by mass spectrometry (Q Exactive from Thermo Scientific). The 
data were searched against Swiss Prot (human protein database) using Mascot. All spectra 
identified as citrullinated with a score of at least 20 were analysed. Values in the table represent 
Mascot scores. Empty cells signify that either no peptides or peptides with a Mascot score 
below 20 were identified. 
 
 
Table 5-2 Citrullinated proteins released from neutrophils undergoing NETosis – LTQ Velos 
Orbitrap ETD MS  
Neutrophils from 4 different donors were stimulated and after 4 h supernatants were collected 
(SN1-4). After stimulation cells were washed 3 x with RPMI and subsequently incubated with 
DNase-I to generate the NET fraction (NET1-4). All fractions were centrifuged and subsequently 
precipitated with TCA. After trypsinisation samples were processed and analysed by mass 
spectrometry (LTQ Velos Orbitrap ETD MS). The data were searched against Swiss Prot 
(human) using Mascot. All spectra identified as citrullinated with a score of at least 20 were 
analysed. Values in the table represent Mascot scores. Empty cells signify that either no 





Table 5-3 Citrullinated proteins detected in the 11 kD band of the NET fraction  
NET fractions from 5 different donors were loaded and analysed by SDS-PAGE and the 11 kD 
bands, which were shown to be citrullinated, were excised from gels, digested with trypsin and 
subjected to LTQ Velos Orbitrap ETD MS analysis. Values in the table represent Mascot scores. 




Figure 5-3 Alignment of protein sequences from histone subtypes 
Protein sequence alignment of the N-terminus of histones H1, H2A, H2B, H3.1, H3.2, H3.3 and 
H3.1t using UniProt. Residues 26 and 49 were found to be citrullinated within 2 peptides in 
NETs (indicated with green boxes) using mass spectrometry by this approach (compare with 
Table 5-3) . Arginine residues at position 2, 8 and 17 are previously described targets of 
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5.4 Purified ACPA specifically recognise an 11 kD band 
within in vitro and ex vivo NETs 
 
After the identification of citrullinated proteins in NETs generated by in vitro 
stimulated neutrophils, it was of interest to determine whether these structures 
were antigenic in RA and, in particular, whether the citrullinated 11 kD protein is 
specifically recognised. For this purpose, Prof Karin Lundberg at the Karolinska 
Institutet in Stockholm kindly provided us with ACPA, which were purified from 
serum and plasma of RA patients using affinity chromatography on columns 
with covalently bound CCP2 peptides (388). The anti-CCP IgG that bound to 
the columns were finally eluted and pooled. The corresponding flow through 
(FT) IgG pool therefore contained all antibodies except for the one reacting with 
CCP2 peptides. Both the ACPA and FT IgG pool were validated for their binding 
specificity for citrullinated proteins. First of all, it was demonstrated that 
citrullinated recombinant vimentin and calf thymus histones (CTH) can be 
specifically detected using Senshu modification and human anti-modified 
citrulline antibody (Figure 5-4A). Finally, the native and citrullinated form of the 
proteins were probed with the same concentration of ACPA and FT IgG to 
confirm and validate the specificity of the eluted antibodies for known 
autoantigens such as vimentin. As shown in Figure 5-4B, the specific binding of 
these purified anti-CCP IgG (purified ACPA) and not FT IgG with the 
citrullinated form but not the native form of vimentin was confirmed. 
Interestingly, this specific binding with the citrullinated form of the protein could 
also be observed for calf thymus histones, which were not previously studied by 
Lundberg and colleagues (personal communication). Furthermore, both the first 
supernatant after 4 h of PMA stimulation of neutrophils (SN) and the DNase-I 
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treated NET-fraction were probed with purified ACPA and human IgG but not 
FT IgG as negative control. This decision was based on the fact that many 
antibodies present in FT IgG may still bind to neutrophil proteins and thus mask 
a specific binding of anti-CCP IgG when compared with this antibody pool. In 
addition, the detection system using the Senshu modification and anti-modified 
citrulline antibodies does not discriminate between citrulline and homocitrulline 
residues (389) so that non-CCP2-cross-reactive anti-carbamylated antibodies 
present in the FT IgG pool could bind to carbamylated neutrophil proteins and 
thus prevent a specific recognition of protein targets. As shown in Figure 5-5, 
purified ACPA could not specifically bind to neutrophil proteins present in the 
SN fraction. In contrast, a strong reactivity of purified ACPA compared with 
human IgG could be observed with an 11 kD band present in the NET fraction, 
although the signal strength exhibited variability between donors (Figure 5-6). 
Additionally, several bands in the molecular weight range 48-75 kD were 
observed, which resembled the pattern of citrullinated proteins in NET fractions 
detected on immunoblots, which were modified with the Senshu method and 
developed with a monoclonal human anti-modified citrulline antibody (compare 
Figure 5-1B). These proteins were, however, not consistently present in the 
NET fraction from all donors. For this reason, analysis concentrated on the 






Figure 5-4 Specific recognition of the citrullinated form of Vimentin and calf thymus histones by 
purified ACPA from RA patient sera 
Recombinant vimentin (Vim) and calf thymus histones (CTH) were in vitro citrullinated with 
enzymatically active PAD4 for 2h. (A) Specificity of citrullination was first demonstrated using 
Senshu modification and human anti-modified citrulline antibody. (B) Citrullinated and non-
citrullinated forms of vimentin and calf thymus histones were probed in parallel with purified 
ACPA and the corresponding flow through fraction (FT) following affinity chromatography on 











Figure 5-5 No specific recognition of antigens in the SN fraction of activated neutrophils by purified 
ACPA 
Supernatants from 4 donors after 4 h of stimulation with PMA (SN) were collected, centrifuged 
and precipitated with TCA. Western blots were probed with purified ACPA and human 



















Figure 5-6 ACPA specifically and consistently recognise a 11 kD antigen in NETs  
After stimulation with PMA neutrophils were washed and subsequently incubated with DNase-I. 
All fractions were centrifuged to remove cell debris. Proteins in the DNase-I treated NET fraction 
were precipitated from supernatants and analysed by western blotting. Purified ACPA and 
human immunoglobulin (hu IgG), which was used as concentration-matched control, were used 
at the same concentration. Four representative blots from four different donors out of eight 
independent experiments with eight different donors are shown. 
162 
 
As antigens could specifically be detected in the NET fraction of in vitro 
stimulated neutrophils, it was of interest to determine whether the same antigen 
of 11 kD size could also be identified within NETs from the SF of RA patients. 
For this purpose, NETs were initially isolated ex vivo from the SF using a 
method modified from the protocol used for the isolation of in vitro generated 
NETs (see Chapter 4.2). As shown in Figure 5-7A, a significantly higher DNA 
concentration could be detected in the DNase-I treated NET fraction (+DNase-I) 
suggesting that NETs can specifically be enriched after eight washing steps 
from the SF. Additionally, similar to the previously shown in vitro NET isolation, 
the presence of neutrophil elastase (NE) and PAD4 could be demonstrated 
specifically in the DNase-I treated NET fraction (+DNase-I), whereas no PAD4 
and NE were detected in the final washing fraction (W8) and in the fraction of 
SF cells, which were solely incubated with RPMI under the same conditions (-
DNase-I) (Figure 5-7B). Finally, the same fractions were incubated with purified 
ACPA to assay whether the same reactivity that was observed with in vitro 
isolated NETs (Figure 5-6) could also be found with ex vivo isolated NETs from 
the SF. As shown in Figure 5-7C, indeed, a specific reactivity of ACPA was 
detected against an 11 kD protein in the NET fraction compared with the W8 
and –DNase-I-control fractions. Although these data suggest that the same 
antigen of an approximate molecular weight of 11 kD was detected as the 
antigen in in vitro NETs, the presence of citrullinated proteins using mass 
spectrometry analysis in these ex vivo NETs could not be studied further in 






Figure 5-7 ACPA recognise an 11kD band within ex vivo NETs 
(A) SF cells were seeded on 12-well plates. The supernatant was then removed and the cells 
attached to the bottom of the well were washed 8 x with RPMI (washing steps W1-W8). After 
the final washing step, cells were incubated with or without DNase-I (+DNase-I and –DNase-I). 
Extracellular DNA was quantified using SYTOX Green. Extracellular DNA could be specifically 
enriched in the supernatant of SF cells treated with DNase-I (Wilcoxon matched-pairs signed 
rank test, n = 7, *p<0.05). Results are shown as mean ±S.D. (B) Western blot of the final 
washing step W8, the DNase-I treated NET fraction (+DNase-I) and the mock-digested NET 
fraction (-DNase-I) probed for the presence of neutrophil elastase (NE) and PAD4; 
representative of at least 3 independent experiments per protein. (C) Ex vivo isolated NETs 
(+DNase-I) from the SF of 3 RA patients were probed with 1.7 µg/ml purified ACPA. The final 












































































5.5 Citrullinated Histone H3 is an autoantigen in RA 
patients 
Core histones were previously reported to account for 70% of all NET-
associated proteins (315). Using immunoblotting we revealed the presence of a 
protein with an approximate molecular weight of 11 kD, which is recognised by 
purified ACPA. In the same samples the presence of two citrullinated histone 
H3 peptides using mass spectrometry were also demonstrated. In the following 
section, characterisation of the immune response towards histones in RA 
patients in more detail is reported using the citrullinated and native form of 
recombinant histone H3 and compared with the reactivity for histones H2A and 
H4. For this purpose all three types of histones in vitro were citrullinated using 
the PAD4 enzyme. As shown in Figure 5-8A, 5 mU enzyme per 1 μg protein for 
the enzyme-to-substrate-ratio was sufficient to detect maximum citrullination on 
immunoblots. Interestingly, it could be detected that despite using the same 
enzyme- and substrate- concentrations under exactly the same reaction 
conditions, the efficiency of citrullination of different histone types differed. 
Indeed this efficiency was highest for citrullinated H3.3, but decreased for 
citrullinated H2A and was the lowest for histone H4 (Figure 5-8B). Similarly, a 
strong reactivity of ACPA was found for citrullinated H3.3, however, despite the 
low citrullination efficiency, a faint signal was detected for citrullinated H4 
whereas no reactivity was found with H2A, which was citrullinated more 
efficiently than histone H4 (Figure 5-8B). Since the purified ACPA that were 
used for the previous experiments reflect a global reactivity of all antibodies 
present in pooled sera from at least 10 different ACPA positive RA patients, it is 
conceivable that the observed reactivity in our experiments derives from 
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antibodies present in relatively few patient sera. For this reason, it was decided 
to examine the reactivity with recombinant histones in individual patient sera. In 
agreement with results using purified ACPA, practically no reactivity with 
histone H2A was observed in the 8 tested sera, which derived from treatment-
naïve RA patients (Figure 5-9). The strongest response, similarly to the purified 
ACPA, was however detected with citrullinated histone H3.3 in 2 out of the 4 
tested ACPA positive RA sera. The same sera also reacted to a lesser degree 
with citrullinated histone H4. Interestingly, serum 8 also reacted additionally with 
the native form of histone H4 but not the native form of histone H3.3. In 
conclusion, both purified ACPA as well as RA patient sera seem to most 
strongly recognise the citrullinated form of recombinant histone H3 compared 
with the native form and other histone types. These data support our findings of 
strong reactivity of anti-citrullinated histone H3 antibodies and purified ACPA 






Figure 5-8 Purified ACPA strongly react with in vitro citrullinated histone H3.3 
In vitro citrullination of recombinant human histone H3.3, H2A and H4 for 2 h. (A) Different 
enzyme-substrate ratios for PAD4 and its substrate H3.3 were used to test for maximum signal 
on immunoblot after Senshu modification and incubation with anti-modified citrulline antibody. 
(B) Immunoblot revealing different efficiency of in vitro citrullination of 400 ng histone H3.3, H2A 
and H4 by PAD4 (5 mU) under the same reaction conditions. One representative blot out of 
three independent experiments is shown. The same blot is shown below after re-probing with 





Figure 5-9 ACPA positive RA patient sera recognise histones 
Native and citrullinated form of histone H3.3, H2A and H4 (400 ng) probed with RA sera from 4 ACPA positive and 4 ACPA negative RA patients diluted 
1:100 in 5% milk/TBS-Tween.   










5.6 Antibodies derived from SF B cells recognise 
histones 
 
Anti-citrullinated protein antibodies, especially a high abundance of ACPA from 
the IgM isotype, were previously reported to be enriched in the SF compared 
with serum (365) suggesting a continuous autoimmune response in the joints. In 
light of data that demonstrated the presence of NETs in the SF of RA patients, 
we wished to investigate whether histones in NETs could be recognised by local 
B cells in the joints of RA patients and thus represent a potential local driver for 
the immune response. In collaboration with Prof Vivianne Malmstrӧm from the 
Karolinska Institutet, single B cells were sorted from the SF of patients with 
active RA and their Ig variable region genes were sequenced and subsequently 
expressed to generate recombinant monoclonal antibodies as has been 
previously described (235). This part of the project was undertaken by Dr 
Khaled Amara from the Karolinska Institutet, Stockholm, and Lorraine Yeo from 
the University of Birmingham. Equal amounts of non-citrullinated native 
recombinant histones (nat) alongside in vitro citrullinated histones (cit) were 
probed with an equal concentration of these recombinant antibodies from RA 
patients on immunoblots. The antibodies used were all derived from ACPA 
postivie RA patients. Initially 14 different antibodies were tested at a 
concentration of 5 μg/ml. From these 14 antibodies, 4 derived from 3 different 
patients and showed reactivity with histones H3.3 and H4 whereas no reactivity 
with histone H2A could be detected (data not shown). As shown in Figure 5-10, 
the reactivity of these antibodies from 3 ACPA positive RA patients are 
analysed at a higher concentration of 10 μg/ml. Purified ACPA and human IgG 
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were used as positive and negative controls, respectively. Whereas antibodies 
from B cells from patient 1 and 2 showed only a weak or comparable reactivity 
with the native and citrullinated form of H3.3 and/or H4, the three recombinant 
antibodies from patient 3 (clone 4-6) reacted more strongly with the citrullinated 
form of histone H3.3 and H4 compared to the native form (Figure 5-10). In 
conclusion, although these data are preliminary and a wider range of different 
antibodies would need to be screened for reactivity with histones, they suggest 
that joints of RA patients contain B cell clones with a stronger reactivity with the 
citrullinated form of histone H3 and H4 compared with the non-citrullinated form. 
Additionally, similar to purified ACPA and RA patient sera, no reactivity could be 
detected with histone H2A (data not shown). Histones released into the 
extracellular space during NETosis in the SF may therefore well be recognised 











Figure 5-10 Antibodies from SF B cells react with both the native and citrullinated form of histone H3 and H4 
 
Single B cells were sorted from the SF of patients with active RA. Their Ig variable region genes were sequenced and subsequently expressed to 
generate recombinant monoclonal antibodies. Equal amounts of non-citrullinated recombinant histones H3.3 and H4 (nat) alongside in vitro citrullinated 
histones (cit) were probed with an equal concentration of recombinant antibodies (10 μg/ml) derived from 6 B cell clones from 3 ACPA positive RA 
patients (patient 1: clone 1; patient 2: clone 2 & 3; patient 3: clone 4-6) using immunoblotting. Purified ACPA and human IgG were used as positive and 
negative controls, respectively.  
H3.3 
H4
patient 1 patient 2 patient 3
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5.7 RA patient sera recognise citrullinated epitopes in 
histone H3 
 
Several different experimental approaches presented in this chapter have 
supported the notion of the presence and antigenicity of citrullinated histone H3 
in NETs. To further characterise the reactivity of RA patient sera with this 
protein it was decided to investigate different epitopes of this protein in more 
detail. Based on mass spectrometry analysis (see chapter 5.3), two native and 
two citrullinated peptide sequences from the N-terminus of histone H3 were 
designed, and termed peptide 2 and 3 (Figure 5-11A). The citrullinated form of 
peptide 2 also contained a dimethylated lysine at position 27, which was 
present in in vitro generated NETs (see chapter 5.3). In addition, another 
citrullinated peptide sequence, cit peptide 1, was generated, which contained 
citrullinated residues at three positions (2, 8 and 17). This epitope was chosen 
due to the fact that it is an important target of PAD4 during decondensation of 
chromatin in NETosis (34,43). Furthermore, some reactivity of sera from SLE 
patients has recently been demonstrated against this post-translationally 
modified epitope (390) making it therefore an interesting antigenic target. All 
three peptides were coated on ELISA binding plates and tested for antigenicity 
with sera from 14 treatment-naïve RA patients. Pooled sera from 4 healthy 
individuals was used to determine the background level and was set to the 
value 0.0 as shown in Figure 5-11B. In total 10 out of 14 sera reacted with the 
citrullinated form of peptide 1 while only 3 sera reacted with the native form. 
Although the number of sera in these preliminary experiments was very low, a 
significantly higher reactivity could be found with the citrullinated form of peptide 
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Figure 5-11 Reactivity of RA patient sera with three synthetic citrullinated cyclic peptides from 
histone H3 
(A) Three different peptides from the N-terminus of histone H3 (peptide 1-3) with native 
arginine-residues (nat) (shown in the sequence alignment) and the corresponding 3 peptide 
sequences, in which the arginine residues were replaced by citrulline (cit) or the lysine residues 
by dimethylene residues (K-Me2), were synthesised by the company Innovagen. In total, six 
different protein sequences were synthesised. For the use of these peptides in ELISA assays, 
one cysteine residue at the N- and C-terminus was added (highlighted in red). (B) ELISA with 
the synthesised peptides were generated and their antigenicity was tested using sera from 14 
RA patients. The background level was determined using pooled sera from healthy individuals 
(n=4) and set to 0.0 (dashed line). A significantly higher reactivity of RA sera against the 
citrullinated form of peptide 1 compared to the native form could be detected (Wilcoxon 
matched-pairs signed rank test, n=14, ***p<0.001). 
 
2             8                   17                 26 49
A 
B
nat peptide 1 nat peptide 2 nat peptide 3
cit peptide 1: (NH2-) CMA(Cit)TKQTA(Cit)KSTGGKAP(Cit)KQC (-CONH2)
cit peptide 2: (NH2-) CLATKAA(Cit)(K-Me2)SAPATGC (-CONH2)
















































































The overarching aim of the work presented in this chapter was to address the 
question as to whether citrullinated proteins are released during NETosis and 
whether they could serve as autoantigens in ACPA positive RA patients. Firstly, 
the release of free and NET-bound citrullinated proteins was demonstrated. 
Purified ACPA from RA sera were then found to specifically react with a 
citrullinated antigen of 11 kD in NETs from activated neutrophils. A band 
running at the same apparent molecular weight was recognised by anti-
citrullinated histone H3 antibodies. Mass spectrometric analysis detected only 
two citrullinated peptides in gel slices from this molecular weight. These were 
identified as citrullinated histone H3. In further confirmatory studies, antibodies 
from RA patients were shown to strongly and specifically react with citrullinated 
recombinant histone H3 and with citrullinated epitopes from histone H3. 
Therefore results from a range of different experimental strategies point towards 
a strong immune response to citrullinated histone H3 in RA patients. 
 
Post-translational modifications (PTMs) are known to lead to the generation of 
neo-epitopes and are proposed to initiate autoimmune responses in a range of 
autoimmune diseases (391–393). These modifications have also been 
described to occur in different forms of cell death, such as in apoptosis (394–
396). With regard to rheumatoid arthritis the PTM citrullination is of utmost 
interest as anticitrulline autoimmunity is highly specific for this disease (70). In 
this study it was therefore interesting to observe that a large number of 
citrullinated proteins can be generated during PMA-induced NETosis. However, 
in agreement with previous work using HL-60 cells and human primary 
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neutrophils (34,44,390) no citrullinated proteins could be observed in 
unstimulated neutrophils using immunoblotting, although some degree of 
citrullination in unstimulated cells would be conceivable due to its role in gene 
transcription (50). It is possible that the levels of citrullination in the context of 
gene regulation are too low to be detected with the methods used here. Indeed 
global de novo generation of a wide range of citrullinated proteins after 
neutrophil activation observed in this study, which in some publications is 
referred to as hypercitrullination (43,44,53), could therefore be regarded as a 
consequence of activation and NETosis.  
 
Citrullination of a range of proteins such as fibrinogen, filaggrin, collagen and 
histones has previously been described to induce a shift in the mobility of the 
citrullinated form of the proteins during reducing SDS-PAGE analysis. Whereas 
citrullination of filaggrin and fibrinogen by PAD2 and PAD4, was shown to 
induce a decrease in the mobility compared with the native form of the proteins 
(175,372,397), an increased mobility in reducing SDS-PAGE analysis has been 
demonstrated for citrullinated histones (50,315,398) and was indeed confirmed 
in data presented here. Interestingly, although a mobility shift for fibrinogen 
chains under reducing conditions was confirmed by Okumura and colleagues in 
another study, the authors did not observe this mobility shift when using non-
reducing conditions (397). For this reason, this phenomenon cannot simply be 
explained by a loss of protein charge after citrullination alone. It is conceivable 
that the number and position of citrullinated arginine residues within the protein 
alters intermolecular interactions in a way that affects its susceptibility to 
reducing conditions, which can ultimately result in decreased or increased 
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mobility through the SDS-PAGE-gel. Citrullination could therefore be one 
explanation for the detection of histone H3 in in vitro NETs at the size of 11 
instead of 15 kD. Since the citrullination of recombinant histone H3.3 expressed 
in E.coli, which is devoid of eukaryotic posttranslational modifications, could not 
induce a mobility shift to 11 kD in these experiments, additional post-
translational modifications other than citrullination may also add to the observed 
shift in the mobility of histones generated during NETosis.  
 
Currently, there are several lines of evidence indicating the occurrence of 
histone citrullination as a result of PAD4 activity. PAD4 was shown to citrullinate 
arginine residues at the positions 2, 8, 17 and 26 in histone H3 (194) and at 
position 3 on the N-terminal sequence shared by histone H2A and H4 (382), 
whereas the citrullination of histone H2B, to our knowledge, has yet to be  
described in the literature. These results are consistent with our observation of 
recombinant histone H3, H2A and H4 in vitro citrullination by PAD4. In NETs 
citrullinated histone H3 has been detected in several reports using confocal 
microscopy (34,354,399) with the same antibody that was used in the approach 
presented here using immunoblots, thus supporting the presence of this histone 
subtype in NETs. Furthermore, histone citrullination in NETs from in vitro 
stimulated neutrophils in our study could also be demonstrated using mass 
spectrometry. In excised 11 kD gel slices from NET fractions separated on 
SDS-PAGE gels two citrullinated peptides derived from histone H3 were 
detected and among these one was found to be citrullinated at the arginine 
residue 26. The second H3 peptide was shown to be citrullinated at position 49. 
This finding is intriguing as this same peptide was the only citrullinated peptide 
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detected in the SF of RA patients by van Beers and colleagues (375) and thus 
supports our notion that histone H3 citrullination occurs during NETosis in the 
SF. Furthermore, similar to our approach, Pratesi et al. recently reported the 
reactivity of RA patient sera with an 11 kD band using NET fractions generated 
with PMA (400), which is also in agreement with findings presented here. At 
variance with this data, however, Pratesi et al. only identified one citrullinated 
peptide from histone H4, which was citrullinated at arginine residue 3 and no 
citrullinated peptides from histone H3 were detected (400). Although Arg3 in 
histone H4 is a well-described target of PAD4 (390) and a weak reactivity of 
citrullinated recombinant histone H4 with purified ACPA could also be 
demonstrated in experiments presented here, this peptide was not found in the 
SF by van Beers and colleagues (375). The discrepancy in the data may be 
explained by the different protocols used for processing of protein samples for 
mass spectrometry, the use of different analytical instruments and also the 
search parameters used in the downstream analysis in the study.  
It is interesting to note in this context that Neeli et al. recently proposed that 
although PMA is able to induce NETosis it would neither cause PAD4 activation 
nor histone citrullination (52). However citrullination of histones induced by PMA 
has been shown not only in data presented here but also previously by others  
(399–401). Furthermore, the finding described by Neeli and colleagues also 
challenge the current view that citrullination is a requirement for chromatin 
decondensation during NETosis (44,46). One possible explanation, however, 
could be that a shorter PMA stimulation time of 2 h compared with 4 h as 
undertaken here, did not allow sufficient histone citrullination.  Additionally, 
differences in the concentration of the PMA stimulus may be responsible for 
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these strikingly different results. Since it is not known how PAD4 is activated 
during NET formation and how it exactly leads to the citrullination of histones 
(402), further investigations are required to elucidate the role of PAD4 in NET 
formation. 
 
PAD4 is the only PAD isoenzyme with a nuclear localisation signal, which 
allows the translocation of the enzyme into the nucleus enabling the 
citrullination of histones (196). However, recent studies have also reported on 
the presence and activity of PAD2 in the cell nucleus (403,404). Indeed Zhang 
et al. have described that the arginine at position 26 in recombinant histone H3 
is citrullinated more efficiently by PAD2 than by  PAD4 (403) suggesting that 
more than one PAD isoform may be involved in the citrullination of different 
arginine residues and/or  histone types during NET formation. In this context, 
data presented here indeed showed a difference in the efficiency between 
citrullination of histones H3, H2A and H4 by PAD4 enzyme. This observation is 
in agreement with a report from Darrah et al. which demonstrated that although 
PAD2 and PAD4 are in principle both capable of citrullinating histones, only 
PAD4 would target histone H3 in cell lysates whereas PAD2 would show an 
instrinsic substrate preference for other targets such as beta actins (203). It is 
therefore necessary to consider that both detected citrullinated peptides from 
histone H3 are likely to be citrullinated by PAD4 during NET formation.  
In addition to citrullinated peptides derived from histone H3 we detected three 
additional citrullinated peptides derived from vimentin, myeloid cell nuclear 
differentiation antigen (MNDA) and coronin-1A released from in vitro activated 
neutrophils. Coronin-1A was identified in both the SN as well as the NET 
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fraction whereas vimentin and MNDA were exclusively present in NETs. 
Interestingly, citrullinated peptides from all three proteins were among 53 
citrullinated proteins detected in albumin depleted SF samples from RA patients 
in the previously mentioned study by van Beers and colleagues (375). Together 
with the evidence that vimentin and MNDA are both known ACPA targets it can 
thus be assumed that NETosis might be a source for the generation of not only 
citrullinated histone H3 but also of further known autoantigens in the SF of RA 
patients. Since synthetic citrullinated peptides, which were used for the 
purification of ACPA, however, do not represent physiologic peptides, it can be 
assumed that potentially not all anti-citrulline reactive ACPA could be purified 
using this method. Future experiments with in vitro NETs and ACPA positive RA 
patient sera may therefore reveal whether the additionally identified citrullinated 
proteins such as coronin-1A could be specifically targeted by autoantibodies in 
RA patients. Additionally, it should be considered that the mass spectrometry 
data revealed a large variability between donors and different instruments and 
therefore not all citrullinated peptides were consistently present in all samples 
analysed. Methods are therefore under development to control for this issue 
and thereby reduce the risk of obtaining false-positive or false-negative hits. 
 
As demonstrated in this chapter the isolation of ex vivo NETs was not as 
efficient as in the in vitro experiments leading to mean DNA concentrations in 
the NET fractions being four times lower than in vitro (compare Chapter 4, 
Figure 4-2). The low abundance of NETs released after DNase-I treatment 
could, however, be explained by the fact that cell associated NETs are less 
frequently present in the SF due to the fragile nature of these structures. 
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Mechanical stress during the assay procedure could lead to the dissociation of 
NETs from neutrophils over time, which may decrease the efficiency of the ex 
vivo NET isolation approach. Nevertheless, although the stimulus of PMA used 
in the experiments here is not physiological and therefore unlikely represents a 
stimulus for NET formation in the joints, it was interesting to find that purified 
ACPA showed not only a specific reactivity with a protein at 11 kD in PMA 
induced in vitro NETs, but also with a protein of the same size in NETs isolated 
ex vivo from the SF of RA patients. Although the identity of this protein could so 
far not be determined in this thesis it is tempting to speculate at this point that 
this protein at 11 kD may be citrullinated histone H3. Indeed, a preliminary 
proteomic analysis of the total protein composition in an 11 kD gel slice from the 
ex vivo NET fraction of one RA patient sample showed the presence of histone 
H3.1 (data not shown). An analysis of citrullinated proteins, however, has not 
been performed yet. 
 
Following the identification of citrullinated peptides from histone H3 in in vitro 
NETs, several validation experiments have been performed with recombinant 
histones to demonstrate antibody reactivity with citrullinated histone H3 in RA 
patients. The antigenicity of citrullinated and native histones was not only 
assessed using purified ACPA from pooled patient sera, but also using single 
RA patient sera and with antibodies derived from single SF B cells. Both purified 
ACPA and two out of four analysed ACPA positive RA patient sera showed 
similar results with the strongest reactivity indeed detected against citrullinated 
recombinant histone H3. In addition, despite lower citrullination efficiency by 
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PAD4, some reactivity against citrullinated recombinant histone H4 was 
present.  
In comparison, the reactivity pattern of antibodies derived from SF B cells 
showed a high degree of variability and thus slightly differed from the results 
obtained with antibodies present in RA patient sera. With a low number of only 
14 antibodies from SF B cells analysed on western blots so far, the strongest 
reactivity of one antibody was noted with citrullinated histone H4. The same 
reactivity pattern could also be seen with two other clones from the same 
patient, although not all analysed B cell clones from the same patient showed 
reactivity with histones (data not shown). Concomitantly, the same antibody 
also displayed some cross-reactivity with citrullinated histone H3. Interestingly, 
Amara et al. reported in this context that a high proportion of these IgG-
expressing memory B cells and early plasmablasts  from the joints of ACPA 
positive RA patients are biased toward reactivity with known citrullinated 
autoantigens and subsequently suggested that the generation of citrulline-
specific antibodies may result from T cell-dependent B cell immune responses 
(235). Based on these studies it is therefore tempting to speculate that synovial 
IgG-expressing B cells specific for citrullinated autoantigens such as 
citrullinated histones could represent APCs important for T cell reactivation. 
 
Overall, the work detailed in this chapter demonstrates that citrullinated histone 
H3 and citrullinated histone H4 can be recognised not only by antibodies in RA 
patient sera but also by antibodies derived from SF B cells. Two recent studies 
indeed reported about the reactivity of RA patient sera with citrullinated histones 
present in NETs. Whereas Pratesi et al. identified a strong reactivity of RA 
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patient sera with citrullinated histone H4 (400), Dwivedi and colleagues, 
however, found the strongest reactivity of patient sera with Felty’s syndrome 
and RA directed against citrullinated histone H3 (398). These different results 
may be explained by different experimental protocols of the ELISA or a different 
degree of the purity of histones. Additionally, due to the different type of linear 
or conformational epitopes detected in western blotting or ELISA, discrepancies 
may be found in the results depending on the technique. Finally, core histones 
are known to be heavily post-translationally modified and anti-histone antibodies 
can be found in healthy individuals, RA, SLE, drug-induced SLE and different 
other conditions (390,405,406). The use of total histones in combination with 
patient sera from different cohorts may thus also lead to differences in the 
background and impede the detection of antibodies that target citrullinated 
histones. Future studies with a higher number of patient sera and antibodies 
from SF B cells would be needed to investigate the disease specificity and 
citrulline specificity of the anti-citrullinated histone H3 response in RA patients 
with peptide ELISAs as a potential method of choice. 
 
Currently, it is still not known whether ACPA are directly pathogenic or whether 
they contribute to local perpetuation of synovial inflammation. Assuming that 
ACPA indeed just enhance synovial inflammation, the continuous supply of 
citrullinated ACPA targets from newly recruited neutrophils would potentially 
provide an explanation for the persistence of B cell clones specific for 
citrullinated proteins in the inflamed synovium and the enrichment of ACPA in 































The main purpose of the immune system is to rapidly detect and destroy 
pathogens. Only when the pathogen is removed from the body can the immune 
response return to its homeostatic state which is essential to prevent 
development of chronic inflammation and subsequent tissue damage. In 
autoimmune diseases the immune system is directed against self-molecules 
and can ultimately fail to remove these autoantigens from the body so that 
subsequently the inflammation finally evolves into a chronic state. While 
autoantibody responses in some autoimmune diseases are well-characterised, 
the initiating triggers and source of autoantigens still remain largely unknown. In 
ACPA positive RA patients the generation of citrullinated autoantigens after 
protein deimination by PADs is a key stage in the autoimmune response (168). 
Nevertheless, the mechanisms behind the activation of PADs, as well as the 
sites and circumstances of citrullination of autoantigens in RA have remained 
unclear. In this thesis I have investigated whether neutrophils undergoing 
NETosis can contribute to the production of citrullinated autoantigens in RA 
patients. Using different experimental approaches NETosis was identified as a 
source of freely diffusible enzymatically active PADs as well as of citrullinated 
proteins. Moreover, I have provided evidence that isolated NETs are antigenic 
and have demonstrated a reactivity of RA patient sera with citrullinated 
histones, particularly with citrullinated histone H3. Altogether, these data 
suggest a central role for neutrophils in the generation of autoantigens in RA.  
 
Neutrophils are the most abundant cell type present in the SF of patients with 
RA (102,105), where they are found in an activated state producing ROS and 
releasing cytokines and proteases with cytotoxic potential (109,117,407,408). 
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Similar to what has been previously reported regarding the presence of NETs in 
infections (409), autoinflammatory conditions (339) and autoimmune diseases 
such as SLE (410) or ANCA vasculitis (33), the data presented here show that 
neutrophils undergo NETosis in the joints of patients with inflammatory arthritis 
and thereby release decondensed DNA. In agreement with a previous study by 
Khandpur and colleagues (120) extracellular DNA in RA joints was observed 
within neutrophil infiltrates attached to the surface of the synovial lining layer. In 
addition to these findings the presence of NETs on synovial fluid preparations 
was demonstrated. 
 
The data presented here indicate that extracellular DNA levels and neutrophil 
concentrations in the SF correlate with PAD activity in agreement with the 
proposition that PADs are released and activated as a result of NETosis in the 
joints of patients with RA while in SF from patients with OA minimal PAD activity 
was demonstrated. PAD enzymatic activity is regulated by calcium ions (47), 
indeed intracellular Ca2+ levels are below the level required for in vitro PAD 
activity, indicating further yet undefined regulatory mechanisms (411). Hence, in 
vitro PAD activity was initially measured at supraphysiological calcium 
concentrations. However, while the PAD activity measured in RA SF at 
physiological calcium concentrations was lower, it was still detectable with the 
ABAP assay used in this study and was significantly higher than in OA SF. This 
observation was also confirmed by others in a recent relatively small study 
using human fibrinogen as the substrate for PAD activity (412). In agreement 
with the data presented in this thesis, calcium concentrations in RA SF samples 
in that publication were found to be sufficient to support PAD activity. It can 
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therefore be concluded that the conditions for optimal activity in vitro differ from 
the conditions in vivo. In this regard, a recent study by Darrah et al. reported a 
mismatch between the in vitro and in vivo calcium requirements for PAD4 
activity and explained this by the presence of PAD3/PAD4 cross-reactive 
antibodies that may play a major role in decreasing the enzyme’s requirement 
for calcium into the physiologic range in vivo (369). Future studies are needed 
to identify the contribution of different isoenzymes to the overall PAD activity 
observed during NETosis and to investigate regulatory factors that might 
modulate enzymatic activity.  
As the assay used for measuring PAD activity does not distinguish between 
different PAD isoforms, a contribution to the total PAD activity by PAD2, PAD3 
and PAD4 is possible (411). Interestingly, mass spectrometry data did not 
identify any unique peptides matching PAD3 as being present in neutrophils. 
Identification of PAD isoforms that are responsible for the observed PAD activity 
is of interest as it was recently reported that different PAD enzymes display 
distinct substrate specificities (203) and could therefore lead to the citrullination 
of different autoantigens. 
Additionally, the mass spectrometry data shown here could demonstrate that 
PAD2 and PAD4 both diffuse freely into the supernatant during NETosis and 
also remain attached to the DNA/protein complex of the NETs. This finding is 
important since PADs that remained exclusively tethered to NETs, would 
potentially limit the role of neutrophil-derived PADs to the SF. The lack of a 
basement membrane and tight junctions in the synovial lining together with 
these results regarding freely diffusible PADs therefore suggest that freely 
diffusible PADs released from neutrophils within the SF could enter synovial 
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tissue and potentially contribute to the local production of autoantigens 
throughout the inflamed synovium (250). 
 
Though currently topical, the discovery of extracellular DNA in autoimmune 
diseases is not novel. Circulating nucleosomal DNA has been observed in 
patients with SLE (413), scleroderma, Sjögren syndrome and ANCA-associated 
vasculitis (414). DNA has also been found in the SF of RA patients (340,341). 
For many years, the presence of extracellular DNA in these diseases has been 
explained with clearance defects and secondary necrosis of apoptotic cells and 
linked to the pathogenesis of autoimmune diseases, particularly SLE (415). 
When studying cell death mechanisms, however, we must be aware that 
different cell death mechanisms are difficult to distinguish due to the lack of 
understanding of their complexity. In many publications at present, for example, 
the most widely accepted way to define necrosis has been to demonstrate the 
absence of apoptosis (416). Furthermore, since NETosis shares many features 
initially ascribed to apoptosis and necrosis in systemic autoimmunity, and since 
the exact signalling pathways inducing NETosis are not fully investigated yet 
(compare section 1.1.4.1), the discovery of NETs has added layers of more 
complexity. The data presented in this thesis cannot exclude the possibility of 
cells other than neutrophils contributing to the extracellular DNA levels, PAD 
activity and/or citrullination detected in the SF of RA patients. In addition, 
activation of other cell death mechanisms in neutrophils other than NETosis 
cannot entirely be ruled out. Intracellular citrullination was reported in several 
cell populations in the synovium (250,251) and in SF cells (53), and cell lysis 
induced by immune-mediated membranolytic pathways, for example, could 
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represent another source of PADs and citrullinated proteins (53). Furthermore, 
monocytes and macrophages can also be a source of PADs (195), and cells 
such as eosinophils, mast cells or macrophages can reportedly release their 
chromatin in a process related to NETosis (346). However, eosinophils and 
mast cells are present in relatively very low numbers in RA SF (417). Moreover, 
extracellular DNA levels in the SF showed no significant correlation with 
macrophage counts while there was a highly significant association between 
DNA levels and neutrophil numbers. In addition, comparison of neutrophils 
undergoing necrosis and NETosis showed that there is significantly less release 
of soluble extracellular DNA from necrotic neutrophils (411). This difference 
may be explained by the high level of nuclear decondensation during the 
process of NETosis. However, these results should be interpreted with caution 
as they may not reflect the true situation in the joints in vivo.  
 
While the role of NETs during infections was identified primarily as a process for 
the immobilisation of microbes (24,36,315), the reason for their release in 
autoimmune diseases remains less clear. NETs could theoretically be involved 
in the initiation of autoimmunity based on the concept of cryptic antigens 
originally proposed by Sercarz and colleagues (418). According to this 
hypothesis cryptic antigens that are otherwise located intracellularly and are not 
visible to the immune system could become exposed during NETosis and 
activate autoreactive lymphocytes. A further possibility is that NETs could 
contribute to the propagation of inflammation at a later stage of the 
inflammatory process after the breakdown of tolerance and thereby fuel the 
chronic inflammatory cycle by releasing cytotoxic proteins and autoantigens 
188 
 
(419,420). Interestingly, a large amount of NET-associated proteins are known 
autoantigens in systemic autoimmune diseases (21,66,315,361,419) (compare 
section 1.1.4.3) suggesting that autoantigens present in NETs may be targeted 
across the broad spectrum of different autoimmune diseases (361). Importantly, 
these autoantigens clearly differ from the ones exposed during apoptosis with a 
different range of post-translational modifications (PTMs). Nuclear autoantigens 
such as Ro, La and Sm have not been detected in NETs previously (419,421) 
and were also not identified in the experiments performed here. Additionally, 
PTMs of autoantigens that have been described in apoptotic cells, for example, 
phosphorylation or transglutamination (361,422) have also not been detected in 
NETs thus far. One exception with regard to PTMs appears, however, to exist 
with regard to methylation and acetylation. Similar to data previously reported in 
apoptotic cells (395,396) both PTMs were detected in a recent study in NETs 
(390) and a dimethlyated lysine residue in histone H3 was observed in the study 
presented here. Nevertheless, the induction of PTMs in NETs seems to be 
much more limited than in apoptosis. A further PTM in addition to methylation 
and acetylation has been described in NETosis: citrullination. While apoptotic 
cells have yet not been reported to generate citrullinated proteins (34), PAD4 
induced citrullination is known to be essential for NETosis (43,44,46). Indeed, 
the mass spectrometry data presented in this thesis has revealed a number of 
citrullinated proteins in NETs and among these were vimentin and MNDA which 
are already known autoantigens in RA (304,352,375). Furthermore, certain 
proteins including several peptides were identified which are already published 
as being present in the SF of patients with inflammatory arthritis (249,375,423) 
supporting the supposition that NETs are a possible source for these 
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citrullinated proteins. The view that NETosis contributes to citrullination in the 
joints of RA patients is also supported by data from De Rycke et al. who 
observed localisation of citrullinated proteins within extra-synovial deposits of 
polymorphonuclear cells on the surface of the lining layer in RA patients (248).  
 
To determine whether the citrullinated proteins released during NETosis could 
represent antigenic targets in RA patients, experimental approaches in this 
thesis, including immunoblotting and ELISAs using total proteins or cyclic 
peptides, were undertaken to narrow the broad range of possible candidates. In 
concordance with recently published work (398,400) a particularly prominent 
and consistent reactivity against citrullinated histones within NETs could be 
observed. Whereas Pratesi et al. identified a strong reactivity of RA patient sera 
with citrullinated histone H4 using peptide ELISA (400), Dwivedi and colleagues 
used ELISA with total histone proteins and found the strongest reactivity against 
citrullinated histone H3 with sera from patients with Felty’s syndrome and some 
reactivity with RA patient sera (398). In agreement with Pratesi and co-workers 
a strong reactivity of ACPA and RA patient sera with a citrullinated protein of the 
size of 11 kD in in vitro NETs was observed in this study. Notably, ACPA were 
also found to react with ex vivo NETs isolated from the SF of RA patients. In 
addition, similar to the data reported by Pratesi et al., some reactivity of RA 
patient sera with citrullinated histone H4 (400) on immunoblots was detected, 
however, a much stronger reactivity was observed with citrullinated H3. 
Moreover, no peptides from citrullinated H4 could be detected after in-gel 
digestion of 11 kD gel slices from NET fractions in the work presented here. 
Instead, peptides from citrullinated H3 were identified in the gel slices and a 
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reactivity of RA patient sera could be observed against these peptides. The 
number of citrullinated proteins identified with mass spectrometry is relatively 
small and the very rigorous validation process used to minimise false positives 
(as described in the Materials and Methods Chapter 2 and the Appendix 
Chapter 8) may have contributed to this. Further work therefore remains to be 
undertaken to ensure more consistency in the detection of citrullinated proteins 
using mass spectrometry analysis. Additional citrullinated antigens, such as, for 
example, autocitrullinated PAD4 have been identified by others and could 
(199,200) well be also generated during NETosis.  
 
One of the major questions in autoimmunity is why many autoantibodies are 
already generated before the onset of clinical symptoms and which role these 
autoantibodies play in the pathogenesis. ACPA can be found several years 
before onset of clinical symptoms (81) and ACPA positive RA patients generally 
develop a more severe disease (204,205). In addition, genetic susceptibility and 
environmental factors in RA are associated with autoimmunity to citrullinated 
proteins (210,211). Taken together, these observations suggest that ACPA are 
likely to be involved in the pathogenesis of RA (23) but that they on their own 
are not sufficient to cause disease. For this reason, we need to determine the 
answer to the question as to how exactly the pathogenesis in ACPA positive 
individuals differs from ACPA negative individuals as this would provide a major 
step forward in our understanding of the disease process. One possible 
mechanism as to how ACPA could contribute to an aggravation of disease was 
demonstrated in a recent study in which anti-citrullinated vimentin antibodies 
were able to directly interact with osteoclasts and induce osteoclastogenesis 
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and bone loss (312). Interesting in this context is also the finding that other 
autoantibodies such as ANCA in ANCA-associated vasculitides were shown to 
activate neutrophils in vitro (55), and are able to induce vasculitis in animal 
models (56,57). The exact mechanisms responsible for this activation, however, 
still remain to be characterised. A further possibility as to how ACPA may be 
involved in disease pathogenesis may depend on the formation of ICs and 
activation of the complement system. While neither the injection of NETs (390), 
nor of apoptotic or necrotic debris on their own have been shown to be able to 
induce inflammation in animal models (424–426), autoantibodies were found to 
convert cell debris into immunostimulatory ICs, which bind to Fc receptors on 
macrophages, neutrophils and B cells, leading to their activation (112,305,427). 
This effect may also be enhanced by the presence of RF, which was suggested 
to participate in forming ICs by crosslinking IgG (161,428). Indeed, data 
presented in this thesis suggest that PEG enriched ICs from SF of RA patients 
appear to have the potential to induce NETosis. Since the preliminary results in 
this study, however, were not able to show that this phenomenon is mediated 
through Fc receptors, additional molecules within NETs, such as damage-
associated molecular patterns (DAMPs) may contribute to the activation of 
immune cells through their binding to PRRs (429,430). To follow up on the 
findings reported here, it would therefore be interesting to investigate which 
mechanisms may contribute to the induction of NETosis in the SF of RA 
patients to potentially develop therapeutic compounds, which may inhibit the 




Several studies indicate that the absence of synovial inflammation (as 
determined histologically and by imaging) in individuals who have RA-specific 
autoantibodies and joint pain but no clinically apparent joint swelling (85,87,88), 
and therefore propose the concept that the initiating event leading to ACPA 
production is more likely to occur outside the joint. Recent findings of increased 
protein citrullination and ACPA enrichment in the lungs (431) or the 
periodontium (432) early after disease onset support this notion. Based on 
findings of NETs in inflamed gingiva (433) and lungs (342) it is possible that 
PAD release during NETosis contributes to generation of citrullinated proteins 
initiating the ACPA response at these sites. In addition, other mechanisms such 
as the generation of citrullinated peptide-MHC complexes in autophagosomes 
of APCs followed by the induction of autoimmunity are possible (434). The 
production of citrullinated proteins during NETosis in the joint is therefore 
unlikely to represent the original breakdown of immune tolerance to citrullinated 
proteins.  
Based on the work presented in this thesis and as illustrated in Figure 6-1, 
release of PADs from neutrophils in the joints of RA patients is more likely to 
represent a later event in the disease process where citrullinated proteins and 
pre-existing ACPA form pro-inflammatory immune complexes drive a 
continuous inflammatory response in the joints. This notion is also supported by 
the finding of significantly higher DNA levels in ACPA positive RA patients 
compared with ACPA negative RA patients. In this context a recent publication 
reporting that PAD4 is not essential for disease in the K/BxN murine 
autoantibody-mediated model of arthritis does not conflict with these 
observations, as this model does not depend upon autoimmunity to citrullinated 
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proteins (435). According to our proposed model (Figure 6-1), NETosis and the 
release of enzymatically active PADs in the SF of patients with inflammatory 
arthritis may, as has been described by Vossenaar et al., represent 'sparks that 
may ignite the fire of RA' (247). The continuous supply of citrullinated ACPA 
targets from newly recruited neutrophils could potentially provide an explanation 
for the persistence of B cell clones specific for citrullinated proteins in the 
inflamed synovium of RA patients (235) and the enrichment of ACPA in the SF 
compared to serum (352).  
 
Since the data presented in this thesis cannot prove a causal relationship 
between the observed neutrophil concentration and DNA levels and PAD 
activity in the SF, future investigations into different cell death mechanisms of 
neutrophils and other cells in RA patients is warranted. Furthermore studies in 
patients with other forms of autoimmune diseases, where cell death of 
neutrophils appears to play an essential role, may provide important insights 
into the role of these cells in autoimmunity. Assuming that neutrophils are cells 
that are particularly prone to die at the site of inflammation and expose 
autoantigens, the mechanisms of recruitment and activation in sterile 
inflammation requires further research with the aim of development of novel 
therapeutic interventions which antagonise their recruitment to the site of 
inflammation and modulate their death and clearance. 
Although NETs can be distinguished morphologically from other cell death 
mechanisms in vitro, further studies of signalling pathways and specific markers 
of NETosis would be useful to avoid difficulties in distinguishing NETosis from 
other modes of cell death in vivo. This may enable a much better understanding 
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of the in vivo pathogenic mechanisms relating to this process which occur within 
the joints of RA patients. 
Another aspect that would be interesting to address in future studies concerns 
the possibility that the composition of NETs may also change depending on the 
stimulus that is used for their induction. This has already been demonstrated for 
the total amount of NET proteins (12) and would be also interesting to explore 
with regard to citrullinated proteins. Currently, there are experiments under way 
in house which utilise a larger cohort of RA patients, disease and healthy 
control subjects to validate the preliminary ELISA results presented here, and to 
address the question as to which degree RA patient sera react with different 
citrulline-containing epitopes of histone H3.  
Although each serum sample from an RA patient has its own pattern of 
reactivity, many sera are known to react with more than just one citrullinated 
antigen (70,436). Recent studies have started to characterise the fine specificity 
and epitope spreading in RA patients with the aim to define ACPA reactivities 
predictive of a particular clinical phenotype and disease development 
(215,216,267,437,438). Likewise, it would be interesting to extend these studies 
by investigating a broader spectrum of reactivities and/or targets such as, for 
example, citrullinated histones. In this context it is interesting to highlight the 
fact that patients with the previously mentioned Felty's syndrome (FS), which is 
characterised by a severe arthritis and neutropenia, also seem to produce 
antibodies against citrullinated histones (398). FS has been reported to occur in 
1-3% of RA patients after an average of 10-15 years of arthritis (439,440) and it 
has been proposed to be a more aggressive form of RA (441). While 
preferential binding to citrullinated histones over non-citrullinated histones by 
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ELISA was found in the majority of sera from FS patients in the previously 
mentioned study by Dwivedi and colleagues (398), RA sera generally bound 
less avidly to histones and a smaller proportion of RA sera showed preference 
for citrullinated histones (398). It is tempting to speculate in this context that the 
existence of APCA fine specificities that are reactive against citrullinated 
histones before the onset of disease may predispose ACPA positive individuals 
to develop a more aggressive arthritis or certain clinical symptoms that are 








Figure 6-1 Model of NETs as a source of PADs and citrullinated proteins in RA pathogenesis 
Upon activation of neutrophils by as yet unknown mechanisms, for example, DAMPs in 
combination with immune complexes, these cells undergo NETosis and release NETs 
decorated with citrullinated proteins such as citrullinated histone H3 (cit H3) (1.). In addition, 
NETosis may lead to the release of PAD enzymes, which are activated by the increased 
calcium levels in the extracellular space and generate citrullinated proteins (2.). In ACPA 
positive RA patients citrullinated proteins within NETs and/or citrullinated proteins that are 
generated in the extracellular space can be recognised by pre-existing ACPA that have entered 
the joints. These processes result in the formation of immune complexes and chronic 
inflammation. ACPA are believed to be generated at mucosal surfaces (f.ex. gingiva, the lungs 
or the gut) in individuals with a certain genetic background and upon exposure of certain 
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8.1 Patient clinical data 
 
Table 8-1 Clinical data for RA patients  
Synovial fluid samples from these patients were used for experiments described in Chapter 3, 
Chapter 4 and Chapter 5. Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), 
Rheumatoid Factor (RF), Cyclic Citrullinated Peptide Antibody (CCP), Tender Joint Count 28 
(TJC), Swollen Joint Count 28 (SJC), Disease Activity Score 28 (DAS28), data not available 
(NA). 
 
Table 8-2 Clinical data for PsA patients 
Synovial fluid samples from these patients were used for experiments described in Chapter 3, 
Chapter 4 and Chapter 5. Erythrocyte Sedimentation Rate (ESR), C Reactive Protein (CRP), 
Rheumatoid Factor (RF), Cyclic Citrullinated Peptide Antibody (CCP), Tender Joint Count 28 






factor (value) ACPA (value) TJC (28) SJC (28) ESR CRP DAS 28 ESR Medication
1 f 52 NA 58.1 261 20 8 26 52 NA NSAID
2 m 67 1 128 96 1 1 29 48 4.23 nil
3 f 65 4 148 6.8 7 4 41 10 5.62 MTX, SSZ, HCQ, RTX
4 m 85 4 13.4 >340 3 1 na 138 NA SSZ, prednisolone
5 m 65 3 713 231 3 12 72 81 5.33 nil
6 m 42 6 <11 NA 4 3 27 95 5.00 SSZ, MTX, prednisolone, TCZ
7 m 58 2 50.8 >340 18 6 46 22 6.86 nil
8 m 42 6 5120 NA 2 2 7 23 3.45 MTX, prednisolone, RTX
9 f 65 4 148 6.8 15 4 72 33 6.51 SSZ, HCQ, MTX, RTX
10 m 43 7 5120 NA 2 13 31 64 5.40 MTX, prednisolone, RTX
11 f 72 3 NA 0.7 1 2 31 0 3.65 MTX, HCQ, etanercept
12 m 82 1 NA >340 21 12 76 31 7.88 prednisolone, adalimumab
13 m 50 2 12.3 5 13 16 117 184 7.52 MTX, SSZ, etanercept
14 f 35 1 100 100 8 11 23 4 6.11 MTX 
15 f 26 1 47 71 3 3 25 8 3.71 MTX
16 f 43 10 343 NA 3 1 44 0 4.86 leflunomide, HCQ
17 m 72 27 61.4 >340 22 5 16 51 5.85 MTX
18 f 44 6 1in128 261 5 1 37 16 4.06 etanercept, MTX, prednisolone
19 f 57 1 0 1 5 5 28 20 5.33 nil
20 f 61 11 NA 54 9 9 21 27 4.65 diclofenac
21 f 56 12 61.7 >340 3 3 23 0 4.91 cimzia, HCQ
22 f 58 8 80 >340 6 5 124 99 6.70 MTX
23 f 47 0 140 91 10 7 34 17 6.24 ibuprofen
24 f 82 8 31.2 <7 26 7 11 0 6.67 HCQ, prednisolone TCZ
25 f 76 12 476 272 2 2 NA NA NA leflunomide
26 f 70 7 24.7 >340 19 12 NA 56 NA MTX
27 f 62 10 27.2 71 28 10 46 108 7.84 MTX, prednisolone, nabumetone
28 f 75 24 NA NA 7 6 18 7 4.19 MTX
29 m 71 16 661 188 1 1 NA NA NA MTX, HCQ, etanercept
30 f 56 0 22 58 9 3 48 47 5.92 naproxen
31 f 57 1 37.7 NA 3 2 68 55 4.46 HCQ, MTX, prednisolone
32 m 54 1 583 >340 5 7 NA <5 NA MTX, prednisolone
33 f 48 2 417 >340 11 7 70 22 5.41 MTX, HCQ, 
34 f 59 24 NA NA 1 5 18 3 4.19 etanercept
35 f 32 13 <11 2.1 1 1 17 17 3.48 MTX, HCQ, prednisolone, RTX
36 m 61 5 338 33 7 7 30 21 5.58 prednisolone, leflunomide
37 f 50 1 48 340 3 3 49 64 5.19 HCQ
38 f 58 0 57 52 2 2 43 11 5.08 ibuprofen
39 f 77 3 NA 84 5 5 19 5 4.64 SSZ, HCQ
40 f 23 0 15 1 12 5 3 16 4.39 nil
41 f 56 6 324 100 9 7 NA 58 NA MTX, SSZ
42 f 51 3 0 1.8 6 2 26 19 5.03 MTX, SSZ, HCQ
43 m 60 0 0 1 3 3 10 5 3.77 ibuprofen
44 f 58 3 0 1 1 1 NA 8 NA MTX, HCQ
45 f 64 18 NA 34 6 1 8 2 4.10 MTX
46 m 71 2 14.7 >340 2 1 16 9 3.29 MTX HCQ 
47 m 72 NA 661 188 NA NA 13 3 NA MTX, HLQ, etanercept 
48 f 49 7 780 180 10 10 48 58 NA prednisolone
49 f 40 9 <11 117 NA NA 24 12 NA MTX
50 f 52 3 524 359 14 10 34 13 6.54 NA
51 f 33 2 1211 >340 8 6 48 15 5.90 ibuprofen, loratidine 
52 f 42 11 <11 1.3 5 2 52 77 5.62 MTX, etanercept 





factor (value) ACPA (value) TJC (28) SJC (28) ESR CRP DAS 28 ESR Medication
1 f 44 NA NA NA 1 1 NA NA NA nil
2 f 26 1 <11 1.3 4 2 100 25 5.90 SSZ, ibuprofen
3 m 51 21 NA NA 1 1 8 3 3.00 etanercept
4 m 46 NA <11 1 4 1 5 <5 2.85 NA
5 m 43 NA <11 1.5 2 2 2 10 2 etanercept, prednisolone
6 f 43 19 NA NA 1 1 6 9 2.09 MTX, infliximab
7 m 31 10 NA NA 2 4 2 0 2.26 adalimumab 
8 m 58 NA NA NA NA NA NA NA NA MTX
9 m 39 5 NA NA NA NA 6 NA NA MTX
10 m 58 9 NA 3 3 NA NA NA NA MTX
11 f 41 7 NA NA NA NA 3 NA NA topical steroids







8.2 Quantitative proteomics data on the protein 
composition in the supernatant of cells going into 
NETosis 
 
Pellets from the D (+DNase-I, alias "NET fractions") and SN supernatant 
fractions isolated from 7 patients were cleaned using acetone precipitation and 
resuspended in 2 % SDS. The protein concentrations were determined by the 
Pierce BCA protein assay kit (Thermo Fisher, USA).  10 µg of each sample 
were reduced, alkylated and digested in-solution according to Ytterberg et al. 
2006 (442). After zip tipping (Merck Millipore Ltd, Irland), 1 µg of each sample 
 
Table 8-3 Clinical data for OA patients 




Table 8-4 Clinical data for OA patients 
Synovial fluid samples from these patients were used for experiments described in Chapter 
4. 
Gender Age (yrs) BMI (Scales) Hip:Waist Height (cm) Weight (kg) Waist (cm) Hip (cm) Fat % systolic BP diastolic BP
1 m 50 31.3 1.06 179 100.4 116 109 30.1 131 87
2 f 65 22.6 0.83 161.5 58.7 81 98 33.6 120 62
3 f 64 20.3 0.70 172 60.1 66 94 30.1 177 99
4 m 68 21.2 0.90 186 73.4 94 104 18.7 159 102
5 f 44 33.1 0.88 174 100.1 105 119 46.3 123 75
6 m 70 34.4 1.05 176.5 107.3 118 112 34.4 171 88
7 m 71 27 0.88 173 80.7 95 108 28 139 88
8 f 53 43.7 0.74 150 105.1 102 137 45.8 130 73
9 m 65 21.4 0.87 182.5 71.800 86 99 18.6 119 66
10 f 53 29.3 0.82 164 78.8 93 114 41.5 146 94
11 f 52 25.7 0.80 160 65.75 80 100 35.7 110 59
12 f 54 29.9 0.89 169 85.5 104 117 42.8 122 68
13 m 66 23.4 0.90 175 72.1 94 104 21.4 136 76
14 f 67 32.5 0.96 164 87.5 110 114 45.6 152 83
15 m 64 24.9 0.97 170 72.1 96 99 25.6 129 85
Gender Age BMI (Scales) Hip:Waist Height (cm) Weight (kg) Waist (cm) Hip (cm) Fat % systolic BP diastolic BP
1 f 53 28.9 0.79 167 80.5 88 111 44.2 120 76
2 f 63 29.2 0.83 155 70.2 95 115 45.2 153 81
3 f 71 30.7 0.88 163 81.6 101 115 44.5 140 75
4 f 50 43.1 0.92 161 111.8 47 51 49.2 137 80
5 f 44 33.1 0.88 174 100.1 105 119 46.3 123 75
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was separated using C18 RP columns coupled on-line to an LC-MS/MS. The 
chromatographic separation was achieved using an ACN/water solvent system 
containing 0.1 % formic acid. The gradient was set up as following: 3−35 % 
ACN in 89 min, 35−95 % ACN in 5 min and 95 % ACN for 8 min all at a flow 
rate of 300 nl/min. The samples from 4 patients were analyzed by LTQ Orbitrap 
Velos ETD and 3 by Q Exactive MS (Thermo Fisher Scientific, Germany). The 
spectra were acquired on the Velos with a resolution of 60,000 in MS mode, 
and the top 5 precursors were selected for fragmentation using CID. The 
spectra on the Q Exactive were acquired with a resolution of 70,000 in MS 
mode, and the top 10 precursors were selected for HCD fragmentation with a 
resolution of 17,000. 
The data acquired using the Velos and the Q Exactive were quantified in 
separate analyses. Mass lists were extracted from the raw data using 
Raw2MGF v2.1.3 and combined into one file using Cluster MGF v2.1.1, 
programs part of the Quanti work flow (319). The data was searched against a 
concatenated version of the human complete proteome database (2013/4) 
using the Mascot search engine v2.4.1 (Matrix Science Ltd., London, UK). The 
following parameters were used: tryptic digestion (max 2 miscleavages); 
carbamethylation (C) as fixed modification; oxidation (M), pyroglutamate (Q) as 
variable modifications; 5 ppm as precursor tolerance; 0.25 Da (Velos) or 0.01 
Da (Q Exactive) as fragment tolerance. The threshold for 2% FDR was 
calculated to a peptide score of 22.80 (Velos) and 13.97 (Q Exactive). The 
quantification was done using the Quanti work flow, which is a quantification 
software based on extracted ion chromatograms.(319) In short, after searching 
the combined mgf against the human complete proteome, the resulting dat file 
and the 6 respectively 8 raw files (representing D and SN fractions from 3 
respectively 4 patients) were uploaded into Quanti v2.5.4.3. The following 
parameters were used: score threshold 20.8 (Velos) or 13.97 (Q Exactive); 
mass tolerance 10 ppm; minimum peptides/protein 2; maximum allowed 
deviation in retention time 3% or 5 min; rt order 50 (Velos) or 70 (Q Exactive); 
only “charge deconvolution” and “use best mascot peptide” were used. The 
quantitative values were further processed by multiplying the values with the 
reference abundance and normalizing each sample to the median of the 
summed intensities for all the samples. The values were finally log 10 
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transformed. p-values were calculated using Student’s t-test and expectation 
values were calculated by multiplying the p-values with the number of 







8.2.1 Proteins enriched in the NET (D) fraction 
Data were analysed using 
268 proteins from 3 matched D/SN samples were quantified using 1%FDR and 2 peptides per 
protein. Abundance of proteins in D compared to SN was calculated using t-test (cut-off 
p<0.05). 14 proteins were found to be enriched in all 3 matched samples. 
 
 List of enriched proteins in D (DNase-I treated NET fraction) fraction 
Histone 4 (p=0.015)
Neutrophil elastase (p=0.0026)
Histone 2B type 2-E (p=0.016)
A B 























Figure 8-1 Enriched protei s in D (DNase-I tr ated NET fraction) fraction 
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8.2.2 Total list of proteins quantified in SN and NET 
fraction 
 
Quantitative comparison of protein levels in supernatants and NETs
PROTEIN ID DESCRIPTION PROTEIN IDs log2(D/SN) P (D vs SN) E (n = 294) PROTEIN ID DESCRIPTION PROTEIN IDs log2(D/SN) P (D vs SN) E (n =555)
PADI2_HUMAN Protein-arginine deiminase type-2 
PADI2_HUMAN;B4DIU3_HUMAN;Q
96DA7_HUMAN




PADI4_HUMAN Protein-arginine deiminase type-4 
PADI4_HUMAN;KI26B_HUMAN;B7
WPD9_HUMAN




1433B_HUMAN 14-3-3 protein beta/alpha 
1433B_HUMAN;Q4VY19_HUMAN;
Q4VY20_HUMAN




1433E_HUMAN 14-3-3 protein epsilon 
1433E_HUMAN;K7EM20_HUMAN;
K7EIT4_HUMAN





1433G_HUMAN 14-3-3 protein gamma 1433G_HUMAN 13.05 2.16E-03 7.05E-01 1433G_HUMAN 14-3-3 protein gamma 1433G_HUMAN -2.06 5.64E-01 3.13E+02
1433T_HUMAN 14-3-3 protein theta 1433T_HUMAN;E9PG15_HUMAN -4.70 1.76E-04 5.73E-02 1433T_HUMAN 14-3-3 protein theta 1433T_HUMAN;E9PG15_HUMAN -0.04 6.09E-01 3.38E+02



































Spectrin alpha chain, non-erythrocytic 
1 
SPTN1_HUMAN;A6NG51_HUMAN -3.12 9.55E-07 3.11E-04 A6NG51_HUMAN
Spectrin alpha chain, non-erythrocytic 
1 
SPTN1_HUMAN;A6NG51_HUMAN -3.63 2.21E-02 1.23E+01
A6NKB8_HUMAN Aminopeptidase B 
AMPB_HUMAN;A6NKB8_HUMAN;C
9JMZ3_HUMAN;H7C2T3_HUMAN









-2.97 1.66E-02 5.42E+00 EF1A3_HUMAN


















































































































ANXA1_HUMAN Annexin A1 
ANXA1_HUMAN;Q5T3N1_HUMAN;
Q5T3N0_HUMAN






















-2.30 2.21E-02 7.20E+00 APEX1_HUMAN






























-4.48 7.16E-03 2.33E+00 ARC1B_HUMAN










ARGI1_HUMAN Arginase-1 ARGI1_HUMAN -4.66 1.14E-03 3.71E-01 ARGI1_HUMAN Arginase-1 ARGI1_HUMAN -4.12 1.33E-02 7.41E+00
ARP2_HUMAN Actin-related protein 2 ARP2_HUMAN;F5H6T1_HUMAN -4.49 1.32E-03 4.32E-01 ARP2_HUMAN Actin-related protein 2 ARP2_HUMAN;F5H6T1_HUMAN -3.90 2.32E-02 1.29E+01



















-4.81 2.22E-04 7.23E-02 ARPC2_HUMAN











-5.37 7.91E-05 2.58E-02 ARPC3_HUMAN










Actin-related protein 2/3 complex 
subunit 5 
ARPC5_HUMAN;B1ALC0_HUMAN -3.80 6.04E-04 1.97E-01 ARPC5_HUMAN






Apoptosis-associated speck-like protein 
containing a CARD 
ASC_HUMAN;H3BP42_HUMAN -5.13 1.94E-05 6.34E-03 ASC_HUMAN
Apoptosis-associated speck-like 
protein containing a CARD 
ASC_HUMAN;H3BP42_HUMAN -0.27 5.80E-01 3.22E+02



























0.56 3.14E-01 1.02E+02 B1AHC9_HUMAN






Capping protein (Actin fi lament) muscle 




-5.20 2.60E-03 8.46E-01 B1AK88_HUMAN
Capping protein (Actin fi lament) 






B3AT_HUMAN Band 3 anion transport protein B3AT_HUMAN 1.94 1.20E-02 3.90E+00 B3AT_HUMAN Band 3 anion transport protein B3AT_HUMAN 3.93 1.38E-01 7.66E+01
B4DJP7_HUMAN Small nuclear ribonucleoprotein Sm D3 
SMD3_HUMAN;B4DJP7_HUMAN;H
3BT13_HUMAN
-3.26 2.59E-06 8.44E-04 B4DJP7_HUMAN




















B4DTG2_HUMAN Elongation factor 1-gamma 
EF1G_HUMAN;B4DTG2_HUMAN;E7
EMT2_HUMAN





























Erythrocyte band 7 integral membrane 
protein 
STOM_HUMAN;B4E2V5_HUMAN 0.11 5.30E-01 1.73E+02 B4E2V5_HUMAN
Erythrocyte band 7 integral membrane 
protein 
STOM_HUMAN;B4E2V5_HUMAN 2.91 1.61E-01 8.92E+01

















B7Z3I9_HUMAN Delta-aminolevulinic acid dehydratase 
HEM2_HUMAN;B7Z3I9_HUMAN;B7
ZBK6_HUMAN






B7Z7E9_HUMAN Aspartate aminotransferase AATC_HUMAN;B7Z7E9_HUMAN -5.06 9.24E-04 3.01E-01 AATC_HUMAN
Aspartate aminotransferase, 
cytoplasmic 
AATC_HUMAN;B7Z7E9_HUMAN -3.84 9.76E-04 5.42E-01
B7Z9G5_HUMAN BRO1 domain-containing protein BROX 
BROX_HUMAN;B7Z9G5_HUMAN;Q
5VW33_HUMAN;F5GXQ0_HUMAN
-0.67 6.99E-01 2.28E+02 B7Z9G5_HUMAN




















BPI_HUMAN;H0Y738_HUMAN 0.00 8.48E-01 2.77E+02 BPI_HUMAN
Bactericidal permeability-increasing 
protein 
BPI_HUMAN;H0Y738_HUMAN 0.77 8.57E-01 4.76E+02


































Guanine nucleotide-binding protein 





Guanine nucleotide-binding protein 
























CAH2_HUMAN Carbonic anhydrase 2 
CAH2_HUMAN;E5RID5_HUMAN;E5
RK37_HUMAN




CALR_HUMAN Calreticulin CALR_HUMAN -3.78 1.60E-05 5.23E-03 CALR_HUMAN Calreticulin CALR_HUMAN;K7EJB9_HUMAN -2.44 3.24E-03 1.80E+00
CAN1_HUMAN Calpain-1 catalytic subunit 
CAN1_HUMAN;E9PRM1_HUMAN;E
9PL37_HUMAN







































5.35 2.19E-05 7.15E-03 CAP7_HUMAN Azurocidin CAP7_HUMAN 6.37 2.84E-03 1.58E+00
CATA_HUMAN Catalase CATA_HUMAN -4.26 2.09E-05 6.82E-03 CATA_HUMAN Catalase CATA_HUMAN -4.00 1.78E-03 9.89E-01
CATG_HUMAN Cathepsin G CATG_HUMAN 5.55 2.69E-07 8.77E-05 CATG_HUMAN Cathepsin G CATG_HUMAN 5.86 2.50E-03 1.39E+00
1.48E+00 CAZA1_HUMAN
F-actin-capping protein subunit alpha-
1 
CAZA1_HUMAN -3.01 1.56E-02 8.68E+00
1.48E+00 CAZA2_HUMAN







Cell division control protein 42 
homolog 
CDC42_HUMAN;E7ETU3_HUMAN -0.73 8.32E-02 2.71E+01 CDC42_HUMAN





CDD_HUMAN Cytidine deaminase CDD_HUMAN -5.59 5.58E-03 1.82E+00 CDD_HUMAN Cytidine deaminase CDD_HUMAN -6.18 2.52E-03 1.40E+00
C9JIS1_HUMAN
Guanine nucleotide-binding protein 



















Carcinoembryonic antigen-related cell  




-1.84 6.62E-03 2.16E+00 CEAM8_HUMAN
Carcinoembryonic antigen-related cell  





CH3L1_HUMAN Chitinase-3-like protein 1 
CH3L1_HUMAN;H0Y3U8_HUMAN;Z
N423_HUMAN;F5H7S1_HUMAN
-2.90 9.32E-03 3.04E+00 CH3L1_HUMAN Chitinase-3-like protein 1 CH3L1_HUMAN;H0Y3U8_HUMAN -5.73 7.95E-04 4.41E-01















-3.82 1.12E-02 3.64E+00 CLIC1_HUMAN







































domain-containing protein 1 
CPPED_HUMAN;B4DQ68_HUMAN -3.25 8.90E-03 2.90E+00 CPPED_HUMAN
Calcineurin-like phosphoesterase 
domain-containing protein 1 
CPPED_HUMAN;B4DQ68_HUMAN -4.82 1.64E-03 9.08E-01
D6R9A6_HUMAN
High mobility group protein B2 
(Fragment) 















































































-6.38 7.40E-03 2.41E+00 E7EMG9_HUMAN
















E7ERI3_HUMAN Threonine--tRNA ligase, cytoplasmic 
SYTC_HUMAN;G3XAN9_HUMAN;E7
ERI3_HUMAN




































































E9PDB2_HUMAN Malate dehydrogenase, mitochondrial 
MDHM_HUMAN;G3XAL0_HUMAN;
E9PDB2_HUMAN

























RAB8A_HUMAN Ras-related protein Rab-8A RAB8A_HUMAN;B4DEK7_HUMAN -4.18 1.46E-02 8.10E+00




ECP_HUMAN Eosinophil cationic protein ECP_HUMAN 1.29 5.44E-02 1.77E+01 ECP_HUMAN Eosinophil cationic protein ECP_HUMAN 2.18 1.19E-02 6.61E+00









































































F5H6I0_HUMAN Beta-2-microglobulin form pI 5.3 
B2MG_HUMAN;F5H6I0_HUMAN;H
0YLF3_HUMAN

























































































-3.63 5.90E-05 1.92E-02 ARPC4_HUMAN



























-4.18 1.24E-04 4.03E-02 FKB1A_HUMAN






























G3V2F7_HUMAN HCG2044781 UB2V1_HUMAN;G3V2F7_HUMAN -4.71 4.85E-04 2.69E-01
UB2V2_HUMAN














-1.64 1.09E-01 3.55E+01 G3V5V7_HUMAN
Heterogeneous nuclear 



















G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase 
G6PD_HUMAN;E9PD92_HUMAN;E
7EM57_HUMAN;E7EUI8_HUMAN
-5.12 5.48E-09 1.79E-06 G6PD_HUMAN
Glucose-6-phosphate 1-
dehydrogenase 
G6PD_HUMAN;E9PD92_HUMAN -3.96 1.31E-02 7.27E+00





































-2.46 7.46E-02 2.43E+01 G8JLH9_HUMAN
























GLGB_HUMAN 1,4-alpha-glucan-branching enzyme GLGB_HUMAN;E9PGM4_HUMAN -5.88 3.82E-05 1.25E-02 GLGB_HUMAN 1,4-alpha-glucan-branching enzyme GLGB_HUMAN;E9PGM4_HUMAN -4.31 1.76E-02 9.79E+00
GLRX1_HUMAN Glutaredoxin-1 GLRX1_HUMAN -5.52 9.92E-05 3.23E-02 GLRX1_HUMAN Glutaredoxin-1 GLRX1_HUMAN -4.72 6.64E-04 3.68E-01
GRP78_HUMAN 78 kDa glucose-regulated protein GRP78_HUMAN -2.22 9.74E-03 3.18E+00 GRP78_HUMAN 78 kDa glucose-regulated protein GRP78_HUMAN -2.50 9.86E-03 5.47E+00
GSHR_HUMAN Glutathione reductase, mitochondrial 
GSHR_HUMAN;E5RI06_HUMAN;H0
YBD4_HUMAN




GSTP1_HUMAN Glutathione S-transferase P GSTP1_HUMAN;A8MX94_HUMAN -5.47 4.83E-06 1.57E-03 GSTP1_HUMAN Glutathione S-transferase P GSTP1_HUMAN;A8MX94_HUMAN -4.82 2.31E-02 1.28E+01



















Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
AN32A_HUMAN;AN32C_HUMAN;A
N32D_HUMAN;H0YN26_HUMAN
-4.67 5.26E-03 1.71E+00 H0YN26_HUMAN
Acidic leucine-rich nuclear 















































H7BZJ3_HUMAN Thioredoxin (Fragment) 
PDIA3_HUMAN;G5EA52_HUMAN;H
7BZJ3_HUMAN
0.34 9.40E-01 3.06E+02 G5EA52_HUMAN
Protein disulfide isomerase family A, 











NGAL_HUMAN;H9KV70_HUMAN -6.17 3.18E-03 1.04E+00 H9KV70_HUMAN
Neutrophil gelatinase-associated 
lipocalin 
NGAL_HUMAN;H9KV70_HUMAN -6.09 2.76E-03 1.53E+00
HBA_HUMAN Hemoglobin subunit alpha HBA_HUMAN -0.14 4.27E-01 1.39E+02 HBA_HUMAN Hemoglobin subunit alpha HBA_HUMAN -0.45 4.77E-01 2.65E+02
HBB_HUMAN Hemoglobin subunit beta HBB_HUMAN;F8W6P5_HUMAN -0.74 1.32E-01 4.31E+01 HBB_HUMAN Hemoglobin subunit beta HBB_HUMAN;F8W6P5_HUMAN -1.02 2.82E-01 1.56E+02
HBD_HUMAN Hemoglobin subunit delta 
HBD_HUMAN;E9PEW8_HUMAN;E9
PFT6_HUMAN;C9JRG0_HUMAN




HBG2_HUMAN Hemoglobin subunit gamma-2 
HBG1_HUMAN;HBG2_HUMAN;E9P
BW4_HUMAN








HPRT_HUMAN -4.20 1.21E-04 3.93E-02 HPRT_HUMAN
Hypoxanthine-guanine 
phosphoribosyltransferase 
HPRT_HUMAN;PRDC1_HUMAN -3.44 1.56E-02 8.64E+00






















































































acetylhydrolase IB subunit alpha 
LIS1_HUMAN;I3L2U8_HUMAN;B4D
F38_HUMAN;I3L3N5_HUMAN
-4.98 3.40E-03 1.11E+00 LIS1_HUMAN
Platelet-activating factor 










-4.30 8.78E-03 2.86E+00 GLOD4_HUMAN






Isocitrate dehydrogenase [NADP] 
cytoplasmic 
IDHC_HUMAN;C9J4N6_HUMAN -4.20 1.78E-04 5.79E-02 IDHC_HUMAN







IGHA1_HUMAN Ig alpha-1 chain C region IGHA1_HUMAN;IGHA2_HUMAN -4.56 9.42E-03 3.07E+00 IGHA1_HUMAN Ig alpha-1 chain C region IGHA1_HUMAN;IGHA2_HUMAN -4.77 1.55E-02 8.62E+00
IGHG1_HUMAN Ig gamma-1 chain C region IGHG1_HUMAN -4.40 2.82E-02 1.57E+01
IGHG2_HUMAN Ig gamma-2 chain C region IGHG2_HUMAN -3.99 2.84E-02 1.58E+01
IGKC_HUMAN Ig kappa chain C region IGKC_HUMAN -6.33 5.67E-08 1.85E-05 IGKC_HUMAN Ig kappa chain C region IGKC_HUMAN -4.73 7.54E-02 4.19E+01
ILEU_HUMAN Leukocyte elastase inhibitor ILEU_HUMAN;B4DNT0_HUMAN -2.97 2.28E-05 7.42E-03 ILEU_HUMAN Leukocyte elastase inhibitor ILEU_HUMAN;B4DNT0_HUMAN -3.32 2.81E-02 1.56E+01
IMB1_HUMAN Importin subunit beta-1 
IMB1_HUMAN;J3QR48_HUMAN;B7
ZAV6_HUMAN










-4.77 1.26E-06 4.12E-04 IQGA1_HUMAN
















J3KPA1_HUMAN Cysteine-rich secretory protein 3 
CRIS3_HUMAN;J3KPA1_HUMAN;I3
L0A1_HUMAN;J3KQX0_HUMAN











-2.56 7.60E-04 2.48E-01 J3KQE5_HUMAN











-4.52 2.59E-02 8.43E+00 J3QKR3_HUMAN





J3QLI9_HUMAN Small nuclear ribonucleoprotein Sm D1 SMD1_HUMAN;J3QLI9_HUMAN -2.11 1.94E-03 6.31E-01 SMD1_HUMAN



















J3QRS3_HUMAN Myosin regulatory l ight chain 12A 
ML12A_HUMAN;ML12B_HUMAN;
MYL9_HUMAN;J3QRS3_HUMAN





K7ELW0_HUMAN Protein DJ-1 
PARK7_HUMAN;K7ELW0_HUMAN;
K7EN27_HUMAN


































-2.09 3.36E-04 1.10E-01 KPYM_HUMAN Pyruvate kinase isozymes M1/M2 KPYM_HUMAN -3.33 8.10E-02 4.50E+01

















LDHB_HUMAN L-lactate dehydrogenase B chain 
LDHB_HUMAN;A8MW50_HUMAN;
C9J7H8_HUMAN;F5H793_HUMAN




LEG3_HUMAN Galectin-3 LEG3_HUMAN;G3V3R6_HUMAN -4.98 2.58E-04 8.41E-02 LEG3_HUMAN Galectin-3 LEG3_HUMAN;G3V3R6_HUMAN -3.85 2.16E-02 1.20E+01
LKHA4_HUMAN Leukotriene A-4 hydrolase LKHA4_HUMAN;B4DEH5_HUMAN -4.61 1.90E-03 6.20E-01 LKHA4_HUMAN Leukotriene A-4 hydrolase LKHA4_HUMAN;B4DEH5_HUMAN -3.42 1.74E-02 9.66E+00
LMNB1_HUMAN Lamin-B1 LMNB1_HUMAN;E9PBF6_HUMAN -2.57 5.16E-04 1.68E-01 LMNB1_HUMAN Lamin-B1 LMNB1_HUMAN;E9PBF6_HUMAN -5.57 1.26E-02 7.02E+00
LPPL_HUMAN Eosinophil lysophospholipase LPPL_HUMAN -5.00 9.19E-04 3.00E-01 LPPL_HUMAN Eosinophil lysophospholipase LPPL_HUMAN;LEG16_HUMAN -5.10 3.77E-05 2.09E-02
LYSC_HUMAN Lysozyme C LYSC_HUMAN;F8VV32_HUMAN -3.35 8.83E-04 2.88E-01 LYSC_HUMAN Lysozyme C LYSC_HUMAN;F8VV32_HUMAN -2.08 4.08E-02 2.27E+01














M0R192_HUMAN Flavin reductase (NADPH) 
BLVRB_HUMAN;M0R192_HUMAN;
M0QZL1_HUMAN














MIF_HUMAN Macrophage migration inhibitory factor MIF_HUMAN -6.10 9.56E-03 3.12E+00 MIF_HUMAN
Macrophage migration inhibitory 
factor 
MIF_HUMAN -1.56 1.51E-02 8.37E+00




MMP9_HUMAN Matrix metalloproteinase-9 MMP9_HUMAN -7.21 1.32E-03 4.30E-01 MMP9_HUMAN Matrix metalloproteinase-9 MMP9_HUMAN -9.79 7.54E-03 4.18E+00
MNDA_HUMAN
Myeloid cell  nuclear differentiation 
antigen 
MNDA_HUMAN;H0Y6P3_HUMAN 3.85 7.66E-05 2.50E-02 MNDA_HUMAN
Myeloid cell  nuclear differentiation 
antigen 
MNDA_HUMAN;H0Y6P3_HUMAN 4.50 1.62E-03 8.98E-01




MTPN_HUMAN Myotrophin MTPN_HUMAN;C9JL85_HUMAN -2.40 3.18E-02 1.04E+01 MTPN_HUMAN Myotrophin MTPN_HUMAN;C9JL85_HUMAN -1.07 2.80E-01 1.55E+02










































































NIT2_HUMAN Omega-amidase NIT2 
NIT2_HUMAN;H7C579_HUMAN;F8
WF70_HUMAN












OSTF1_HUMAN Osteoclast-stimulating factor 1 OSTF1_HUMAN -0.73 4.94E-01 1.61E+02 OSTF1_HUMAN Osteoclast-stimulating factor 1 OSTF1_HUMAN 0.60 7.08E-01 3.93E+02
PDC6I_HUMAN
Programmed cell  death 6-interacting 
protein 
PDC6I_HUMAN;F8WDK9_HUMAN 0.31 5.40E-01 1.76E+02 PDC6I_HUMAN









PEBP1_HUMAN -3.81 1.39E-02 4.52E+00 PEBP1_HUMAN
Phosphatidylethanolamine-binding 
protein 1 
PEBP1_HUMAN -2.32 1.26E-02 7.00E+00
PERE_HUMAN Eosinophil peroxidase PERE_HUMAN 3.50 4.44E-03 1.45E+00 PERE_HUMAN Eosinophil peroxidase PERE_HUMAN 1.96 1.14E-01 6.32E+01
PERM_HUMAN Myeloperoxidase PERM_HUMAN;J3QSF7_HUMAN 4.38 4.87E-06 1.59E-03 PERM_HUMAN Myeloperoxidase PERM_HUMAN;J3QSF7_HUMAN 4.64 2.62E-03 1.46E+00
PGAM1_HUMAN Phosphoglycerate mutase 1 
PGAM1_HUMAN;PGAM4_HUMAN;
PGAM2_HUMAN




PGK1_HUMAN Phosphoglycerate kinase 1 
PGK1_HUMAN;PGK2_HUMAN;E7ER
H5_HUMAN;B7Z7A9_HUMAN



























PGRP1_HUMAN Peptidoglycan recognition protein 1 PGRP1_HUMAN -6.71 2.74E-03 8.94E-01 PGRP1_HUMAN Peptidoglycan recognition protein 1 PGRP1_HUMAN -7.96 1.42E-03 7.91E-01















































PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B PPIB_HUMAN -2.68 8.74E-02 2.85E+01 PPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B PPIB_HUMAN -3.39 2.31E-02 1.28E+01
PRDX2_HUMAN Peroxiredoxin-2 PRDX2_HUMAN;A6NIW5_HUMAN -1.39 3.66E-02 1.19E+01 PRDX2_HUMAN Peroxiredoxin-2 PRDX2_HUMAN;A6NIW5_HUMAN -0.90 4.61E-01 2.56E+02
PRDX6_HUMAN Peroxiredoxin-6 PRDX6_HUMAN -3.59 1.00E-03 3.26E-01 PRDX6_HUMAN Peroxiredoxin-6 PRDX6_HUMAN -1.39 1.45E-01 8.03E+01













PRTN3_HUMAN Myeloblastin PRTN3_HUMAN -3.19 3.64E-04 1.19E-01 PRTN3_HUMAN Myeloblastin PRTN3_HUMAN -3.58 2.66E-03 1.48E+00
PSA1_HUMAN Proteasome subunit alpha type-1 
PSA1_HUMAN;B4DEV8_HUMAN;F5
GX11_HUMAN













PSA3_HUMAN Proteasome subunit alpha type-3 
PSA3_HUMAN;G3V5N4_HUMAN;G
3V3W4_HUMAN





PSA5_HUMAN Proteasome subunit alpha type-5 PSA5_HUMAN -3.46 1.56E-03 5.10E-01 PSA5_HUMAN Proteasome subunit alpha type-5 PSA5_HUMAN -3.23 2.39E-02 1.33E+01









PSB10_HUMAN Proteasome subunit beta type-10 
PSB10_HUMAN;J3QQN1_HUMAN;J
3QL48_HUMAN
1.49 5.71E-02 1.86E+01 PSB10_HUMAN Proteasome subunit beta type-10 PSB10_HUMAN;J3QQN1_HUMAN -1.79 2.31E-01 1.28E+02
PSB2_HUMAN Proteasome subunit beta type-2 PSB2_HUMAN -2.39 1.30E-02 4.25E+00 PSB2_HUMAN Proteasome subunit beta type-2 PSB2_HUMAN -1.86 3.95E-01 2.19E+02
PSB4_HUMAN Proteasome subunit beta type-4 PSB4_HUMAN -3.97 1.76E-04 5.73E-02 PSB4_HUMAN Proteasome subunit beta type-4 PSB4_HUMAN -1.72 3.43E-02 1.90E+01
PSB6_HUMAN Proteasome subunit beta type-6 PSB6_HUMAN;I3L3X7_HUMAN -2.68 1.88E-03 6.12E-01 PSB6_HUMAN Proteasome subunit beta type-6 PSB6_HUMAN;I3L3X7_HUMAN -1.98 1.85E-02 1.03E+01
PSB8_HUMAN Proteasome subunit beta type-8 
PSB8_HUMAN;Q5JNW7_HUMAN;B
0UZC1_HUMAN










-3.79 1.81E-02 5.89E+00 H0YNE3_HUMAN












-3.34 1.43E-02 4.66E+00 PTN6_HUMAN
Tyrosine-protein phosphatase non-








PTX3_HUMAN Pentraxin-related protein PTX3 PTX3_HUMAN -4.64 6.70E-03 2.18E+00 PTX3_HUMAN Pentraxin-related protein PTX3 PTX3_HUMAN -4.65 1.69E-02 9.36E+00
PURA2_HUMAN Adenylosuccinate synthetase isozyme 2 PURA2_HUMAN -5.12 8.24E-03 2.69E+00 PURA2_HUMAN












PYGB_HUMAN Glycogen phosphorylase, brain form PYGB_HUMAN;H0Y4Z6_HUMAN -0.16 5.30E-01 2.94E+02
Q5T123_HUMAN
SH3 domain-binding glutamic acid-rich-
like protein 3 
SH3L3_HUMAN;Q5T123_HUMAN -3.35 6.24E-04 2.03E-01 Q5T123_HUMAN
SH3 domain-binding glutamic acid-
rich-like protein 3 



















-3.75 1.66E-03 5.40E-01 Q5TA02_HUMAN
































RAB5C_HUMAN Ras-related protein Rab-5C 
RAB5C_HUMAN;K7ERI8_HUMAN;K
7ENY4_HUMAN;K7ERQ8_HUMAN












-0.05 5.36E-01 1.75E+02 RAC2_HUMAN





























RETN_HUMAN Resistin RETN_HUMAN;Q76B53_HUMAN -4.36 5.56E-05 1.81E-02 RETN_HUMAN Resistin RETN_HUMAN;Q76B53_HUMAN -6.21 2.33E-02 1.30E+01
RHG01_HUMAN Rho GTPase-activating protein 1 
RHG01_HUMAN;H0YE29_HUMAN;E
9PNR6_HUMAN









-3.75 1.17E-02 3.83E+00 RHG30_HUMAN Rho GTPase-activating protein 30 RHG30_HUMAN;E9PLT5_HUMAN -3.30 6.43E-02 3.57E+01

































ROA2_HUMAN -5.24 1.01E-04 3.28E-02 ROA2_HUMAN
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
ROA2_HUMAN -2.41 6.66E-02 3.70E+01
RPIA_HUMAN Ribose-5-phosphate isomerase RPIA_HUMAN -3.85 1.02E-03 3.33E-01 RPIA_HUMAN Ribose-5-phosphate isomerase RPIA_HUMAN -3.44 2.94E-02 1.63E+01
RSU1_HUMAN Ras suppressor protein 1 RSU1_HUMAN;F2Z2H2_HUMAN -4.40 5.98E-04 1.95E-01 RSU1_HUMAN Ras suppressor protein 1 RSU1_HUMAN;F2Z2H2_HUMAN -3.65 1.61E-01 8.93E+01
S100P_HUMAN Protein S100-P S100P_HUMAN -3.93 2.63E-04 8.59E-02 S100P_HUMAN Protein S100-P S100P_HUMAN -4.94 2.95E-02 1.64E+01
S10A4_HUMAN Protein S100-A4 S10A4_HUMAN -4.72 8.62E-03 2.81E+00 S10A4_HUMAN Protein S100-A4 S10A4_HUMAN -3.23 2.30E-02 1.27E+01








Table 8-5 Quantitative comparison of protein levels in SN and D (DNase-I treated NET fraction) 
fraction 
Samples from 4 donors (on the left) were acquired using LTQ Orbitrap Velos ETD and samples 
from 3 donors (on the right) using Q Exactive MS. The data was subsequently quantified in 










S10A6_HUMAN Protein S100-A6 S10A6_HUMAN -2.26 9.80E-03 3.19E+00 S10A6_HUMAN Protein S100-A6 S10A6_HUMAN -3.56 5.89E-02 3.27E+01
S10A8_HUMAN Protein S100-A8 S10A8_HUMAN -3.40 5.02E-04 1.64E-01 S10A8_HUMAN Protein S100-A8 S10A8_HUMAN -3.91 1.22E-01 6.78E+01
S10A9_HUMAN Protein S100-A9 S10A9_HUMAN -4.92 9.81E-05 3.20E-02 S10A9_HUMAN Protein S100-A9 S10A9_HUMAN -2.62 2.06E-01 1.14E+02
S10AB_HUMAN Protein S100-A11 S10AB_HUMAN -4.12 9.32E-03 3.04E+00 S10AB_HUMAN Protein S100-A11 S10AB_HUMAN -3.29 1.54E-01 8.55E+01
S10AC_HUMAN Protein S100-A12 S10AC_HUMAN -3.38 8.17E-05 2.66E-02 S10AC_HUMAN Protein S100-A12 S10AC_HUMAN -2.13 2.79E-01 1.55E+02
SAHH_HUMAN Adenosylhomocysteinase SAHH_HUMAN -5.09 3.56E-04 1.16E-01 SAHH_HUMAN Adenosylhomocysteinase SAHH_HUMAN -2.97 4.12E-03 2.29E+00
SH3L1_HUMAN
SH3 domain-binding glutamic acid-rich-
like protein 
SH3L1_HUMAN -4.40 2.62E-04 8.53E-02 SH3L1_HUMAN
SH3 domain-binding glutamic acid-
rich-like protein 
SH3L1_HUMAN -1.50 1.99E-01 1.10E+02
SODC_HUMAN Superoxide dismutase [Cu-Zn] SODC_HUMAN;H7BYH4_HUMAN -2.08 1.26E-02 4.10E+00 SODC_HUMAN Superoxide dismutase [Cu-Zn] SODC_HUMAN;H7BYH4_HUMAN -2.95 6.31E-02 3.50E+01
SPB10_HUMAN Serpin B10 
SPB10_HUMAN;H7BYS2_HUMAN;H
7C004_HUMAN
-4.73 2.58E-04 8.40E-02 SPB10_HUMAN Serpin B10 SPB10_HUMAN -5.28 1.06E-02 5.86E+00
SPB6_HUMAN Serpin B6 SPB6_HUMAN;H0Y3G3_HUMAN -4.24 2.05E-04 6.68E-02 SPB6_HUMAN Serpin B6 SPB6_HUMAN;H0Y3G3_HUMAN -4.42 5.04E-03 2.80E+00




































-3.10 1.11E-02 3.63E+00 TERA_HUMAN

































TYB4_HUMAN Thymosin beta-4 TYB4_HUMAN;Q5T4B6_HUMAN -3.28 5.34E-01 1.74E+02 TYB4_HUMAN Thymosin beta-4 TYB4_HUMAN;Q5T4B6_HUMAN -3.63 6.63E-01 3.68E+02






















URP2_HUMAN Fermitin family homolog 3 
URP2_HUMAN;F5H1C6_HUMAN;H
0YFT5_HUMAN




VASP_HUMAN Vasodilator-stimulated phosphoprotein 
VASP_HUMAN;K7EM16_HUMAN;K
7EQD0_HUMAN














-3.48 3.92E-02 1.28E+01 VAT1_HUMAN
















WDR1_HUMAN WD repeat-containing protein 1 WDR1_HUMAN;D6RD66_HUMAN -3.63 4.42E-05 1.44E-02 WDR1_HUMAN WD repeat-containing protein 1 WDR1_HUMAN;D6RD66_HUMAN -3.41 6.24E-03 3.46E+00
XRCC5_HUMAN
X-ray repair cross-complementing 
protein 5 
XRCC5_HUMAN -2.50 8.43E-02 2.75E+01 XRCC5_HUMAN
X-ray repair cross-complementing 
protein 5 
XRCC5_HUMAN 1.87 9.32E-02 5.17E+01
